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Abstract
Recent data suggest that, in addition to hormones, growth factors and their 
receptors play a role in human breast cancer. The epidermal growth factor 
receptor (EGFR) is proposed to play a significant part in breast tumour cell 
m itogenesis and has been used as a marker o f poor patient prognosis. Utilising a 
ligand binding assay system it was demonstrated that EGFR was present in 38% 
(75/199) o f  primary breast tumours analysed. Concentrations o f  EGFR found 
ranged from 69.6 - 28201.0 fmoles. mg" 1 tumour cell DNA for the high affinity , 
low capacity binding site, and 163.0 - 9680.0 fmoles mg"1. DNA for the low affinity 
binding site. Mean values were 1581 ± 3647.4 and 5223.8 ± 6233.5 fmoles. mg ' 1 D N A  
respectively, median values were 686.5 and 3557.4 fmoles. mg" 1 DNA respectively. 
Within the EGFR positive group only 14 (7%) contained oestrogen receptors (ER). 
This contrasts with the EGFR negative group in which 99/124 (79%) were ER 
positive. These results help to confirm the hypothesis that there is a negative 
correlation between ER and EGFR in human breast cancer, and that there are two
subclasses o f primary breast tumours in terms o f their receptor biochemistry. The
ER positive subclass is assumed to be under endocrine control and the EGFR 
subclass is assumed to be under more local paracrine/autocrine control.
W hilst it is accepted that the majority o f  EGFR is located within the 
cytoplasmic portion o f cells, there has been some suggestion within the literature 
that there is an EGF binding component located within the nuclear fraction of 
mammalian cells  in tissue culture and in placental tissue. Studies contained
within this thesis indicate that there may be a single high affinity, low capacity 
EGF binding component within the nuclear fraction o f  a "bulk” breast tumour 
preparation (82 .4  fm oles. m g ' 1 DNA; Kd: 0.013 nm oles, litre-1 ). High salt
extraction o f  the nuclear fraction with 2M Nacl failed to dislodge this binding 
component.
XV
Western blotting with a polyclonal antibody to EGFR (BG 48) revealed the 
presence o f the 170 kDa. native receptor in both the membrane fraction and in 
the nuclear fraction both before and after salt extraction. To confirm that there 
was no contamination o f the nuclear fraction by membrane proteins, the nuclear 
fraction was assayed for the presence o f two known plasma membrane enzymes, 
5' Nucleotidase and Alkaline phosphatase. No activity was found in the detergent 
washed nuclear fraction for either enzyme. These results imply that there is an 
EGF binding component in the nuclear fraction o f  breast tumours which is 
im m unologically recognised as the same m olecular w eight as the membrane 
bound form.
The regulation o f EGFR was studied in an ER positive breast cancer cell line 
(ZR-75-1) . Studies within this cell line revealed that ovine prolactin (oPRL) at a 
pharmacological concentration o f 1 p g .m l " 1 was able to enhance EGF stimulated 
mitogenesis. This was demonstrated to be through its ability to increase EGFR 
availability. Peak levels o f EGFR were observed after four days exposure to the 
hormone in media containing phenol red (1600 fm oles EGFR. m g - 1  DNA in 
hormone treated cell membrane fraction compared to 400 fmoles EGFR. mg"1.D N A  
in control ce ll membrane fraction). Treatment with the protein synthesis  
in h ib itor , c y c lo h ex im id e  (40 n m oles, litre" 1) com p lete ly  inh ib ited  this  
stim u la tio n .
W hole ce ll binding was also increased by human PRL (hPRL) at a 
physiological concentration o f  40 ng. m l" 1 ( 153% stimulation) after 48 hours 
incubation in phenol red free m edia. H owever the greatest increases were 
observed with hPRL and oestradiol (E 2 ) at a concentration o f  10"9M (251%
stim u la tio n ).
Subsequent Scatchard analysis revealed that the increase in EGFR binding 
was due to an increase in receptor concentration with no apparent effects on 
binding affin ity .
XVI
Studies using other parameters to assess increases in EGFR levels such as 
ind irect im m unofluorescent and im m unoprecip itation  u sin g  the EGFR 1 
m o n o clo n a l an tib od y , revea l in crea ses  in s p e c if ic  f lu o r e sc e n c e  and 
immunoprecipitated receptor respectively. Studies as to the possib le mechanism  
o f receptor induction point to a paracrine/autocrine approach. It is possible that 
the induction o f EGFR is due to a heat labile polypeptide.
XVII
Chapter 1. INTRODUCTION
1 .1 . Historical Perspective
The first recorded instances o f breast cancer can be seen in the Edwin 
Smith Surgical papyrus which dates around 3000 - 3500 B.C. In it there are 
descriptions o f eight cases o f tumours or ulcers o f the breast . Tumours that were 
hard, were cool to touch, and contained flu id  were d istinguished  from  
inflammations and abscesses ; for the former the author admits " there is no 
treatment" . Reference is made however to one case treated by cauterisation 
with a fire stick.
Other instances have been recorded throughout early civ ilisations. One of  
the most famous being that o f Hippocrates (460-370 B.C .). When he described 
what must have been a common course o f the disease. "... and hard tumours 
appear in the breast, some larger and some smaller, these do not suppurate, but
continually grow harder and harder. From these grow hidden cancers  and
everything (the patients) eat tastes bitter, and if  you give them more to eat, they 
refuse it, and shut their mouths. They become delirious, their eyes are hard, and 
they do not see clearly and pains dart from the breast to the neck and beneath 
the shoulder blades, thirst seizes upon them, the nipples are dry, and the whole
body becomes emaciated .........  When they have gone as far as this, they do not
recover, but die o f this disease ! ". In his own experience he counselled, " It is 
better not to apply any treatment o f occult cancer, for i f  treated, the patients die 
quickly, but if  not treated they hold for a long time " .
The first real attempts at treatment o f the disease where performed in the 
second century by Galen (131-203 A.D .). He concluded that breast cancer was 
brought about by an excess o f  black bile in the body, caused by a local 
m anifestation o f  the constitutional disturbance, M elancholia. He likened the 
tumour growth to a crab with the large veins extending from all sides giving
the appearance o f  legs. Where possible he advised " Make accurate incisions
surrounding the whole tumour, so as not leave a single root " .
This advice has been carried out in one form or another according to the
prevailing medical dictates right up to the twentieth century.
1 .2  Epidem iology
Cancer o f  the breast frequently occurs in m ice, rats, dogs, and humans, 
and almost exclusively affects the female o f the species. Low rates are found in 
Japan, A sia and African countries, intermediate rates in Southern European 
countries, and high rates in North America and Northern European countries. 
(Seidman & M ushinski, 1983). The incidence rate for England and W ales has 
risen steadily during the last twenty years and is around 2 1 , 0 0 0  registrations per 
year, a similar rise in the number o f  deaths recorded has also been observed 
(Brinkley et a l .., 1984). The distribution pattern o f occurrence in terms o f age
differs from that o f most other common epithelial m alignancies. A steep rise 
through to the menopausal age group with a slight plateau between 45-55 and 
then a slow  but steady rise thereafter (W illiams & Buchanan, 1987). The age
adjusted mortality rate for the United Kingdom as a whole is around 34 per
100,000 women. The disease is the predominant cause o f death in women between 
the ages o f 15-74 with 40-54 being the years during which it exceeds all other 
causes o f death.
An Am erican study (Silverberg, 1987) estim ated that the lifetim e  
probability o f  developing breast carcinoma among girls bom  in 1987, was 10 
per cent and eventually dying o f  breast cancer 3 per cent.
1 .3 . Prognostic Factors
A thorough review o f this field is outwith the scope o f  this thesis. Many 
factors have been suggested to play a role. The identification o f  prognostic 
factors is critical for two reasons in that it (a) provides invaluable insights into
2
the biology o f breast cancer and, (b) allows first line o f therapy to be selected 
on the basis o f expected short or long term survival.
1 .3 .1  H istological Classification
Several classification  system s have been proposed. The m ost commonly 
used system is that o f  the World Health organisation (1981). In essence, this 
relies on the identification  o f  the degree o f  tumour ce ll d ifferentiation  
compared to normal cell type histology and that o f the original germinal cell 
tissue type. As can be seen from table 1 .1 ,  m alignant epithelial tumours 
comprise the majority o f  cancers o f the breast and can be divided into three 
p a rts.
(1) N on-invasive tumours
(2) Invasive tumours o f various types
(3) Paget’s disease o f  the nipple
The most common histological subtype is invasive ductal carcinoma follow ed by 
invasive lobular carcinoma.
1 .3 .2 . Tumour Grade
The hisological grade o f  a tumour is normally classified by the Bloom & 
Richardson technique (Bloom  & Richardson, 1957). This involves a subjective 
assessment o f  the degree o f tubule formation, nuclear pleomorphism, elastosis, 
and the frequency o f  hyperchromatic and mitotic figures.
1 .3 .3 . Blood vessel and Lymphatic invasion
The frequency o f blood vessel invasion varies greatly (5-45%)
(Stewart & Rubens, 1984); prognostic outcome appears to negatively correlate 
with degree o f vascular invasion (Sampat et a l ., 1977). A similar pattern is also
3
Table 1.1 Histologcal c lassification o f breast tumours
Epithelial Tumours II Mixed connective tissue and epithelial tumours
A. Benign
A. Fibroadenoma
B. Phyllodes tumour (cytosarcoma)
C. Carcinosarcoma
1. Intraductal papilloma'
2. Adenoma of the nipple
3. Adenoma a. Tubular
b. Lactating
III Miscellaneous tumours
A. Soft tissue tumours
B. Skin Tumours
C. Tumours of hematopoeitic 
and lymphoid tissues.
B. Malignant
1. Non-invasive
a. Intraductal carcinoma
b. Lobular carcinoma in situ
IV Unclassified tumours
2. Invasive
a. Invasive ductal carcinoma
b. Invasive ductal carcinoma with a 
predominant intraductal component
c. Invasive lobular carcinoma
d. Mucinous carcinoma
e. Medullary carcinoma
f. Pappillary carcinoma
g. Tubular carcinoma
h. Adenoid cystic Carcinoma
i. Secretory (juvenile) carcinoma 
k. Carcinoma with metaplasia
i Squamous type
ii Spindle-cell type
iii Cartiliginous and osseeous type
iv Mixed type 
1. Others
V Mammary dysplasia/fibrocystic disease
VI Tumour-like lesions
A. Duct ectasia
B. Inflammatory pseudotumours
C. Hamartoma
d. Gynecomastia
e. Others
3. Paget's disease of the nipple
From WHO (1981) International Histological Classification of Tumours, No2.
seen with the degree o f lymphatic invasion (Fisher et al., 1975).
1 .3 .4 . Elastosis
It has been observed that some tumours contain bundles o f  elastic fibres in 
the stromal compartment. The sign ificance o f  their presence is at best 
controversial. Shivas & Douglas (1972) found improved survival with increased 
elastosis. This contrasts with the findings o f Fisher et al. (1980) who found no 
such correlation. Masters et al. (1978; 1979) suggested that there may be a 
correlation between elastosis, menopausal status and the presence o f oestrogen  
receptors (another index o f  long term survival).
1.3.5. Tumour N ecrosis
Tumour necrosis is most commonly seen in high grade (grade III) tumours. 
Several studies (Canter et a l., 1978; Fisher et al., 1978) have shown that the 
presence o f  necrosis correlates with poor patient survival.
1.3.6. Staging (TNM)
The characteristics o f  the primary tumour and the presence or absence o f  
axillary lymph node involvem ent are strongly correlated with survival. They 
account for two elements o f the TNM system, the third being metastatic disease 
(see table 1 .2 ) .  Developed over thirty five years ago it has been updated by 
subsequent UICC committees. The rules governing the use o f the system are set 
out in the TNM classification o f malignant tumours handbook. They have been 
reviewed extensively (Israel & Chaniman, 1975; Salvadori, 1984), patients can be 
grouped into stages (see table 1 .3 ) . With a relatively short fo llow  up period 
there is a clear correlation between the risk o f  recurrent disease and increasing 
stage. (Paterson et al., 1984). Nodal involvement is generally agreed to be the 
best single prognostic single index.
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1.3.7. Tumour Growth Rate
The favoured method o f assessing growth rate is that o f mammography. In
a study (Galante et al ., 1984) o f 196 women comparing mammograms at the time
o f tumour detection to those immediately after surgery (mean interval 30 days),
it was found that 16% o f the patients had a "fast" doubling time defined as less 
than 20 days. Alm ost equal numbers were reported as having " intermediate" 
(31-90 days) or "slow" ( more than 90 days) doubling times. The median doubling 
time was 60 days, which suggests that breast cancer takes an average o f five  
years to reach 1 cm in diameter. This is relatively slow when compared to other 
m a lig n a n c ie s .
1 .4 . The Biochemistry o f Breast Cancer Growth
W hilst the physical manifestations o f  breast cancer can y ield  information 
on patient survival, it is obvious that this is a reflection o f  the biochemical 
events controlling the tumour cell growth, and must therefore depend on those 
factors w hich in flu en ce  th ese  even ts. From a b ioch em ica l v iew p oin t  
carcin ogen esis relies on the interactions betw een chem ical carcinogens, 
radiations, oncogenic viruses, inherited genetic factors, m itogenic hormones, 
and other promotional agents (Bishop, 1987).
One o f the first observations that m itogenic hormones may play a role in 
tumour promotion was that o f Beatson (1896), when he noted that some o f  his 
patients obtained significant breast disease regression follow ing oophorectomy. 
Further clinical observations (Huggins & Bergestal, 1952; Luft & Olivecrona, 
1955; Dao, 1972; Kennedy, 1974) have indicated that 25 to 40 per cent o f breast 
cancers respond to the surgical removal o f endocrine producing glands.
1.4.1. Oestrogens in normal breast tissue
Oestrogens are o f major importance in the development o f  normal breast 
epithelium . They are essentia l for the ductal phases o f  mammary gland
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development ( Nandi, 1958; Kratochwil, 1987 ) and administered systematically to 
castrated fem ale m ice cause quiescent ductal end buds to synthesise DNA and 
effect ductal elongation (Bresciani, 1968). However this effect is negated by the 
prior removal o f  the pituitary glands in addition to the ovaries (Lyons, 1958; 
Lieberman et al., 1978)
These results have been used to postulate that oestrogen does not act 
directly on mammary tissue, but possibly via an endocrine agent such as growth 
hormone or prolactin. In vitro studies using normal mammary epithelial cell 
cultures would seem to support this hypothesis (Yang et al., 1980; Stampfer & 
Bartley, 1987). Oestrogen induced epithelial proliferation has been observed  
only when ep ithelia l c e lls  are cocultured w ith mammary strom al ce lls  
(MacGrath, 1983; Haslem & Levely, 1985). Supporting the view  that oestrogen 
action is an indirect local mechanism involving close comm unication between 
strom al and ep ithelia l com ponents. In vivo  studies involving the topical 
application o f  oestradiol to one nipple area o f  a mammary gland in monkeys, 
rabbits and equine pigs promotes lobuloalveolar growth only in the treated 
gland ( Lyons & Sulco, 1940; Chamberlin et al., 1941; Nelson, 1941). Daniel et al. 
(1987) using implanted oestrogen containing pellets, demonstrated local but not 
distant oestrogen  induced a lveolar developm ent in m ice . Further, the 
autoradiographic localisation o f oestrogen receptors was observed in the ductal, 
epithelial and luminal cells o f the end bud, but not in the proliferation cap cells 
o f the end bud.
The postulation that oestrogen effects target tissue by loca l indirect 
mediators draws support from both in vivo and in vitro studies. If adolescent 
fem ale m ice are "primed" with oestrogen and progesterone, their glands are 
capable o f  lobuloalveolar developm ent when transferred to primary tissue  
culture in response to a combination o f  hormones and growth factors. Insulin, 
prolactin, aldosterone, and hydrocortisone, can act along with an extract o f  
"primed" gland to induce in vitro developm ent in organ culture. The gland
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extract contains epidermal growth factor binding activity. Either epidermal 
growth factor (EGF) or transforming growth factor alpha (TG Fa) can substitute 
for the activity supplied by the gland extract. EGF and TGFa are both able to 
promote lobuloalveolar developm ent in vitro in isolated ductal end buds from 
mice ( Richards et al., 1982; Vonderhaar et al., 1988). Oestradiol stimulation o f  
uterine growth may depend on both the induction o f  the EGF receptor and an 
EGF related growth factor ( DiAugustin et al., 1988; Lingham et al., 1988). Cell 
lines derived from reduction mammoplasties display low levels o f  oestrogen 
receptor be they o f epithelial or myoepithelial origin, contain high levels o f  
EGF receptor and TGFa. ( Hacket et al., 1977; Stampfer, 1985; Le Vay-Young et al., 
1987; Rudland, 1987 ).
In summary, the interaction o f  m ultiple hormones including oestrogen
regulates mammary gland developm ent. W hile there is som e ev idence for
oestrogen receptors in the epithelium, it is not clear if  growth response o f the
normal epithelium is in direct response to oestrogen. It is likely that stromal 
epithelial interactions and growth factor mediators such as TGFa appear to be
in v o lv e d .
1.4.2. Oestrogen role in Breast Neoplasia
Oestrogenic regulation o f neoplastic growth is a modified remnant o f  the 
normal regulatory m echanism s involved in mammary ep ithelial proliferation  
and differentiation. It has been demonstrated that pharm acological amounts o f  
oestrogens can be carcinogenic (Dickson et al., 1980; Fishman, 1980; Fishman e t  
a l . ,  1983; Degan & M etzler, 1987; M etzler, 1987). This resulted from the 
observations showing increased risk o f  vaginal cancer in daughters o f  women  
who took diethylstilbestrol (DES) to prevent spontaneous abortions.
Oestrogens are m itogenic for both normal and malignant breast epithelia. 
The hypothalamic pituitary axis is indirectly involved in the control o f  ovarian 
oestrogen secretion by virtue o f  gonadotrophin releasing hormone (GnRH) and
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gonadotropin (R oss et al., 1980). In addition the pituitary gland (or other 
organs) may also secrete other direct or indirect acting m itogens (Eide et al., 
1985; Wilding et al., 1987) such as insulin like growth factor II (IGF II), basic and 
acid ic fibroblast growth factor (FGF) and lu ten isin g  horm one releasing  
h o r m o n e .
Murine m odel system s have shown that oestrogen can control breast 
tumour growth by inducing pituitary hyperplasia and prolactin secretion. 
Sirbasku has employed the term "estromedin" for other analogous but still 
hypothetical oestrogen induced endocrine acting m itogens (Peres et al., 1987). 
O estrogen m ight also act by allow ing breast cancers to overcom e growth 
inhibitory agents in their environm ent by synergy with other stimulatory 
agents (L ykkesfeldt & Briand, 1986; D evleeschow er et al., 1987, Soto & 
Sonneschein, 1987). These interacting components could be serum derived or 
produced by the cancer itself or nearby tissue.
Studies into the hormonal control o f  breast cancer have been facilitated by 
the availability o f cell lines usually derived from pleural or ascites fluid o f  
patients. Several oestrogen responsive cell lines exist including MCF-7, T47-D, 
MDA-MB-134, ZR-75-1, PMC42 and CAMA-1. MCF-7 (Brooks et al., 1973) display an 
absolute requirement for oestrogen for tumour formation when introduced into 
athymic(nude) m ice (Soule & MacGrath, 1980). In vitro hormone sensitivity o f
cell lines, in particular that o f  the m ost intensively studied, M CF-7 have  
produced conflicting results with regard to oestrogen sensitivity .
Lippman et al. (1976) have demonstrated oestrogen receptors and direct 
responses to physiological doses o f 17-p-O estradiol in v i t ro , this has been 
confirmed by others ( Chablose et al., 1982; Darbre et al., 1983; K atzenellenbogen  
et al., 1983; Page et al., 1983; Berthois et al., 1986; Nelson et al., 1987; Osborne e t  
al . ,  1987). Initially a number o f other groups have failed to note this response ( 
Edward et al., 1980 ; Butler et al., 1981; Lykkesfeldt & Briand, 1986; Devleeschower 
et al., 1987; Soto & Sonneschein, 1987 ). This may be due to studies with an
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incorrectly identified or characterised cell line (Osborne et al ., 1987). Another 
problem is a more complete understanding o f the relevant variables in culture 
conditions. Serum is a rich source o f  oestrogenic compounds including sulphate 
conjugates, and it has been shown that phenol red may act as oestrogen (Nelson 
et a l ,  1987).
Numerous oestrogen independent cell lines have been used as m odels for 
horm one u n resp on sive  breast carcinom a such as the adenocarcinom a  
M DA-M B-231 or the carcinosarcoma HS5787 (Butcher et a l ,  1981). Whilst these 
models can be categorised according to their sensitivity to oestrogen. It is worth 
noting that all are derived from metastatic sites and are fully malignant in that 
sense. Therefore it is difficult to assess the biological significance when related 
to premetastatic tumour, or the influence that the metastatic process has had on 
the original tumour population.
1 .4 .3 . Biochemical effects o f Oestrogen
Oestrogen has been shown to induce a large number o f enzymes and other 
proteins involved  in nucleic acid synthesis in breast cancer ce ll lines, 
including DNA polymerase, C-myc protooncogene (Dubik et al., 1987), thymidine 
and uridine k inases, thym idylate synthetase, carbam yl-phoshate synthetase, 
a sp a r ta te  t r a n s c a r b a m y la s e , d ih y d r o o r o ta s e ,  g l u c o s e - 6 -p h o s p h a te  
dehydrogenase and dihydrofolate reductase (Edwards et al., 1980; Aitken & 
Lippman, 1983, 1985; Dickson et al., 1987). Physiological concentrations stimulate 
DNA synthesis by both scavenger and de novo biosynthetic pathways. Oestrogen  
regulates thymidine kinase and dihydrofolate reductase at the m RNA level 
(Cowan et a l ,  1982; Kasid et al., 1986). Oestrogen appears to induce progesterone 
receptor protein (Horwitz & M acGuire, 1978, Chablos & R ochefort, 1981; 
Lippman, 1985) and mRNA levels (Read et al., 1988). The progesterone receptor is 
generally coupled to functional growth regulation by oestrogens in vivo and in  
v i t r o  . Progesterone receptor content in breast tumours has been used as a
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marker of oestrogen and antioestrogen responsiveness (Nardulli et al., 1988).
Oestrogen has been shown to alter cellular synthesis and/or secretion o f  
several other proteins, whose roles in growth control is unclear. These include 
various proteases which could contribute to tumour growth and progress by 
allow ing the tumour to d igest and transverse the encapsulating basement 
membrane (H uff & Lippman, 1984; Liotta et al., 1986; Terranova et al., 1986; 
Butler et al., 1987). Another possib ility  is that proteases may facilitate the 
release o f  active growth factors from carrier proteins, processing inactive  
precursor growth factors and other proteases to active species (Kaufman et al., 
1977). It has been noted that oestrogen induces the secretion o f proteins o f  
various molecular weights o f  which little is known, 24 kilodaton (kDa.) (Cioca e t  
al. ,  1983), 52 kDa. and 160 kDa. (Westley and Rochefort, 1980; W estley and May, 
1987), 37-39 kDa., 32 kDa. (Bronzert et al., 1987; Sheen & Katzenellenbogen, 1987) 
and 7 kDa. (Jakolew et al., 1984, Nunez et al., 1987). The function o f the proteins 
are still open to conjecture. The 52 kDa. glycoprotein is one o f the major secreted 
proteins and it has beeen indentified  as cathepsin D , w hich has been  
demonstrated to be m itogenic to MCF-7 cells in vitro (V ignon et al., 1986; 
Caponay et al., 1987).
1 .4 .4 . The Oestrogen Receptor
The actions associated with oestrogen are presumed to be mediated via its 
specific receptor. Gorski et al. (1968) and Jensen et al. (1968) from results 
gained in retention studies using tritiated oestradiol in rat uteri, proposed the 
now classical "two step" model for oestrogen. In this model binding o f oestradiol 
to its soluble "cytosol" receptor results in translocation to the nuclear  
compartment, where it was assumed that the hormone receptor com plex bound 
to the chromatin and initiated the responses attributed to oestrogen action. Both 
the unoccupied and occupied receptor are now believed to reside in the nuclear 
fraction. Receptor is produced in the cytoplasm  by the ribosom al assembly
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proteins. The mechanism o f  transfer to the nuclear matrix is unknown but a 
sequence conferring karyophilic properties has recently been indentified by 
M ilgrom et al. (1990). W elshons et al. (1984 & 1985) using cell separation and 
ligand binding techniques, have dem onstrated that "empty" receptors are 
loosely  attached to the nucleus and that tight nuclear binding occurs once 
h o rm o n e  b in d s  to  th e  r e ce p to r . T h is  has b e e n  c o n fir m ed  
immunohistochemically by King & Greene (1984) using a number o f monoclonal 
antibodies (recognising different ep itopes), w hich have show n exc lu sive ly  
nuclear staining in fixed sections o f  human breast tumours, human uterus, 
rabbit uterus, and in MCF-7 cells.
Toft and colleagues (Shuh et a l ., 1985) have shown that receptors for 
oestrogen and other steroids associate (at least in vitro ) with a 90 kDa. heat 
shock protein (HSP-90), which may play a role in stabilisation o f  the unbound 
receptor. Loss o f HSP-90 binding to the oestrogen receptor is thought to greatly 
facilitate steroid binding. Work within this laboratory by Chalmers (1990) has 
dem onstrated nuclear m igration o f  H SP-90 upon heat shock. Under these  
conditions total loss o f  oestrogen binding was observed, although almost two 
thirds o f  total im m uno-recognisable oestrogen receptor lev e ls  were present. 
Another protein, a 29 kDa. phosphoprotein may also associate with the oestrogen 
receptor . Its function is unknown, but its presence in breast cancer appears to 
correlate with hormone responsiveness (Cano et al., 1986).
cDNA clones for the oestrogen receptor have been obtained from MCF-7 
cells (Walter et al., 1985). The mRNA codes for a 6 6  kDa. protein which contains a 
long 3 '-untranslatable region similar to the glucocorticiod receptor (Gigume e t  
a l . ,  1986). The DNA binding dom ains o f  the receptors for oestrogen,
g lucocorticoid , m ineralocorticoid, vitam in D 3 , progesterone, and retinoic acid
share a strong sequence hom ology with one o f  the transforming proteins o f  
avian erythroblastosis virus v-erb-A (Greene et al., 1986; Green et  al., 1986; 
Arriza et al., 1987; deThe et al., 1987; Giguere et al., 1987,1988; MacDonnell et a l ,
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1987; Thom son et al., 1987, Evans, 1988;). The cellular hom olog o f  v-erb-A is 
known as c-erb-A and is a receptor for thyroid hormones. (Sampat et al., 1986; 
W einberger et al., 1986). The DNA binding domains o f each receptor is highly 
conserved (Lumar et al., 1986).
1.4.5. The Oestrogen Receptor in Breast Cancer
Oestrogen receptors are found by ligand binding assay in 50-70% o f breast 
carcinomas. Nuclear receptors are found in 26-46% o f  cases depending on 
menopausal status o f the patients (Pregoraro et al., 1980; Leake et al., 1984). 
Nuclear receptors are usually found in tumours with cytoplasm ic receptors, but 
can occur without cytosolic receptors (Leake et al., 1981a).
In terms o f patient prognosis, cytosolic oestrogen receptor positive patients 
have a better prognosis, better d isease free interval and overall survival 
(Osborne & MacGuire, 1978; Stewart & Rubens, 1984). This can be further
enhanced by the the addition o f data on nuclear receptor presence (Leake et al., 
1981b). The inclusion o f  progesterone receptor presence appears to further
enhance predictive response. (Bertuzzi et al., 1981). The significance o f  steroid 
receptors in other gynaecologica l m alignancies is  s till unclear, though  
progesterone receptors indentify the majority o f  hormone sensitive tumours in 
Endometrial (for a review see Soutter & Leake, 1987) and ovarian cancer 
(Harding et al., 1990)
1.5. Growth Factors Activities in Normal and Malignant Epithelium
It is now becoming clear that the action o f oestrogen and other hormones 
is mediated at least in part by the regulation o f local growth
control mechanisms. These may be autocrine and/or paracrine in their mode o f  
action. These local mechanisms have been termed growth factors. Experimental 
evidence suggests that growth factors play extensive roles in the growth o f
both the epithelial and stromal compartments in the breast.
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1 .5 .1 . Insulin and Insulin-like Growth Factors and their Receptors
The insulin family o f growth factors is a complex group o f cross reacting 
ligands and receptors. Alternative splicing o f  the mRNA for insulin-like growth 
factors, particularly IGF-I (Rotwein, 1986) further adds to the com plexity. 
Insulin is a two chain disulphide linked growth factor, processed from a single 
gene product whose primary site o f synthesis is the pancreas. In contrast, the 
single chain o f (uncleaved 7.5 kDa. size) IGF-I and IGF-II (somatomedins) are 
synthesised by many body tissues (including the liver) and are under different 
hormonal regulation particularly that o f growth hormone (Daughaday et al ., 
1987; Hymes et al., 1987). Several other growth factors, such as relaxin and 
lentropin (which controls lens fibre formation) are members o f  an even larger 
insulin related family (Beebe et al., 1987).
Somatomedins are required both for anchorage dependent and independent 
proliferation o f fibroblasts. IGF-I is m itogenic in some breast cancer cells i n 
v i tro  (Furlanetto & DiCarlo, 1984). An IGF-I related species has been found to be 
secreted by all breast cancer cell lines examined by radioimmunoassay (Baxter 
et al., 1983; Huff et al., 1986). Oestrogen induction o f IGF-I like growth factor has 
been noted, along with insulin, TGF a  and EGF (Huff et al., 1988). Secretion of 
IGF-I related factors are inhibited by antioestrogen, transforming growth factor 
beta (2) and glucocorticoids. Growth hormone stimulation o f  IGF-I in liver, 
fibroblasts, and other normal tissue is not seen in the MCF-7 cell line (D'ercole e t  
al., 1980; Clemmons et al., 1983; Jansen et al., 1983).
It is unknown whether IGF-I produced by breast cancer acts primarily on 
breast cancer itself in an autostimularory mode or on the surrounding stroma to 
promote chem otaxis and growth. A lternatively it may be true that breast 
cancers induce the surrounding m esenchym e to produce IGF activities which 
may stimulate the mesenchyme or breast epithelium. Antibody blockade o f  the 
IGF-I receptor (Flier et al., 1986) is capable o f inhibiting in vitro cloning o f the
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M DA-MB-231 cell line (Rohlick et al., 1981), and tumour growth in vivo (Arteaga 
et al., 1981) suggesting the importance o f an autocrine role.
1 .5 .2 . Transforming Growth Factor Beta
TGF p is a 25 kDa. polypeptide initially purified from platelets and various 
normal tissues. It is required, along with other growth factors, for the full 
induction o f the transformed phenotype in fibroblasts. It is also produced 
autonomously in fibroblasts transformed by oncogenes (Spom et al., 1987). TGF p 
is a member o f  a m ultigene fam ily which includes m ullerian inhibiting
substance, inhibins, and activins (Carter et al., 1986). Breast cancer cells i n  
v i t r o ,  like normal breast epithelium is inhibited by TGF p , which has been 
proposed to be an autocrine inhibiting substance in breast cancer (Wang & Hsu,
1986).
TGF p like activity has been noted in breast cancer cells (Knabbe et al., 1988; 
Derynck et al., 1985) and has been shown to transform AKR-2B and NRK
fib rob lasts. C om igration on gel ex c lu sio n  colum ns w ith  TGF p and 
immunoprecipitation with TGF p antiserum has been documented (Knabbe et al.,
1987). A ll Breast cancer cell lines analysed express the 2.5 kb mRNA species
(Derynck et al., 1987). Secretion is inhibited in the MCF-7 cell line by oestrogen 
and insulin. Knabbe et al. (1987) have shown growth inhibitory antioestrogens 
and glucocorticoids strongly stimulate its secretion. TGF p also inhibits the 
growth o f an oestrogen receptor negative cell line (M DA-M B-231). Alleviation o f  
inhibition is achieved by the addition o f a polyclonal antibody to native TGF p.
The TGF p receptor is a high m olecular weight com plex o f  615 kDa.,
consisting o f  two 280 kDa. receptor subunits, together with two other binding
subunits o f  65 kDa. and 85 kDa. (Cheifetz et al., 1986). The receptor does not
appear to contain tyrosine kinase activity (Goustin et  al., 1986). W hilst the
receptor has not been purified, cloned or sequenced, an alternate gene for TGF p 
exists (Ikeda et al., 1987). The gene product forms either a homodimeric or a
1 4
heterodimeric com plex with TGF (5, and appears to bind the 280 kDa. receptor 
species as does TGF p but has a lower affinity for the 65 and 85 kDa. forms o f the
receptor (Cheifetz et al ., 1987; Segarini et al., 1987). It is equipotent in inhibiting
epithelial cell proliferation (Ohta et al., 1987). High affinity receptors appear to 
be present in greater numbers in oestrogen receptor negative breast cancer 
cell lines. H owever both oestrogen receptor positive and negative cell lines
have been reported to be growth inhibited by both TGF p and TGF P2  (Z u gm aier  
et al., 1988). The mechanism(s) o f action o f TGF p is largely unknown.
1 .5 .3 . Platelet Derived Growth Factor
Found in high concentrations in platelets, PDGF is a heterodimeric protein
o f  approximately 30 kDa.. The v-sis oncogene is related to the PDGF B chain
homodimer and can transform PDGF receptor containing cell types. In tumours
derived from cell types lacking receptor, v -sis is not transforming. PDGF is 
presumed to act in a paracrine manner, stimulating angiogenesis (desm oplasia), 
ch em otax is, strom al proliferation  and degranulation o f  m on ocytes and 
neutrophils (Ross et al., 1986).
Many breast cancer cell lines secrete PDGF related activity as detected by
anchorage independent growth stim ulation o f  m ouse 3T3 fibroblasts in the 
presence o f platelet poor plasma (Rosengurt, 1986); 25 kDa. and 16 kDa. species of 
PDGF have been observed by im m unoprecipitation o f  m etabolically  labelled  
MCF-7, MDA-MB-231 and other cell lines. Upon examination o f Poly-(A)-selected  
mRNA from either cell line, transcripts o f  both PDGF A and B chains were 
observed (Rosengurt et al., 1985; Betscholtz et al., 1986; Bronzert et  al., 1987; 
Peres et al., 1987)
It is likely that in breast cancer, oestrogen induced PDGF (along with other 
growth factors) act in a paracrine m anner on fibrob lasts and other  
surrounding tissue. This could result in the proliferation o f fibroblasts, and 
further enhance tumour growth by released mediators such as IGF-I. It is
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possib le that fibroblast derived IGF-I might be one o f  the stromal factors 
required in vivo to initiate all the effects associated with oestrogen action on 
epithelial proliferation. Ro et al. (1987) have reported that there is a correlation 
between PDGF mRNA expression and the degree o f stromal desm oplasia in 
primary breast cancer.
1 .5 .4 . Fibroblast Growth Factor
Members o f this family include acidic and basic fibroblast growth factor 
(aFGF and bFGF) (Esch et al ., 1985), Kaposi's FGF (Ks FGF), and Int 2 ( Delli Bovi et 
al., 1987; D ickson & Peters, 1987), a more distant hom ology exists with 
interleukin 1 (IL-1) (Thomas et al ., 1985). Both aFGF and bFGF bind to a 140-210 
kDa. receptor and stimulate its tyrosine kinase activity (Coughlin et  al ., 1988). 
bFGF is capable o f  acting as an oncogene when expressed in fibroblasts ( Rogel 
et al ., 1988; Sasada et al ., 1988). Uncertainty exists as to the principal target o f  
FGF in normal mammary glands. Rudland (1987a) proposed that the effects are 
restricted to the myoepithelium and stroma, but Karey and Sirbasku (1988) have 
found that MCF-7 and T47-D cell lines respond.
1.5.5. P r o la c t in
P r o la ctin  (PRL) has been proposed to have a role in human breast cancer 
both in terms o f  a marker o f breast cancer risk and due to its ability to stimulate 
breast cancer ce ll growth in vi tro  (see section 4 .3 .1 ) .  PRL is a 22 kDa. 
polypeptide secreted by the hypothalamic pituitary axis. R ecently it has been 
shown that in addition to the 22 kDa. form, other forms exist. A 16 kDa. form 
which is extremely m itogenic to breast cancer cells in culture (Mittra, 1980), 
w hilst being lactogenic (Clapp et al ., 1988) appears to have som e different 
properties from the intact hormone. It inhibits the proliferation o f  endothelial 
cells in culture, while the 22 kDa. form is inactive (Ferrara et al ., 1988). Studies 
by Clapp et al. (1989) have revealed that iodinated 16 kDa. fragment specifically
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bound to membranes o f  kidney, liver, brain and skeletal m uscle o f  the rat. Five
other novel peptides within the molecular weight range o f between 13 - 18 kDa. 
which appear to be related to PRL have been reported ( Sinha et al., 1989). In 
several mammalian species including man, these peptides have been detected but 
their physiological properties are still unknown. Polymeric forms o f PRL have 
also been found which appear to have a reduced biological action (Fraser et al., 
1989; Jackson et al., 1989).
Some o f  the better known functions o f  PRL include osm oregulation and 
electrolyte metabolism in fish (Loretz & Bern, 1982), pigeon crop sac mucosa 
growth and differentiation (Horseman, 1987), mammary gland growth and
lactation (Topper, 1970). Luteotropic and luteolytic functions in the ovary (
Gitay-Goren et al., 1989; Krasnow et al., 1990), growth and secretion of the male 
sex accessory organs (Bartke & Lloyd, 1970) and maternal and parental
behaviour in birds and rodents (Bridges et al., 1985; Horseman, 1987). Recent
studies also indicate that PRL has an imm unoregulatory role involv ing  T
lym phocyte modulation (Russel et al., 1985; Heistad et al., 1986; Bemton et al., 
1988; Hartmann et a l ,  1989).
I .5 .5 .I . Regulation o f  Prolactin
The regulation o f  PRL secretion is controlled largely by inhibitory factors ,
partial p urification  o f  these factors has been ach ieved  but com plete  
characterisation has not. It is recognised that dopamine inhibits secretion both 
in vitro and in vivo possib ly through a pertussis toxin sensitive G protein
which is cAM P independent (Boyd et a l ,  1988). There is a suggestion that
dopamine itse lf  is a physiological PRL release inhibiting factor (PIF) (N eil, 
1980). Thyrotrophin releasing hormone (TRH), vasoactive intestinal peptide
(VIP) , opiate peptides, enkephalins and p-endorphin are know n to cause
secretion o f  PRL. In addition, PRL release is induced by suckling (N eill, 1974), 
stress (N eill, 1978) and ovarian hormones primarily oestrogen (Veldhuis et a l ,
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1989; Brann et al., 1989). Recent data by Carlson (1989) indicated that dietary 
factors such as amino acids particularly tyrosine and phenylalanine can play a 
role in stimulating PRL secretion.
The biochemical mechanisms involved in PRL release appear to involve the 
interaction o f  intracellular m echanism s such as cAM P adenlylate cyclase, 
phospholipid hydrolysis and arachidonate m etabolism  (M acLeod et al ., 1986).
However there is some debate as to the role o f  protein kinase C (PKC). Whilst it is 
clear that phorbol ester (TPA) addition can stimulate PRL secretion in pituitary
cell in culture (Boyd & Wallis, 1989), as studies by Judd et al. (1989) have shown
that chronic exposure by PKC activators such TPA and phorbol dibutyrate did not
e ffec t stim ulation o f  secretion  by other prolactin secretagogue such as 
thyroliberin, angiotensin II and neurotensin.
I.5.5.2. Prolactin Receptor (PRL-R)
PRL belongs to a fam ily o f  hormones including growth hormone (GH), 
placental lactogen and proliferin (Linzer & Nathans, 1984). N icoll (1982)
described the com plications inherent in the estim ation o f  PRL-R using
heterologous ligand binding assays. The main objection is that, in some cases, 
ovine PRL can bind in addition to the PRL-R other members o f the PRL family's 
receptors resulting in false estimates o f  concentration and affinity. Little data is 
at yet available as to the nature o f the PRL-R.
Immunoprecipitation studies reveal that the PRL-R in both rabbit and pig 
mammary tissue is composed o f a single PRL binding subunit o f  42 kDa. which 
may be covalently attached to other units o f a higher molecular weight 70 - 80 
kDa. (Dusanter-Fourt et al., 1987). Ligand crosslinking studies in the rabbit 
mammary gland reveal both a 34 kDa. receptor and a 78 kDa. receptor which was 
directly regulated by bivalent cations (Sakai & Khomoto, 1989). Binding o f  PRL to
its receptor appears to be a hydrophobic process (Sakai & Suzuki, 1989). To our
knowledge no cloning o f  the specific genes for PRL-R and establishment o f the
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amino acid sequence has yet been published. However a cDNA clone for the 
receptor precursor has been isolated from rat liver (Boustin et al., 1988). The 
predicted receptor precursor is 310 amino acids which is similar to that o f  the 
GH receptor (Leung et al., 1987).
No data is as yet available as to the mechanisms by which the hormone 
binding signal is transduced. Characterisation o f the cDNA clones available has
not pointed to the their possible modes o f  action. To further complicate the 
elucidation process Davis & Linzer (1989) have demonstrated m ultiple forms of  
the receptor which may be part o f distinct signal transduction pathways. Few  
reports are as yet available as to the mechanisms o f receptor regulation. This is 
partly due the lack o f antibodies to the receptor and appropriate mRNA probes.
1.5.5.3. Biochem ical effects o f Prolactin
In addition to its actions on the phosphatidylinositol pathway (see 4 .3 .9 ) .  
PRL may play a role in the adenylate cyclase signal transduction system. Strong
evidence has accumulated that PRL acts through a cholera toxin sensitive G 
protein( Gs) when m itogenically stimulating NB2 lymphoma cell line (Larsen e t  
al., 1988; Too et al., 1989; 1990).
1 .5.5.4. Prolactin  Summary
To summarise, PRL has many effects within different organisms and target 
tissues. There is some confusion as to what actually constitutes the native form of 
the hormone. The precise nature o f  the receptor and receptor ligand interaction 
has yet to be elucidated. The biochemical events associated with ligand binding 
have still to be studied in greater detail.
1.5.6. Other Pituitary Hormones, Steroids and Growth Factors
In vivo growth factors and/or oestrogen are thought to act in concert with 
other system ic m itogens to promote tumour growth. Dem binski et al. (1985)
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iso lated  pituitary derived activity which enhances the m itogenic effects of 
oestradiol in MCF-7 cells. One pituitary factor already identified is IGF-II (Shiu e t  
a l ., 1988). In addition pituitary derived GnRH may also directly interact with 
breast cancer to inhibit its proliferation (Eidne et al ., 1985).
M CF-7 c e lls  in culture display growth regulation by a variety o f  
lip id-soluble hormones in addition to oestrogen. These include glucocorticoids, 
iodothyronines, androgens, and retinoids (for a review  see Lippman, 1984). 
Progesterone induces a specific protein and can be inhibitory in vitro (for a
review  see Rochefort, 1987); other inhibitory hormones include somatostatin 
(Setyono-han  et a l ., 1987), Interleukin-1 and Interleukin-6 , tumour necrosis
factor and interferon (for a review see Sporn & Todaro, 1988). Receptors and
metabolic effects but little growth response has been shown for other hormones, 
such as grow th horm one, g lu cagon , and ca lc ito n in  (L ippm an, 1984).
Transferrin, a serum iron delivery m olecule, is required for proliferation of
normal and malignant mammary cells (Hanover & Dickson, 1985). Its receptor is
increased in oestrogen independent breast cancer (Tonik et al., 1986). It is clear 
that the complexity o f  growth modulatory hormones observed in studies using in  
v i t r o  breast cancer models, suggest that many serum borne or locally produced
modulators o f growth may play important regulatory roles in vivo. A lternatively,
or in addition, growth factors with a similar spectrum o f  activities could be
elaborated by the breast cancer cells them selves.
1 .6 .1 . Epidermal Growth Factor, Transforming Growth Factor Alpha 
and their Receptor.
W hilst the bulk o f  this thesis is concerned with the EGF receptor, it is
appropriate that the ligands associated with the receptor cited in the literature 
be outlined. Particular emphasis has been placed on EGF and TGFa. Other ligands 
for EGF receptor have been described: amphiregulin, isolated recently from 
serum-free conditioned medium o f MCF-7 cells (Shoyab et al., 1989); and the
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poxvirus growth factors, especially vacinnia virus growth factor (Buller, 1988).
1 .6 .2 . Epidermal Growth Factor ; Structure.
First identified in m ouse submaxillary glands (Cohen, 1962), hom ologous 
human EGF (hEGF) originally designated as urogastrone was isolated from urine 
(Savage et al ., 1972; Gregory, 1975). Native hEGF is a peptide o f 53 amino acid 
residues containing three disulphide bridges (see figure 1 .1 ), with a molecular 
weight o f 6200 amu as assessed by tandem mass spectrometry (Furuya et al., 1989).
Analysis o f  cDNA clones derived from mRNA transcripts encoding murine 
EGF and hEGF, indicate that both peptides are derived from proteolytic processing 
o f a larger precursor molecule. The size o f  this has been estimated to be 1217 and 
1207 residues respectively (Gray et al., 1983; Scott et al ., 1983; Pfeffer & Ullrich,
1985). The human EGF gene is located on chromosome 4 (Brissenden et al., 1984; 
Zabel et al., 1985). Predicted cDNA sequence suggests that hEGF precursor is an 
integral membrane protein having an N-terminal extracellular domain o f  1,012  
amino acids, a single transmembrane domain o f 25 amino acids, and a C-terminal 
intracellular domain o f 150 amino acids. The EGF moiety is in the extracellular 
domain immediately adjacent to the membrane spanning region. A further eight 
regions containing partial sequence identity with EGF have also been noted 
(Gray et al., 1983; Doolittle et al., 1984).
Sequence sim ilarity between the LDL receptor and the murine EGF 
precursor has led to the suggestion that the precursor may be a receptor for an 
as yet unknown ligand (Russel et al., 1984). mRNA for prepro-mEGF has been 
found in many murine tissues, including the submandibular gland, kidney, 
mammary gland, pancreas, duodenum, pituitary, lung, spleen, brain, ovary, and 
uterus (Rail et al., 1985). The observation that the precursor is present in the 
distal tubule in preference to the native form suggests other physio logica l 
functions. Studies using NIH 3T3 cells transfected with kidney hEGF precursor 
cDNA (M rcozkowski et al., 1988), have shown that the expressed precursor could
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com pete with hEGF for receptor binding, could activate receptor, and sustain 
growth in an EGF dependent cell line (Mroczkowski et al ., 1989). Thus proteolytic 
processing may not be essential for activity.
Structure and function studies o f  the native form, by Katsura & Tanak 
(1 9 8 9 ), using m onospecific  polyclonal antibodies directed against specific  
epitopic regions to hEGF, suggest that region 22-32 is responsible for binding to 
the receptor and signal transduction, and regions 35-53 stab ilise the ligand  
receptor interaction.
1 .6 .3 . Biological/Biochemical effects o f EGF
Since its discovery EGF has been implicated in a number o f biochemical and 
biological responses both in vivo and in vitro. In contrast to TGF a , little impetus 
has been placed on EGF action in the breast. Data derived form other model 
systems may still have a relevance within the breast (for reviews see Carpenter 
& Cohen, 1979; Stoschek & Carpenter, 1983; Staros et al., 1985; Carpenter et al.,
1986).
These include the in vitro stim ulation o f  the phosphatidyl inositol (PIP) 
pathway in m ouse m esenchym e cells  (Chepenik & Haystead, 1989), in rat 
hepatocytes (Johnson & Garrison, 1987) and in the A431 human squamous 
carcinoma cell line often used for EGF receptor studies (Hepler et al., 1987; Pike & 
Eakes, 1987). Activation o f  protein kinase C which is associated with increased 
PIP pathway turnover has also been noted (Moscar et al., 1988). Increases in
cytosolic Ca + +  via the PIP pathway, which appears to be necessary for EGF
stimulated mitosis, have also been cited in A431 cells (Mozhayva et al., 1989), in 
the human hepatocellular carcinoma derived cell line PLC/PRF / 8  (G illligan e t
al. ,  1988), in the normal rat kidney cell line NRK-49F (Marks et al., 1988), and rat
fibroblasts (Muldoon et al., 1988).
Shelton Earp and colleagues (1986) demonstrated that EGF can stimulate the 
synthesis o f its own receptor in the rat hepatocyte cell line W B, at both the
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protein and mRNA levels. M oeller et al. (1989) have reported EGF induction of 
T G F a  mRNA in both intact bovine anterior pituitary gland and in tissue culture. 
Other responses have been noted, these include stim ulation o f plasm inogen  
activator secretion and mRNA in hepatocytes (Lucore et  al ., 1988), granulosa cells 
(Galway et al., 1989), A431 cells (Niedbala & Sartorelli, 1989) and in the human 
colon carcinoma cell line GEO (Boyd & Brattain, 1989).
Release o f  arachidonic acid has been observed upon EGF treatment in mouse
em bryonic ce lls  (Chepenik, 1989) probably via  phospholipase A 2  a c t iv a t io n  
(Bonventre et al., 1990), which may be essential for EGF induced m itogenesis 
(Handler et al., 1990). Ornithine decarboxylase activation has been reported in 
A431 cells (Yazigi et al., 1989) and in rat colonic explants (Arlow et al., 1990). 
Stimulation o f casein kinase II has been seen in A431 cells (Ackerman et al., 
1989,1990). and both the mouse adipocyte cell line 3T3-LI and rat hepatoma cells 
H4-IIE (Sommercom et al., 1987).
W hilst EGF has been noted to stimulate synthesis o f its own receptor protein 
in MDA 468 cells (Kudlow et al., 1986). The majority o f studies in breast cancer 
m odels have centred around its m itogenic effects. D avidson et  al. (1987) 
presented evidence that EGF induced m itogenesis was inversely proportional to 
EGF receptor concentration of the cell line studied.
Addition o f  EGF has been shown to alleviate antioestrogen inhibition o f cell 
growth in MCF-7 (Cormier & Jordan, 1988) and T-47D cells (Koga & Sutherland,
1987). Recently Koga and colleagues demonstrated alleviation from progestin  
inhibition (Koga et al., 1989). Loss o f both oestradiol and progesterone binding 
has been observed upon EGF treatment in MCF-7 cells (Cormier et  al., 1989). This 
type o f  data has led to the supposition that in the heterogeneous tumour mass, the 
effects o f  antioestrogen or progestins can be negated by paracrine growth factor 
production within the stromal or ER negative portion o f  the tumour.
Little data is as yet available concerning the regulation o f  EGF in breast 
cancer and its possib le functional sign ificance. Murphy et al. (1 9 8 8 ) have
2 3
demonstrated regulation o f EGF mRNA in T47-D cells by progestins suggesting 
possib le hormonal control.
A study by Kurachi et al. (1985) demonstrated a direct correlation between 
increased mammary tumourigenesis and increases in EGF concentration in the 
submandibular gland o f female virgin m ice (62.5%, n=48). Removal o f  the gland 
(sialoadenoectom y) reduced incidence considerably (12.8% , n=39), reinfusion of  
sialoadenoectom ised m ice with EGF resulted in increased tumour incidence. 
Sialoadenoectom y o f m ice bearing tumours resulted in rapid sustained cessation  
o f growth, reinfusion resulted in the restoration o f tumour growth. Thus within 
murine m odels EGF has a role in the promotion and subsequent growth of  
mammary carcinom a.
1 .7 . Transforming Growth Factor Alpha
De Larco and Todaro (1978) were the first to isolate TGFa in a spectrum of  
grow th prom oting factors from so lid  tum ours, w hich cause reversib le
transformation o f  normal ce lls . TG Fa has been demonstrated in a variety o f  
retrovirally transformed cells , human tumours, and embryonic ce lls  (Ozanne e t  
al., 1980; Todaro et al., 1980; Twardzik et al., 1982).
1.7.1. TGF alpha , Structure
Mature human TG Fa is a (see figure 1 .2 )  single chain polypeptide o f  50
amino acid residues (Derynck et  al., 1984). With a m olecular w eight o f
approximately 6  kilodaltons and is constrained into a three ring structure by
disulphide bonds between six cysteine residues (Marquadt et al., 1983; Lee et al., 
1985), which are essential for biological activity (Lazar et al., 1989).Further
recent studies by D efeo-Jones and co lleagu es (1989) have revealed that
elimination o f arginine residue 42 also results in the loss o f  biological activity, 
suggesting that this residue may be a key contact point in ligand receptor
interaction. Human TG Fa shares a 27% amino acid sequence hom ology with
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Figure 1.2 : Primary Structure of Human TGF alpha
murine EGF and a 37% homology with human EGF. Three dimensional studies by 
Kohda and co-workers (1989) indicate that the gross structure o f  human TGFa 
resembles that o f  a "mitten". Receptor ligand interaction occurs in the manner
o f a "mitten" gripping an object (see figure 1 .3 ) , similar to that proposed earlier 
for murine EGF (Kohda et al., 1988). The area o f  greatest sequence heterogeneity 
is located at the rear o f  the "mitten" suggesting that the N-terminal polypeptide 
segment is not involved in receptor binding.
The gene for TGFa is located on chromosome 2 ( Brissenden et al ., 1985).
cDNA cloning has revealed that human (Derynck et al., 1984) and rat (Lee et al.,
1985) TGFa are synthesised as highly conserved (>90%) precursor proteins o f  160 
and 159 amino acids respectively . Both precursors (proT G Fa) contain an
extracellular N-terminal sequence o f 23 unchanged apolar amino acids that may 
function as a signal peptide, followed by a domain o f 74 or 75 amino acids which
includes the mature growth factor and possible glycosylation sites, a 23 amino
acid hydrophobic transmembrane domain with, finally a cysteine rich sequence 
o f 39 amino acid residues at the COOH-terminal which constitutes the cytoplasmic 
d om ain ..
It has been proposed that the presence o f  transmembrane sequence is a 
sign that pro-TGF a  is synthesised as a transmembrane m olecule and that the 
frequent s ize  heterogeneity encountered is due to d ifferen tia l proteolytic  
cleavages o f the external precursor domain and to N- and O- glycosylation o f the 
larger precursor forms (Bringham et al., 1987; Gentry et al., 1987; Teixido et al.,
1988). The observation that other integral membrane proteins contain EGF/TGF a  
like repeats in their extracellular domains, such as Drosophi la  Notch  (Wharton e t  
al . ,  1985) and Caenorhabditis elegans  lin-12 (Greenwald et al., 1985), both of 
which are known to play roles in cell-cell interaction, has prompted interest in
the biological action o f pro-TGFa.
W ong et al. (1989) has demonstrated BHK cells  transfected with vectors
coding for pro-TG Fa which are resistant to proteolytic cleavage, resulted in
2 5
H
um
an
 
TG
F 
Al
ph
a 
M
ou
se
 
EG
F
'IfLO
CO
CD
i -
3
ra
iZ
coTJ
C
03
-t—<
CO
■4—4
CD
CDx:
CO
D )
c
■q .co
CO
CD
c
CD
* 3
CCS
S§E G
I . ?
~ o
t =^  COC DO C
o  . 2  
g-cS 
2  o
CD 
c  oX3 
O
Id CO
> > H -j - O  °  
C CO* ®
2  b  c
O  CO
CD
CO CD 
O  CO
CD
°  CO
= 1'§ §  CO i—
■ a  T3
O  g
■4—• 5
CO o
E  *=
a  CO 
S Z  CD
o  s z  
CO I—
CD CO 
y= s z
f t
■— LL
C 0 O  
■ t—
w E
03 CD CD  
CO J Z  CZ
i l l
3  £
. 2  co o  
> >
c L ^
■a w 03<D O-C■e q .*-O o  "O
C L  CZ
CD Q- co 
LL O co  © §
L U  . c
m CO ■*-
®  CO CD .E x= x:
o
Q ..=
CD CD ci o
3
E CD
°  O _o
■2 S „
8 " °  J?2  c  <
g  S -S
2  0 3  & CO C .2d,
T3 -g 
CD C  °
§
im m u n o c y to c h e m ic a l id e n t if ic a t io n  o f  p ro -T G F a  on the cell surface. 
Coincubation with A431 ce lls  resulted in EGF receptor autophosphorylation. 
Brachmann and group (1989) using a TGFa precursor which had undergone site 
directed mutagenesis o f two extracellular cleavage sites overexpressed in an EGF 
receptor negative cell line CHO, revealed immunocytochemical localisation o f the 
mutant TG Fa precursor on the cell membrane. Solubilised precursors from this 
source could induce autophosphorylation in a ce ll line overexpressing EGF 
receptors NIH 3T3 and anchorage independent growth in NRK fibroblasts. 
Coculture o f the transfected cell line with cells expressing high levels o f EGF 
receptor, A431 and HERc, resulted in receptor activation as assessed  by
a u to p h o sp h o ry la tio n .
1 .7 .2 . The role o f TGFa in the Transformation Process
Like EGF, TGFa (although less effectively), has been noted to induce c-fos 
and c-m yc expression in CH 10T1/2 cells  (Cutry et a l ., 1988). Brenner and
colleagues (1989) have dem onstrated m itogenesis in quiescent primary rat 
hepatocyte cultures, with a transient increase in the proto-oncogene c-jun and
increased rates o f Na+ uptake. Studies last year from MacGeady et al. (1989) have 
demonstrated that transfection with a TG Fa expression vector results in the 
transformation o f  the normal mouse epithelial cell line NOG-8, but not the 
normal rat fibroblasts. Recent work by Matsui et al. (1990) has shown that 
expression o f human cDNA under the control o f the m ouse mammary tumour
virus enhancer/promoter, led to a range o f  tumour abnorm alities including  
adenom a, adenocarcinom a, lobularhyperp lasia  and cy stic  hyp erp lasia  in
transgenic fem ale m ice. No such abnormalities were observed in transfected  
male m ice. Studies by Jhappan et al. (1990) and Sandgren et al. (1990) using 
transgenic m ice transfected with an expression vector containing the m ouse
m e ta llo th io n e in /T G F a  fusion protein, reported that where TGFa overexpression
occurs epithelial abnormalities can be seen.
2 6
1.7.3. TGFa in Human Breast Epithelial cells in vitro
Exogenous TGF a  is a relatively strong growth promoting agent for the 
non-transformed 184A1N4 mammary epithelial cell line and for the oestrogen 
responsive MCF-7, ZR-75-1 and T47-D cell models under serum free conditions 
(Salomon et al ., 1986; Novak-Hoffer et al.t 1987; Karey & Sirbasku, 1988; Valverius 
et  a l ., 1988). It has been shown that EGF or TGFa can partly attenuate 
anti-oestrogen induced growth inhibition in MCF-7 and T-47D cells (Koga & 
Sutherland, 1987; Arteaga et al ., 1988; Murphy & Dotzlaw, 1989)
A number o f  breast cancer cell lines have been screened to ascertain if  
they synthesise and secrete im m unoreactive and b io log ica lly  active T G F a . 
B iologically  active TGFa was originally detected in the conditioned medium (CM) 
from a number o f different MCF-7 clones and in extracts prepared from MCF-7 
xenografts (Salom on et al., 1984; Dickson et al., 1985; Dickson et al., 1986). 
Subsequent demonstration o f  comparable b iological and im m unological activity  
can be found in the CM o f ZR-75-1, T-47D and MDA-MB-231 cell lines (Perroteau et  
al . ,  1986) which appears represent both the 30 kDa. and the 6 kDa. forms ( 
Dickson et al., 1986; Bates et al., 1988). 17 P-Oestradiol has been shown to induce a 
dose dependent 3 to 5 - fold increase in the secretion o f TGFa protein and mRNA 
expression in MCF-7 cells over a physiological concentration range known to be 
growth prom oting to these ce lls  (Bates et al., 1988). This has also been  
demonstrated in both ZR-75-1 and T-47D cells (Murphy & Dotzlaw, 1989) and in  
vivo with differentiated rat mammary tumours (Liu et al., 1987). It should be 
noted however that antibody blockade o f TGFa binding still resulted in oestradiol 
mediated mitogenesis in the MCF-7 cell line (Arteaga et al., 1988). Further studies 
by Clarke et al. (1989) have shown that the introduction o f a TGFa e x p r e s s io n  
vector into MCF-7 cells both in vitro and in vivo in tumour xenografts did not 
appreciably affect their ability to respond m itogenically to oestrogens. But the 
possibility remains that TGFa may still play a role in mediating oestrogen action.
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As a rule the highest levels o f TGFa activity are found in oestrogen receptor 
negative breast cancer cell lines such as M DA-M B-231 and M DA-M B-468 ( 
Perroteau et al., 1986; Bates et al., 1988; Zajchowski et al., 1988; Bjorge et al., 1989). 
Expression o f TGFa mRNA and biologically active TGFa protein can also be found 
in normal non-im m ortalized populations o f  human mammary epithelia l cell 
strains ( Zajchowski et al., 1988; Valverius et al., 1989). The 184 cell strain secretes 
T G F a  at a level comparable to and even greater than that o f some breast cancer 
cell lines. It has been proposed that mRNA expression o f TGFa in the 184 and the 
184 A1N4 variant is related to cell proliferation rate (Salomon et al., 1989). This is 
not the case in several oestrogen receptor positive and negative ce ll lines 
investigated (Murphy & Dotzlaw, 1989). Up regulation of TGFa production by the 
addition o f  exogenous EGF or TGF a  has been observed in both normal 184 A1N4 
cells (Salomon et al., 1989) and in the MDA-MB-468 breast cancer cell line (Bjorge 
et al., 1989) through what appears to be a autoinductive mechanism.
M acN eill et al. (1986) have shown that both EGF and TG Fa stim ulate  
oestradiol 17-P hydroxy steroid dehydrogenase, increasing the conversion rate o f  
oestrone to oestradiol in cultured human adipose tissue. This may account for the 
observations that oestradiol concentrations are sign ificantly  higher in breast 
tumours compared to normal tissue (Bonney et al., 1983; Van Landeghan et al., 
1985).
1 .7 .4 . TGFa in Human Breast Tissue
Expression o f  TGFa is not limited to normal or malignant epithelial cells in  
v i t ro .  Immunoreactive TGFa ranging from 1 - 7  ng/mg protein has been found in 
normal breast tissu e , fibroadenom as, fib rocystic  les ion s, and 2 2  primary 
infiltrating ductal carcinomas (Perroteau et al., 1986). Macias et al. (1989) found 
that out o f 45 mammary ductal carcinomas, around 31% contained b iologically  
active T G Fa. Gregory et al. (1989) observed that in positive primary breast 
tumours the majority o f the biologically active peptide is in the 6  kilodalton
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form, subsequent tamoxifen treatment resulted in a ten - fold decrease in tumour 
associated TG Fa. Expression o f TGFa mRNA has been noted in a variety o f human 
tumours (Derynck et al ., 1987). Using slot blot and northern blot analysis Bates 
and colleagues (1988) demonstrated the presence o f TGFa mRNA in 70% o f the 40 
tumours analysed.
In situ hybridisation studies by Ciardello et al. (1989) have demonstrated the 
presence o f  TGFa mRNA in the tumour cells o f some primary infiltrating ductal 
carcinomas. Southern blot analysis o f  these tumours provided no evidence for 
any major rearrangement or gross am plification o f  the TG Fa gene when 
compared to patient matched peripheral tissue.
U rinary im m u n o rea ctiv e  T G F a has been detected in patients with 
dissem inated breast cancer, which contrasts with the negative findings in the 
control group (Stromberg et al., 1987). This has led to the proposal that a urinary 
T G F a  assay could complement mammography (Feig, 1984) as a useful method for 
early breast cancer detection.
1.8. The Epidermal Growth Factor Receptor (Isolation and Structure)
The A431 cell line (Giard et al., 1973) which overexpresses the receptor 
(EGFR) greatly facilitated the isolation and biochemical characterisation o f  EGFR 
including cDNA cloning (Haigler et al., 1978; Stoschek & Carpenter, 1983). Whilst 
there is no reason to doubt the information derived from this cell line, EGF 
inhibition o f  growth is noted in most circumstances (G ill & Khazar, 1981). 
H owever, many o f  the early responses to EGF are representative, possib ly  
exaggerated, o f  the "normal" mitogenic response (see section 1 . 6 . 3 ) .
Using affinity chromatography Cohen et al. (1980) purified EGFR from A431 
cells  to near hom ogeneity. The purified receptor had an apparent m olecular 
mass o f  150 kDa., but subsequent purification procedures using buffers which 
eliminated calcium indicated a mass o f 170 kDa. (Cohen et al., 1982). This report 
corresponded to studies using chem ically crosslinked [ 1 2 ^I] - EGF by other
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groups in the field (Das et al ., 1977; Hock et al ., 1979; Wran & Fox, 1979). It has 
been reported that m ost cell homogenates contain a calcium activated protease 
which cleaves EGFR to a 150 kDa. form (Cassel & Glasser, 1982; Gates & King, 1982). 
Prior to the isolation o f EGFR, it was observed that the addition o f EGF to A431 cells 
resulted in a rapid activation o f  specific tyrosine kinase activity (Ushiro & 
Cohen, 1980).
Sequence analysis o f  tryptic peptides derived from EGFR (Downward et al.,
1984) led to cDNA cloning o f the receptor and a deduced amino acid sequence of 
the entire m olecule (Ullrich et al ., 1984). The mature receptor is composed of 
three major regions (see Figure 1 .4 ) . A large glycosylated extracellular ligand 
binding region o f 621 amino acid residues, which is anchored by a single 
transmembrane spanning region o f 23 hydrophobic amino acids, follow ed by the 
internal cytoplasm ic region o f  543 amino acids, which contains the kinase 
domain displaying consensus residues typical o f the tyrosine kinase gene family 
(for a review  see Ullrich & Schlessinger, 1990). The Lys-721 residue and 
consensus sequence G ly-X-G ly-X-Phe-G ly-X-Val- located 15 residues upstream to 
the Lys residue probably function as part o f the ATP binding site (Ruso et al.,
1985) in the kinase domain.
1 .8 .1 . Ligand Binding
Quantitative binding experiments with radiolabelled EGF indicate that the 
stoichiometry o f  ligand binding to EGFR is 1:1 (Weber et al., 1984). However 
analysis o f ligand binding experiments o f [ 1 2 5 I] - EGF to intact cells according to 
Scatchard reveal non linear plots, which are interpreted as an indication of  
different receptor classes with distinct affinities towards EGF. High affinity EGF
receptors with an apparent K<j o f 1-3 x 10‘ ^ M  comprise 5-10% o f  the total
receptors, w hile the remaining low  affinity have an apparent o f 2-15 x
1 0 _1®M (King & Cuatrecasas, 1982). W hilst Scatchard analysis is an invaluable 
tool in assessing receptor affinity and number, a few problems should be noted
3 0
R
es
id
ue
 
N
u
m
b
er
Figure 1.4
NH.
622
644
1186-
e
0
|0
i
e
o
&S
%
Q 1
* 
-4
 
1 
1%---- 654
___ 721
%
6
O
----- 845
----- 992
V -
©
0
%
—  1068 § - v -
-----1148
— — 1173
® — V—  
© - V -
©
E xtracellu lar Domain
M em brane Spanning Region
In trace llu la r Domain
COOH
S tructu ra l f e a tu re s  o f th e  Epidermal Growth F ac to r R eceptor, th e  following 
sym bols a re  shown:
N- Linked g lycosylation s ite s  - •
C ysteine Residues 
Tyrosine Residues
Phosphotyrosine Residues
P hosphothreonine Residues 
Lysine Residues
© - T -
K —
w hich  can in flu en ce  that assessm en t. In the case  o f  h igh  receptor  
concentrations it has been demonstrated that unless the receptor levels are 1 0  -
fold less than the Kd, the "apparent" Kd w ill become a linear function of  
receptor concentration . Other problem s can arise in data extrapolation; 
heterologous ligand populations can produce non linear plots (Taylor et al.,
1975). resolving the curve for the identification o f  low  and high affinity  
receptors is subject to error (Delean et al., 1981); method o f ligand labelling(
Carpenter, 1987).
The ligand binding site o f EGF receptor has still to be established. Studies 
using EGF com petitive monoclonal antibodies suggest that the region between  
Ala -351 and Asp- 264 are crucial in ligand binding (Wu et al., 1989). Chimeric 
receptor studies by Lax and group (1988,1989) proposed that the extracellular 
area, designated domain III, which encompasses the above region was essential 
for optimum binding.
1 .8 .2 . Receptor Biosynthesis
The gene for EGFR is located on the short arm o f  human chromosome 7 ( 
Davies et al., 1980; Kondes & Shimizu, 1983) in the p l2 -p l4  region (Merlino et al.,
1985). Normal and transformed cells that express EGFR have two mRNA species of 
10 Kb and 5.6 Kb which hybridise with cDNA probes ( Xu et al., 1984; Ullrich et al.,
1984). Translation o f EGFR mRNA in vivo is accompanied by co-translational
N-linked glycosylation within the lumen o f  the endoplasmic reticulum (Decker,
1984; Soderquist & Carpenter, 1984; Carlin & Knowles, 1986), which appears to be 
critical for receptor transport from the endoplasmic reticulum (Slieker et al.,
1986). The complete biogenesis time for EGFR, that is the average time required 
from translation to appearance on the ce ll surface has been estim ated at 
approximately 3 hours (Stoshchek et al., 1985; Slieker et al., 1986). H alf o f this
time is used for the conversion o f  the 131 kDa. precursor to the mature 170 kDa. 
form. An additional 75 m ins is required for translocation o f  the new ly
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synthesised receptor from the endoplasmic reticulum the golgi complex. (for a 
review see Soderquist & Carpenter, 1986).
1 .8 .3 . Internalisation and Degradation
Once EGFR has appeared on the cell surface, they do not form an oligomeric 
species or clusters until EGF is added (Haigler et al., 1979). EGF causes rapid 
internalisation o f  its receptor in endocytic v esic les  (Carpenter, 1987) and 
subsequent degradation o f receptors in the lysosom es (Dunn et al., 1983; Bequinot 
et al., 1984). Some evidence suggests that internalisation o f ligand receptor 
com plexes is essential for mitogenic signal generation (Decker, 1989). Studies by 
Honneger et al. (1987, 1989) using site directed mutated receptors demonstrated 
that tyrosine kinase activ ity , w hilst appearing to play no role in the 
internalisation event, is essential for degradation. Further, that the cytoplasm ic 
domain plays a key role in determining m itogenicity, transforming potential and 
receptor routing. Recent electron m icroscope studies suggest that tyrosine  
kinase activity determines the fate o f the internalised receptor within the 
m utlivesicu lar body (Felder et  al., 1990). The role that internalisation and 
degradation play in signal transduction is unclear. Cohen & Fava (1985) have 
shown that internalised ligand receptor com plexes display higher tyrosine  
kinase activity towards exogenous substrates as w ell as altered substrate 
s p e c if ic ity .
1 .8 .4 . EGFR Autophosphorylation
In intact ce lls , EGF induced autophosphorylation o f  EGFR has been
established in three internal residues, Tyr 1068, Tyr 1148 and Tyr 1173
(Downward et al., 1984). Recently a further site has been proposed by Walton and 
colleagues (1990) that o f  Tyr-992. Due to the m ethodological differences, this 
could also be the site found by Margolis and group (1989a) except that they 
assessed it as being Tyr 1086. In vitro k inetic  studies suggest that s e lf
3 2
phosphorylation is readily reversible and that the phosphotyrosine bond formed
is o f a relatively high energy (Hubler et al ., 1989). The functional significance of 
autophosphorylation is unclear, it is possible that autophosphorylation serves an 
inhibitory function with regard to receptor kinase activity.
1 .8 .5 . M echanisms o f  Kinase Activation (Intra vs Intermolecular)
Two m odels have been proposed to explain how ligand binding to the 
external binding domain can alter the catalytic properties o f the kinase region 
o f the receptor. The "flush chain" model (Staros et al., 1985) requires that ligand 
binding alters the interaction o f  the external domain with the transmembrane 
component resulting in the activation o f  the kinase domain. The second and 
more widely cited is the "cluster" theory (Yarden & Schlessinger, 1985) which
proposes that ligand binding leads to aggregation o f the m onom eric receptor 
species to a least a dimeric form and that this process is intimately involved in 
kinase activity.
1.8.6. Interm olecular A ctivation
Intermolecular activation is by far the m ost popular proposal for EGFR 
kinase activation in terms o f data published. EGF receptors are randomly 
distributed on the cell surface (Haigler et al., 1979; Schlessinger et al., 1978), and 
they undergo rapid lateral (H illm an & Schlessinger, 1982) and rotational 
(Zidovezki et al., 1986) diffusion. Follow ing ligand binding, occupied receptors 
cluster in clathrin coated pits, internalised ligand and receptor are then 
degraded by lysosom al enzymes (Carpenter & Cohen, 1979). In the absence o f  
ligand, receptor half life  is 1 0 - 1 2  hours but 1 hour in the presence o f ligand 
(Stoschek et al., 1985; Honegger et al., 1987). Two reports provide evidence 
suggesting that receptor degradation occurs after several rounds o f  receptor 
recycling (Dunn et al., 1986; Murthy et al., 1986).
According to the allosteric oligomerisation model proposed by Yarden &
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Schlessinger (1987 a,b), monomeric EGF receptors are in equilibrium with the 
oligomeric form. It is postulated that the oligomeric form has a higher affinity 
for the ligand. The binding o f EGF presumably stabilises the oligom eric species, 
leading to the activation o f the kinase function. Such a mechanism bypasses the 
energetically unfavourable conformational change proposed for intramolecular 
a c tiv a tio n .
It is well established that EGF induces oligomerisation on the cell surface in  
vivo m orphologically (Haigler et al ., 1979; Carraway et al., 1989), biophysically  
(Zidovezki et al., 1986) and biochemically (Cochet et al., 1988). Schlessinger & 
Yarden (1987a) demonstrated that EGF influenced dim erisation in purified  
preparations as assessed  by non-denaturing gel electrophoresis. The dimers 
appeared to have a higher kinase activ ity  and ligand binding activity. 
T ran sfection  stu d ies by H onegger et al. (1 9 8 9 ) dem onstrated  cross  
phosphorylation at identical sites in the kinase negative mutant K721 A
(M oolenar et al., 1988) when coexpressed with w ild type EGFR. Polyclonal 
antibodies to EGFR co-im munoprecipitate deletion mutants devoid o f  epitopes 
recognised by the antibodies, when transfected with K721 A or w ild type 
receptor. These results suggest that autophosphorylation o f solubilised EGFR is 
mediated by intermolecular cross-phosphorylation, and this is facilitated at least 
in part by oligomerisation which is not kinase dependent.
1 .8 .7 . Phosphorylation o f Exogenous Substrates
The intrinsic tyrosine kinase activ ity  o f  EGFR has been noted to
phosphorylate various exogenous substrates (table 1 .4 )  either in vivo  or i n  
v i t r o .  Potentially the most interesting o f these substrates are the lipocortins and 
phospholipase C-II. Lipocortins have been reported to inhibit the activity o f
phospholipase A 2  (P L A 2 ) (Pepinsky et al., 1986; Wallner et al., 1986), tyrosine
phosphorylation o f  lipocortins relieves this effect (Hirata, 1984). Studies by
Goldberg et al., (1990) using cells transfected with a mutant tyrosine kinase
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Table 1.4 
Proteins reported to be tyrosine 
phopshorylation substrates for EGFR kinase
Substrate
pp 81 (Ezrin)
pp 34-39 
(Lipocortins)
PP 42
Progesterone Receptor 
Gastrin
Growth Hormone 
Middle T Antigen 
Glycolytic Enzymes 
Myosin light Chain 
Erythrocyte band 3 
erb B-2 protein 
Phospholipase C-ll
in vivo
Hunter & Cooper, 1981 
Gould et al, 1986
Cooper & Hunter, 1981 
Erikson et al, 1981 
Guigni etal, 1985 
Sawyer & Cohen, 1985 
Pepinsky & Sinclair, 1986
Cooper et al, 1982 
Gilmore & Martin, 1983 
Nakamura etal, 1983 
Cooper et al, 1984 
Hunter & Alexander, 1985 
Kohno, 1985
Richter King etal, 1988
Margolis et al, 1989 
Meisenhelder et al, 1989
in vitro
Carpenter et al, 1978 
King etal, 1980
Gosh-Dastidar & Fox, 1983 
Fava & Cohen, 1984 
Cohen & Fava 1985 
Dee et al, 1986
Woo et al, 1984
Baldwin etal, 1983a
Baldwin etal, 1983b
Segawa & Ito, 1983
Rice et al, 1986 
Napier etal, 1987 
Gallis etal, 1983
Shiba etal, 1986
Nishibe etal, 1989 
Meisenhelder et al, 1989
defective receptor, demonstrated that tyrosine kinase activity is essential for 
PL A 2  activation. This scheme would suggest that treatment with EGF can result in 
the release o f  free arachidonate metabolites which have been proposed as being 
important in the mitogenic response (Berk et al., 1985; Pentland & Needleham, 
1986; Murumatsu et al ., 1988). Tyrosine phosphorylation o f  PLC-II has recently 
been observed upon treatment with EGF or PDGF serving to enhance its 
enzymatic activity. It has been postulated that this is the link between the 
phosphatidyl inositol signalling pathway and EGFR (see figure 1 .5 ) .
1 .8 .8 . EGFR Transmodulation
Loss o f  the high affinity binding component has been observed upon 
treatment with phorbol esters or PDGF. This results in a decrease in tyrosine 
kinase activity and a marked increase in the state o f  phosphorylation at serine 
and threonine residues (for a review see Schlessinger, 1988).
W hereas it is estab lish ed  that protein k inase C (PKC) m ediated  
phosphorylation o f EGFR at THR-654 is observable both in vivo and in vitro 
(Iwashita & Fox, 1984; Cochet et al., 1984; Hunter et al., 1984; Davis & Czech, 1985b; 
Downward et al., 1985), the precise mechanism o f modulation is unclear. Site 
directed mutagenic studies by Countaway et al. (1990) suggest that modulation of  
binding is  independent o f the major sites o f  phorbol ester  associated  
phosphorylation, and that THR-654 phoshorylation is required for the inhibition 
o f EGFR autophosphorylation, in accord with earlier studies by Livenh et al., 
(1988).
EGF itse lf also regulates its high affinity component. Ligand binding has 
been noted to result in phosporylation o f THR-654 (King & Cooper, 1986; Whitley 
& Glasser, 1986), which has led to the suggestion that EGFR stimulation o f PKC 
activity is a homologous feedback mechanism o f  receptor activation (Sturani et 
al., 1988). Transmodulation o f EGFR by IGF-I and insulin has been demonstrated 
in PKC depleted swiss 3T3 cells (Corps & Brown, 1988).
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1 .8 .9 . Regulation of the EGF Receptor
In vivo  studies in hypophysectom ised m ice by Janssen and colleagues  
(1988, 1989) and Johansson et al. (1989) have shown increases in EGFR mRNA 
upon growth hormone treatment. In v i t ro , retinoic acid has been noted to
regulate EGFR levels, increasing binding and immunoprecipitatable protein in 
foetal rat lung cells (Oberg et al ., 1988). In contrast, reduction o f  both binding 
and receptor levels was recorded in the human epidermoid carcinoma cell line 
ME 108 (Zheng & Goldsmith, 1990). To add further confusion, Yung et al. (1990) 
have reported that in several human gliom a cell lines tested, retinoic acid 
treatment resulted in the loss o f EGFR phosphotyrosine kinase activity. No loss or 
increase in receptor binding or concentration was noted.
Loss o f  both receptor affinity and concentration upon the addition o f a
interferon in cell culture has been reported in both BHK (Zoon et al., 1986) and 
A431 cells (Black et al., 1988). Palombella and group (1987) have demonstrated 
increases in ligand binding and receptor protein levels upon the introduction of
tumour necrosis factor in human fibroblasts. In addition to retinoic acid, 
dexamethasone has been cited as a negative regulator o f  EGFR mRNA levels in 
human skin fibroblasts (Oikarinin et al., 1989, and in foetal rat lung cells (Oberg 
& Carpenter, 1989).
Experimental evidence points to a role for steroids in the regulation o f EGFR 
in breast cancer in vitro m odels. Koga et al. (1988) show ed that 1,25
D ih y d r o x y -v ita m in  D 3  treatment in T47-D and MCF-7 ce lls  resulted in a 
significant reduction in ligand binding capacity. In contrast studies using the ER 
negative cell line BT-20 displayed increased EGFR levels (Falette et al., 1989; 
Frappart et al., 1989). Much more research is needed to explain the differential
regulation o f EGFR in ER negative and positive cell lines . It should be noted
however that 1,25 Dihydroxy -vitamin D 3  treatment led to growth inhibition in 
the three cell lines studied.
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Progestin regulation o f EGFR has been well documented in T47-D and MCF-7 
cells by Sutherland's group (Murphy et al ., 1985; 1986; Koga et al., 1988; 1989) and 
others (Samp et al., 1988). In essence much o f  their research has shown that 
progestins acting directly or via the glucocortocoid  receptor inhibit ligand
binding and mRNA levels resulting in a reduction o f cell growth. Loss of
binding upon treatment with antineoplastic agents cisplatin and vincristine has 
been shown in MCF-7 cells (Hanauske et al., 1987).
Berthois et al. (1989) have demonstrated that incubation with 17p - oestradiol
leads to an initial decrease in ligand binding (24-48 hours), fo llow ed  by 
increased ligand binding from 3 days onwards, in MCF-7 cells. Addition o f 4-OH 
tam oxifen resulted in the inhibition o f  ligand binding. These data appear to
agree with in vivo  studies in the rat uterine model system  with regard to 
oestrogen action (Mukku & Stancel, 1985; Gardner et al., 1989). However the 
Berthois publication is open to question with regard to its m ethodology. Studies 
within our group (Rinaldi & Leake, unpublished) have demonstrated that the cell 
density required to allow continous exponential growth over the time course in
the culture vessels the authors cited is not viable in our hands. Further, the
authors report double site binding kinetics for MCF-7 cells which contrasts with 
ourselves and others (Hanauske et al., 1987; Kosano et al., 1988 ), who have found 
only single high affinity binding.
1 .8 .1 0 . Receptor Related M olecules
One o f  the main reasons that EGFR has been proposed to play a role in the 
carcinogenic process has been the observations that there ex ists oncogenic  
molecules which display tyrosine kinase activity and are homologous to EGFR to 
some extent. There are several proteins closely related to EGFR . There is an
extremely high sequence homology with the sequence o f  the erb B oncogene of 
the avian erythroblastosis virus (AEV) (Yamamoto et al., 1983). Chromosomal 
mapping studies o f the EGFR (Merlino et al., 1985) and v-erb B (Spurr et al., 1984)
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show that both are located on the same region o f chromosome 7. It has been 
postulated that the gene for EGFR is the proto-oncogene from which viral erb B 
gene was derived. A sequence o f nearly 400 residues in the cytoplasmic domain 
displays 95% hom ology ( Ullrich et al., 1984). The main difference between the 
two is a large truncation o f the EGFR extracellular binding domain in the v-erb B 
m olecule and a small truncation at the carboxyterminus.
A second retrovirus, the avian leukosis virus (ALV) also utilises a protein 
related to EGFR. Unlike AEV there is no oncogene within its genom e, ALV  
activates normal cellular sequences by insertion o f a provirus into the host 
genome. Transcription o f  cellular sequences is under viral promoters. Induction 
o f  lymphomas by ALV involves the activation o f  c-m yc sequences. W hile 
induction o f  erythroblastosis invo lves transcriptional activation o f  c-erb B 
sequences ( Nilsen et al., 1985).
1.8.11. Neu (HER-2) Oncogene
The product o f  this gene is a glycoprotein o f 185 kDa. which displays 50% 
sequence homology to EGFR ( Bargmann et al., 1986). The neu protein cross reacts 
with certain antibodies to EGFR (Fendly et al., 1990) and v-erb B probes hybridise 
with the neu oncogene. The neu protein does not bind to EGF, and it has been 
proposed to be a tyrosine kinase receptor for an as yet undiscovered ligand ( 
Stem et al., 1986, Akiyama et al., 1986). The neu oncogene has been sequenced 
cloned and mapped to chromosome 17 ( Bargmann et al., 1986; Fukushige et al.,
1986). This has allowed the identification o f the corresponding proto-oncogene 
(Yamamoto et al., 1986) designated c-erb B-2. The c-erb B-2 gene has been found 
to be amplified (Slamon et al., 1987; Guerin et al., 1988, 1989, Zeillinger et al., 
1989) and overexpressed (Rio et al., 1987 Guerin et al., 1988, 1989) in about 20% of  
breast carcinomas and may be a marker o f poor patient prognosis.
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1 .8 .1 2 . EGFR role in the Transformation Process
In human m alignancies abnorm alities involving growth factor receptors 
most commonly appear to involve gene am plification and/or overexpression of  
seemingly normal RNAs and proteins (Xu et al., 1984, King et al., 1985a,b; Semba 
et al ., 1985; Liebermann et al., 1985, Fukushige et al., 1986, Yokata et al., 1986, 
Kraus et al., 1987, Slamon et al., 1987). These findings suggest that overexpression 
o f a normal growth factor may provide a selective growth advantage to a cell 
p rogressin g  along the m alignant pathw ay. C ellu lar transform ation  by 
overexpression o f exogenous EGFR in rodent fibroblasts has been shown to result 
in phenotypic transformation (Velu et al., 1987; DiFiore et al., 1987; Riedel et al., 
1988; Haley et al., 1989).
1 .8 .13 . EGFR in Breast Cancer
EGFR has been found in various animal and human tissues (Ozanne et al.,
1985). The presence o f  EGFR in human breast tumours has been reported by
several groups using radiolabelled binding techniques. EGFR appears to be 
present in 33-67% o f breast tumours analysed at a concentration range o f 1-275 
fm oles. m g" 1 membrane protein with a median ranging from 3-40 fm oles. mg ' 1 
membrane protein. As can be seen there is considerable variation in the results 
cited. This is probably due to a number o f factors. Two methods have been used to 
assess EGFR levels; multipoint scatchard analysis (Perez et al., 1984; Sainsbury e t  
al. ,  1985; Nicholson et al., 1988; Fekete et al., 1989; Foekens et al., 1989) or single 
point (Fitzpatrick et al., 1984; Battaglia et al., 1988; Cappelletti et al., 1988; 
Bauknecht et al., 1989; Grimuax et al., 1989). Both methods have their advantages 
and disadvantages. M ultipoint analysis is the more accurate and allow s for
resolution o f the two possible binding components, but requires in excess o f  2 0 0  
mg tumour tissue. Single point only requires approximately 50 m g, therefore
allowing a result to be recorded with a small amount o f tissue. This is important if  
one considers that increased research and early detection has resulted in
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in vestiga tors receiv in g  increasing ly  sm aller tissu e  sam ples for analysis. 
V ariations in resu lts are further com pounded by the absence o f  any 
standardisation o f  tissue processing and heterogeneity o f  material analysed. 
Despite these reservations, in the majority o f  studies carried out EGFR presence 
negatively correlates with that o f ER. Follow  up studies indicate that it may be 
marker o f poor patient prognosis (Nicholson et al ., 1989) and reccurence (Toi e t  
a l , 1990).
EGFR levels as assessed by immunocytochemistry would appear to be an ideal 
method as it uses small amounts o f tissue and allows visual assessment o f receptor 
location within the tumour section. Studies reported are subject to wide 
variations in both the incidence reported (20-60% ) and location o f  receptor.
M oller et al. (1989) reported staining in 20% o f  tumours analysed. Further, the 
majority o f staining was present in the myoepithelium and in some cases in the
fibroblasts. This contrasts with the findings o f  Battaglia et a l  (1988) who 
reported staining in the majority o f tumour cells. Studies by Wrba et al. (1988) 
and Toi et al. (1989) have shown staining in 60% and 34% respectively. Both 
noted a negative correlation with respect to ER status, but were unable to agree 
on other prognostic markers. In contrast to Toi, Wrba reported no correlation 
with nodal involvem ent. Using a novel autoradiographic technique Reubi et al.
(1988) although finding EGFR in 29% o f cases, reported that the majority o f
staining was present in the tumour ce lls . Further studies have revealed a 
negative correlation with ER status ( Reubi et al ., 1989). But it must be noted that 
i f  either recepor concentration or affinity is important in determ ining patient 
prognosis, these latter methods would prove inadequate.
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2. M a te r ia l s
2 .1  Suppliers
Amersham International; pic, Amersham, U.K.
BDH/Gurr Chemicals Ltd., c/o MacFarlane Robson Ltd., Glasgow, U.K.
Biogenesis Ltd, Bournemouth, U.K.
Biorad Laboratories, Watford, U.K.
Boehringer Mannheim GmbH, c/o BCL, Lewes, U.K.
BRL-Gibco, Paisley, U.K.
Calbiochem, c/o Novabiochem, Nottingham, U.K.
Du-Pont (U.K.) Ltd., Stevenage, U.K.
Falcon, c/o A. & J. Beveridge Ltd., Edinburgh, U.K.
Flow Labs, Rickmansworth, U.K.
FSA Lab Supplies, Loughborough, U.K.
Kodak Ltd., Manchester, U.K.
May & Baker, Ltd., Dagenham, U.K.
Millipore (U.K.) Ltd., Harrow, U.K.
Northumbria Biologicals Ltd., Cranlington, U.K.
Nunc, c/o BRL-Gibco, Paisley, U.K.
Sarstedt Ltd., Leicester, U.K.
Scottish Antibody Production Unit (SAPU), Law Hospital, Carluke, U.K.
Sigma Chemical Co. Ltd., Poole, U.K.
Sterilin Ltd., Hounslow, U.K.
Whatman, c/o R. & J. Wood, Paisley, U.K.
2 .2 .1  Cell Growth Medium
Dulbecco's modification o f Eagle's medium (DMEM) was originally 
supplied as a 10X concentrate by Gibco and diluted to a final concentration of IX  
with sterile deionised distilled water. To eliminate the action o f phenol red within 
the experimental system this was replaced by phenol red free DMEM powder
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obtained from sigma.
The powder was reconstituted as per manufacturer's instructions to a final 
concentration o f IX. Methionine free DMEM was also supplied from the same 
so u rce .
2 .2 .2  Supplements to Cell Growth Medium
L-Glutamine (200 mM), and Penicillin (10 000 U.mT1) /
Streptomycin (10 000 jig.ml'1 ) were obtained from Gibco. Foetal calf serum 
supplies alternated between Gibco and NBL.
2 .2 .3  Cell Culture Materials 
Biofreeze Vials, Costar
Lab Tek 8  well glass slide/tissue culture vessels, Flow Labs
25, 80, 175 cm2  T/C flasks, Bibby
850 cm 2  plastic tissue culture roller bottles, Bibby
24 well FB plates, Coming
2 .2 .4  Fine Chemicals
All chemicals used were o f  analar grade:
Bacitracin, Sigma
Bovine Serum Albumin, Sigma
Calf Thymus DNA, Sigma
Charcoal (Norit A Activated), Sigma
Cycloheximide, Sigma
Dextran, Sigma
Dimethylsulphoxide, May & Baker
Dithiothreitol, Sigma
Dowex 1X8, 200-400 mesh, Sigma
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EDTA, Fisons 
HEPES, Fisons 
Hydroxyappatite, Biorad 
Soya Bean Inhibitor, Sigma
2.2.4.1 Electrophoresis/Transblotting Fine Chemicals 
Acrylamide, FSA Lab Supplies
Bisacrylamide, FSA Lab Supplies 
Glycine, FSA Lab Supplies 
Hybond N, Amersham 
Mercaptoethanol, BDH  
Standard Proteins, Boehringer 
SDS, FSA Lab Supplies 
TEMED, BDH
2 .2 .4 .2  Enzymes 
RNAase A, Sigma 
Trypsin, Gibco
2.2.4.3 D e terg en ts  
Nonidet P-40, BDH  
Triton X-100, Sigma 
Tween 20, Sigma
2.2.4.4 Hormones/Growth Factors 
Murine Epidermal Growth Factor, Biogenesis 
Insulin, Sigma
Human Prolactin, Sigma
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Ovine Prolactin, Sigma 
Oestradiol, Sigma
2.2.4.5 S ta in s
Amido Black, Gurr
Bromophenol Blue, BDH
Hoechst 33258 (Bisbenzim ide), Sigma
2 .2 .4 .6  Radiochemicals
[ 1 2 ^I] - Epidermal Growth Factor, NEN
[35s] - Methionine, Amersham
[ 1 2 ^I] - Human Prolactin, NEN
[125l] - Protein A, Amersham
[^H] - Oestradiol, Amersham
(specific activity: 100-180 pCi. m g'1) 
(specific activity: 1200 Ci. m m ole'1) 
(specific activity: 20 - 50 pci. mg"1) 
(specific activity: 77 pCi. pg"1) 
(specific activity: 48.5 Ci. mmole"1)
2 .2 .4 .7  Antibodies/Sundries
Rabbit polyclonal Antibody BG 48, Bill Gullick, ICRF
EGFR I mouse monoclonal, Amersham
Flourecsent Labelled goat antimouse IgG, Derek Chalmers, Biochem, G.U. 
Sheep serum, SAPU 
P a n so r b in ™ , Calbiochem
2 .2 .5  M iscellaneous
Ecoscint, Biochem Store
DPX Mountant, PBS Glycerol Mountant, Gurr
RT-30 Tubes, Sterilin
Kodak X-Omat S, KodakHyperfilm, Amersham
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Chapter 3. Methods
To facilitate ease o f  access when referring to the results section, it was 
decided to subdivide this methodology chapter into three major sections.
3 .1  Clinical Research
3 .2  Nuclear Localisation Studies
3 .3  Cell Culture Studies
3 .1  Clinical Research
3 .1 .1  Buffers 
Sucrose/ Glycerol Buffer:
0.25M  Sucrose; 1.5mM Magnesium Chloride; lOmM HEPES, pH 7.4 in 50% (v/v) 
G lycero l
Sucrose Buffer:
0.25M Sucrose; 1.5mM Magnesium Chloride; lOmM HEPES, pH 7.4  
HED Buffer:
20mM Hepes; 1.5 mM EDTA, 0.25mM Dithiothreitol, pH 7.4  
Dextran Coated Charcoal:
20 mM HEPES; 1.5 mM EDTA; 0.5% ( w/v) Charcoal; 0.005% (w/v) Dextran T-70, 
pH 7.4
EGFR Assay Buffer:
lOmM HEPES, 50mM Sodium Chloride, 0.1% (w/v) BSA, pH 7.0
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Buffer A:
2mM Potassium dihydrogen orthophosphate; 2mM Sodium dihydrogen
orthophosphate; 0.154 M Sodium Chloride, 0.007% (w/v) Bacitracin, pH 7.4
Buffer B:
2mM Potassium dihydrogen orthophosphate; 2mM Sodium dihydrogen
orthophosphate; 0 .154 M Sodium Chloride, 0.007% (w/v) Bacitracin 0.1% (w/v) 
BSA, pH 7.4
3.1.2 Tumour collection and storage.
Freshly co llected  breast tumour tissue was stored in Sucrose/G lycerol 
buffer at -20°C prior to receptor assays. Receptor assays ( full scatchard analysis 
for ER and single point screen for EGFR) were carried out within 10 days o f
sample collection . Oestrogen receptor content o f  tumour tissue is stable under
these conditions for at least six months (Crawford et al ,% 1985). Storage o f  breast
tumour receptor positive control tissue under identical conditions reveal that 
EGFR content was stable for at least one month (Porteus, 1987).
3.1.3 T issue Preparation
Tissue preparation was carried out using a m odification o f  the method of  
Leake & Habib (1987). Stored tissue was rehydrated for 15 mins at 4°C in Sucrose 
Buffer. Any obvious fat and necrotic tissue was removed. A section o f  approx.
150-200 mg o f  tissue was hom ogenised in freshly made HED buffer at a
concentration o f 50 mg. ml”1. This involved initial 2 x 10 secs bursts at a setting o f  
150 on an Ultra Turrax hom ogeniser (M odel TP 18/2) fo llow ed  by gentle
homogenisation using a glass/glass tissue grinder (Kontes Duall Size 21) to ensure
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an even suspension. T issue was kept below  8 °C throughout. The resulting 
homogenate was centrifuged for 10 mins at 800 g, 4°C. The crude nuclear pellet 
obtained was resuspended in 3 ml HED buffer and retained for oestrogen receptor 
and DNA estimation. The supernatant was further centrifuged 50,000g for 30 mins, 
4°C.
The resulting supernatant (cytosol) was retained for oestrogen receptor 
and protein estimation. The pellet (membrane fraction) was resuspended in 1 ml 
EGFR assay buffer, and a single point EGFR screen carried out. To ensure 
minimum receptor degradation, it should be noted that all manipulations were 
carried out on ice.
3 .1 .4  Oestrogen Receptor Assay
Cytosol and nuclear oestrogen receptor levels were measured by the 
method o f Leake et al  (1981b). Three series o f ten RT-30 tubes were set up. Tubes 
1-7 received a final concentration range o f 8 , 12, 20, 30, 60, 80 and 120 x 10"
[3 H] - E2  in a volume of 50 pi. Tubes 8-10 received 60, 80, 120 X 10"10M [3 H] - E2  plus 
a 100 - fold excess o f Diethylstilboestrol in a volume o f 50 pi. Series 1 received 150 
p i cytosol, series 2 150 p i nuclear suspension and series 3 150 p i o f buffer (to give
blanks and totals). The final concentration range o f [3 H] - E2  was 2 - 30 X 10'1 0 M .
The tubes were then capped with nescofilm  and incubated overnight (18 hours) at 
4°C.
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3 .1 .4 .1  Cytosol Oestrogen Receptor Assay
Separation o f bound ligand from free ligand was achieved by transferring
the cytosol tubes to an ice bath. There then followed the addition o f 200 p i of
dextran coated charcoal to each tube, incubating on ice for 15 mins at 4°C,
vortexing every 5 mins. The tubes were then centrifuged for 5 mins at lOOOg, 
4°C, 200 p i aliquots o f the supernatant were transferred to scintillation vials to 
which 4 ml o f  ecoscint was added. The scintillation vials were then counted on a 
LKB 1209 rackbeta scintillation counter at a rate o f  3 mins per vial, counting
efficiency  40%.
3 .1 .4 .2  Nuclear Oestrogen Receptor Assay
100 p i aliquots o f nuclear suspension were added to 5 ml portions o f 0.9% 
(v/v) saline immediately prior to pouring onto a pre-wetted filter disc (2.5 cm. 
dia.) held in a m illipore filtration apparatus. The tube which had contained the
saline was washed with a further 5 ml o f  saline and this also poured into the
f u n n e l .
The chimney o f the apparatus was rinsed with 5 ml saline and the filter
rinsed with a final 5 ml. The filter was then dried before transferring to a 
scintillation vial. 4 ml o f ecoscint was added to each vial, and the vials allowed to 
stand for 5 hours at room temperature. Vial radioactivity was assessed by the
method o f  3.1.4.1 at a counting efficiency o f 40%.
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3 .1 .4 .3  Analysis of Data
Scatchard analysis (Scatchard, 1949) o f  ligand binding assay data derived 
was carried out using a BBC microcomputer programmed as described by Leake e t  
al. (1987b).
3.1.5 Protein Estimation
Determination o f tumour cytosolic  fraction protein content was by the
method o f Lowry (1951). The standard curve range used was 0 - 0.7 mg. ml" 1
Bovine Serum Albumin (BSA).
3.1 .6  DNA Estimation
Determination o f  tumour nuclear fraction was by the method o f Burton as
m odified by Katzenellenbogen and Leake (1974), extraction efficiency o f  DNA by 
this method was estimated as 95%. The standard curve range used was 0 - 350 p g . 
m l ' 1 Calf Thymus DNA.
3.1.7 EGF Receptor Assays
Initially all tumour membrane preparations were screened by a single
point assay (3 .1 .7 .1 ) . The remaining sample was stored at -70°C until the result of 
the single point screen was known. Full multipoint analysis (3 .1 .7 .2 )  was carried 
out within a month if  the screen resulted in a value for EGFR o f  greater than 10 
fm oles. m l" 1 o f  membrane fraction. EGFR was assumed be stable with respect to
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concentration and affin ity over this tim e period. Studies using placental
membranes prepared and stored under identical conditions show no losses in
receptor concentration (see fig. 3 .1 )  or affinity (see fig. 3 .2 )  even after 6  months
storage at -70°C.
3 .1 .7 .1  Single Point Screening Assay
This assay was performed in duplicate. To eppendorf polytubes (precoated 
with 0.1% BSA (v/v) in PBS) 50 p i o f tumour membrane preparation was added. To 
one set o f duplicate polytubes 50 p i o f [1 2 ^I] - EGF ( specific activity: 100-180 p C i. 
p g " 1) at a final concentration o f 1 nM in EGFR assay buffer was added. Non 
specific binding was assessed by incubation o f  a further set o f  polytubes with 
[ 1 2 ^I] - EGF at the same final concentration but with a 100 - fold excess of
unlabelled EGF.
Assay incubation was carried out at room temperature (21°C) for 1 hour. 
The binding reaction was terminated by plunging the tubes into an ice bath . 
Immediate addition o f  1 ml ice cold EGFR assay buffer was fo llow ed  by 
centrifugation at 20 000 g for 15 mins at 4°C. After centrifugation the supernatant 
was aspirated and discarded into radioactive waste. The pellet was resuspended in 
100 p i o f 5N sodium hydroxide and transferred to gamma counting tubes.
The tubes were then counted for 60 secs per vial using an LKB 1275 minigamma 
counter. Total binding varied between 1 % and 15% o f  the total counts added, 
non-specific between 0.5% and 3% o f  the total counts. Specific  binding was 
estimated by subtracting non-specific counts from the total bound counts.
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Figure 3.1
Stability of EGFR binding in Placental Membrane preparations
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Stability of EGFR binding in placental membrane preparations 
stored at -70°C over a six months period. Note that no loss 
in either binding component can be observed. Full multipoint 
analysis of breast tumour membranes was carried out within 
one month of single point screen. Assessment of EGFR levels 
was carried out by the method outlined in section 3.1.7.2.
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Figure 3.2
Stability of EGFR affinity in Placental membrane preparations
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Stability of EGFR affinity in placental membrane preparations 
stored at -70°C over a  six months period. Note that no loss 
in either affinity component can be observed. Full multipoint 
analysis of breast tumour membranes was carried out within 
one month of single point screen. Assessment of EGFR affinity 
was carried out by the method outlined in section 3.1.7.2.
3 .1 .7 .2  Multipoint Analysis ( "In house Assay ")
M ultipoint A nalysis was carried out with tw elve points o f  increasing 
concentrations o f 50 p i o f [1 2 ^I] - EGF at the final concentration o f 0.086, 0.208,
0.416, 0.616, 1.67, 5.0, 8.334, 13.34, 15.0, 16.7 nM. Non specific binding was
ascertained by incubating three aliquots containing in addition to the top three 
labelled concentrations a 100 - fold excess o f  unlabelled EGF. Assay incubation, 
separation, and counting conditions were as for 3 .1 .7 .1 .
3 .1 .7 .3  Calculation of Results
All calculations were according to Scatchard (1949). The calculations were 
performed manually, the plot coordinates were resolved on an apple M acintosh 
Plus computer using the MacGraph program.
3.1.7.4 EORTC EGF Receptor Assay
This assay was devised by Benraad & Foekens (1989) and has since recently 
been revised ( Benraad & Foekens, 1990).
To a series o f RT-30 tubes, increasing amounts o f [1 2 5 I] - EGF (10 p i in 
buffer B) at the following final concentrations 0.15, 0.4, 0.7, 0.8, 1.0, 1.4, 2.75,
3.3, 5.5 nM was added along with 30 p i o f buffer B. Determination o f  non-specific
binding was assessed  by adding to three tubes 1 0  p i  o f  the top three 
concentrations o f label with 20 pi o f 5 x 10'^M unlabelled EGF and 10 p i o f buffer 
B. 100 p i o f sample membrane preparation was added to each tube. The tubes were 
then vortexed and incubated for 1 hour at room temperature.
Separation o f bound from free ligand was achieved by the addition o f  100 pi
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o f  hydroxyapatite (HAP) slurry (2:1 v/v in buffer A), incubation for 30 mins at 
4°C, followed by centrifugation at 1000 g for 2 mins at 4°C. The supernatant was 
aspirated and the HAP pellet was washed twice with 1 ml aliquots o f buffer A. 
Follow ing the final wash the pellets were counted using an nuclear enterprise 
(NE 1612) turbo gamma counter. Adsorption o f  labelled EGF to the hydroxyapatite 
slurry in the absence o f  membrane sample was estimated as 0.3% ± 0.12% o f the 
total counts added. Because this adsorption factor was constant, it was not taken 
into account in the final calculations o f specific binding.
3 .1 .7 .4 .1  Calculation of Results
Results were calculated manually according to the method o f  Chamness & 
MacGuire (1978). Data coordinates were resolved as described in section 3 .1 .7 .3 .
3.2 Nuclear Localisation Studies
3 .2 .1  Buffers
HE/Triton Buffer:
20 mM HEPES; 1.5 mM EDTA; 1% (v/v) Triton X-100; pH 7.4 
Laemmli Sample Buffer:
0.0625 M Tris-HCL (pH 6 .8 ); 10% (v/v) (w/v) sucrose; 5% (v/v) p -m ercaptoethanol; 
2% (w/v) SDS; 0.002% (v/v) bromophenol blue. Dispensed into suitable aliquots 
and stored -20°C until required.
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Stacking Buffer:
0.125 M Tris-HCL (pH 6 .8 ); 0.4% (w/v) SDS 
R esolving Buffer:
0.375 M Tris-HCL (pH 8 .8 ); 0.4% (w/v) SDS 
Acrylamide Stock:
30% (w /v) Acrylamide; 0.8% (w/v) N ’N'-methylene bis-acrylam ide 
P ersu lp h a te :
1.5% (w/v) ammonium persulphate, made fresh on the day.
Electrode Buffer Stock ( 10 x):
0.25 M Tris; 1.92 M Glycine; 0.1% (w/v) SDS
Transblot Electrode Buffer:
25 mM Tris; 0.192 M Glycine; 0.01% (w/v) SDS; 20% (v/v) Methanol.
TBST:
10 mM Tris-HCL pH 8.2, 150 mM Sodium Chloride, 0.05% (v/v) Tween 20
All solutions once prepared could be stored for a maximum o f 4 weeks at 4°C unless 
otherw ise stated.
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3 .2 .2  Preparation of Tissue
The methodology for initial tissue preparation is described in section 3 .1 .3  
with the fo llow ing changes incorporated in the preparation o f  the membrane 
fraction. Buffer B at the same volume as before replaced EGFR assay buffer. The 
nuclear fraction was resuspended in 3 ml HE/Triton buffer and centrifuged at 
3000 g for 10 mins at 4°C. The supernatant was discarded and the pellet washed a 
furter two tim es by this method. F inally the "washed" nuclear pellet was 
resuspended in 2 ml buffer B.
3 .2 .3  Salt Extraction of Nuclear Fraction
Aliquots (1ml) o f the "washed" nuclear fraction were salt extracted with 2M 
sodium chloride for 30 mins on ice by the addition o f  an equal volum e of 4M  
sodium chloride. Follow ing incubation the suspension was centrifuged at 3000 g 
for 10 mins at 4°C and the resulting pellet resuspended in buffer B (1ml).
3 .2 .4  Scatchard Analysis
Scatchard Analysis o f the fraction quoted in results section 4 .2  was by the 
EORTC method (Section 3 .1 .7 .4 ).
3.2 .5  SDS/Polyacrylamide Gel Electrophoresis
The m ethodology involved  in SD S/P olyacrylam ide gel electrophoresis  
(SD S/PA G E ) is essen tia lly  the d iscontinuous T ris/G lycine buffered  system  
described by Laemmli (1970)!
3 .2 .6  Preparations of Samples for Electrophoresis
Samples for analysis were mixed 1:1 (v/v) with Leammli sample buffer and 
boiled for 3 - 5  mins before electrophoresis.
3 .2 .7  Gel Preparation
For analytical purposes, gels were cast using a home made apparatus in 
slabs 19 cm x 9. 5 cm x 0.15 mm. Gels were prepared as follows:-
7.5% Slab Gel
Constituent Stacking Gel (ml) Resolving Gel (ml)
Distilled H2 0  11.5 23.0
Buffer 5.0 5.0
Acrylamide Stock 2.5 10.0
Persulphate 1.0 2.0
TEMED 0.02 0.03
F ollow ing the addition o f  TEMED the resolving gel was poured, and
propan-2 -ol added to ensure an even surface during the setting o f  the gel.
Propan-2-ol was then discarded and traces were removed by washing 3 or 4 times 
with distilled water. The top o f the resolving gel was dried with filter paper and 
the stacking gel added.
3.2.8 Electrophoretic Conditions
SDS/PAGE was performed at a constant current o f 40 ma - 60 ma per gel until
the bromophenol blue tracker dye was 0.5 cm from the bottom o f  the gel. The
electrode buffer was a dilution o f the 10 x stock described in 3 .2 .1 .
3.2 .9  Coomassie Blue Staining
Where appropriate the gels were stained for protein in 0.1% (v/v) coomassie 
brilliant blue R250, 50% (v/v) methanol and 10% (v/v) acetic acid for 1 hour at 
room temperature. Destaining o f the gels was accomplished by washing the gels 
several times in a 1 0 % (v/v) methanol and 1 0 % (v/v) acetic acid solution.
3.2 .10  Determination of Mr by SDS/PAGE
The Mr values o f polypeptides resolved by SDS/PAGE was determined by
calibrating with a set o f  standard proteins.
These proteins include:- 
Trypsin Inhibitor M.W. 20 100 
Lactate Dehydrogenase M.W. 36 500 
Glutamate Dehydrogenase M.W. 55 400 
Phosphorylase b M.W. 97 400 
a 2 -Macroglobulin M.W. 170 000
Relative Mobility was calculated as the ratio
Distance migrated by the protein
R f = -----------------------------------------------------------------------------for each protein
Distance migrated by the tracking dye
A plot o f Rf against log ( Mr ) o f  the standards yielded a curved line that was used 
for calibration. Standards and samples were analysed on the same gel.
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3 .2 .1 1  W estern/Immunoblotting/Immune Replica A nalysis
The immunoblotting procedure was em ployed to permit the immunological 
detection o f  polypeptides after their electrophoretic transfer onto nitrocellulose 
paper (Towbin et al., 1979; Batteiger et al., 1982).
Polypeptides were resolved by SDS/PAGE (Section 3 .2 .5 )  and transferred 
electrophoretically onto nitrocellulose paper (Hybond N) at 400 ma for 3 hours or 
40 ma for 16-20 hours using a Bio-rad Trans-B lot™  cell. Blotting methodology was 
according to Ong et al. (1990) using the polyclonal antibody BG 48 raised against
the synthetic peptide 2E, residues 985-996 ( Kris et al., 1985).
F o llow in g  transfer to n itrocellu lose the b lots were b locked in TBST  
containing 2% (w/v) non-fat dried milk for one hour at room temperature ( 21 °C). 
The blot was then washed five times with TBST for a total o f one hour. Polyclonal 
antibody BG 48 at a dilution o f 1:200 in TBST was added for 16 hours at 4°G. The blot 
was then washed five times as before. [125j] - Protein A at concentration o f 0.1 p C i. 
m l - 1  was added in TBST, incubation was allowed to proceed for one hour at room 
temperature. Rem oval o f  unbound radiolabel was achieved by a further five  
washes in TBST. Finally the blots were air dried and exposed for one week to 
Kodak x-omat S film with intensifying screens at -70°C.
To identify the quality o f  transfer and to compare the m olecular weight
standards the blot was stained for 5 mins with 0.1% (w/v) Amido Black dissolved in
45% (v/v) methanol, 10% (v/v) acetic acid followed by destaining with 90% (v/v) 
methanol/2% (v/v) acetic acid (Schaffner & W eissmann, 1973).
3 .2 .1 2  5' Nucleotidase Assay
The activity o f 5' nucleotidase in each fraction was estimated by the method 
o f Lowry & Lopez (1946). The relative activity o f each fraction assayed in
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triplicate, was quoted as the value obtained at OD^Qnm against a standard curve 
range o f 0 - 25 pg KH2 P O 4  (anhydrous) per milligram o f  fraction protein.
3 .2 .1 3  Alkaline Phosphatase Assay
Alkaline phoshatase activity was estimated by the method of Engstrom (1961). 
relative activity was assessed by triplicate estimation o f  the OD6 oonm Per 
fraction protein. No standard curve range was used.
3.3 Cell Culture Studies
3.3.1 Buffers & Serum Preparation
D ialysed Heat Inactivated Dextran Coated Charcoal Stripped Serum (dialysed  
HIDCCFCS)
100 ml o f FCS was dialysed against four 1 litre changes o f  Hank's modified 
buffer over 48 hours at 4°C. Following dialysis the serum was transferred to a 
glass container and heat inactivated for 45 mins at 56°C. The serum was then 
cooled  to 4°C and added to a pellet o f  dextran coated charcoal (0.25%  
C harcoal(w /v), 0.0025%  Dextran (w /v) in 25 ml PB S-A  w hich had been  
centrifuged and the supernatant removed). This solution was allowed to stir at 4°C  
for 30 mins before centrifuging at 10 000 g for 30 mins at 4°C. The supernatant 
was filter sterilised through 0 . 2  micron filters.
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Dulbecco's Phosphate Buffered Saline (PBS-A)
170 mM Sodium Chloride; 3.4 mM Potassium Chloride; 10 mM Di-Sodium hydrogen 
orthophosphate, 2 mM Potassium dihydrogen orthophosphate, pH 7.2.
V e r se n e
125 mM Sodium Chloride; 2.7 mM Potassium Chloride; 6.3 mM Di-Sodium hydrogen 
orthophosphate; 3.2 mM Potassium dihydrogen orthophosphate; 0.5 mM EDTA.
T r y p s in /V e r s e n e
40 ml Versene : 10 ml 0.25% (w/v) Trypsin Solution 
ETN Buffer
10 mM EDTA; 10 mM Tris-HCL; 100 mM Sodium Chloride, pH 7.0 
Phosphate Buffered Saline (PBS)
170 mM Sodium Chloride; 10 mM Di-Sodium hydrogen orthophosphate;
2 mM Potassium dihydrogen orthophosphate, pH 7.2
Tris Buffer
50 mM Sodium Chloride; 10 mM Tris-HCL, pH 7.3 
NP-40 Solution
0.5% (v/v) NP-40 in Tris Buffer 
Hank’s M odified Buffer
Calcium Chloride 1.3 mM; Potassium Chloride 5.4 mM; Magnesium Chloride 0.5 mM, 
M agnesium  Sulphate 0.5 mM, Sodium Chloride 137 mM, Sodium  hydrogen  
carbonate 4  mM, Sodium dihydrogen orthophosphate 0.4 mM, pH 7.2 - 7.4
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Hank's/BS A /G lucose (HBG)
Hank's modified buffer 100 ml; 2% (w/v) BSA; 10 mM Glucose 
HBG/LiCl
HBG 20 ml; 800 pi o f 250 mM LiCl
3.3 .2  ZR-75-1 Cell Line
All results cited in section 4 .3  were from studies using the ZR-75-1 oestrogen 
dependent breast cancer cell model (Engel et al., 1978). This cell line was derived 
from the malignant ascitic effusion o f a metastatic breast tumour.
3.3.3 Routine Cell Culture
ZR-75-1 cells were routinely grown at 37°C in a 5% CO2  atm osphere. A ll
aseptic manipulations were performed within the confines o f  a laminar air flow  
cabinet (Flow Labs).
Initia lly  routine subculture was performed using D ulbecco's m odification  o f  
Eagle's medium (DMEM) supplemented with 10% (v/v) foetal ca lf serum (FCS), 
HEPES, pH 7.3 (10 mM ), Insulin (5 p g . m l- 1 ), p e n ic illin  (1 0 0 0  iu.
m l- ^/streptom ycin (100 pg. ml-1) and Glutamine (2 mM). Cell doubling time of
ZR-75-1 cells in culture when grown routinely was estimated as 14 hours by the
Hoechst DNA method, and 15.7 hours by trypan blue exclusion. Cell medium was 
changed every two to three days. The majority o f routine subculture was carried 
out using phenol red free DMEM supplied as a powder, reconstituted as per 
m anufacturers in structions. Supplem entation  was as ab ove, h ow ever  no 
glutamine was required. Stocks o f cells were grown routinely in 175 cm 2  p la s tic
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tissue culture flasks seeded at a concentration density o f 4 x 10^ cells per flask in 
40 ml DMEM + 10% (v/v) FCS. For the large scale imm unoprecipitation
experim ents (section  4 .3 .7 .1 )  850 cm 2  plastic tissue culture roller bottles were 
used, seeded at a density o f 2 x 107  cells per bottle in 100 ml DMEM + 10% (v/v) FCS. 
Most experiments used 175 cm 2  flasks or 24 well F.B. plates seeded at a cell density 
o f 11-15 x 104  cells per well. Cells were subcultured by washing twice with sterile 
PBS-A followed by the addition o f trypsin/versene. Incubation at 37°C was allowed 
to proceed until detachment from the substrate layer was observed. The required
concentration o f medium was added and the suspension thoroughly resuspended.
The cells were then seeded as described above.
3 .3 .3 .1  Mycoplasma Screening
ZR-75-1 cells were tested for contamination every 2 - 3  months. Cells were 
grown in glass slide/tissue culture vessels for 48 hours. The medium was aspirated 
and the wells washed with three changes o f PBS-A.
Fixation was achieved by the addition o f  acetone:methanol (1:1) cooled to 
-20°C for 4 - 5  minutes. After air drying, the cells were stained with Hoechst
33258 stain (100 ng. ml"1) for 10 mins at room temperature. The slides were then
washed in three changes o f PBS-A and mounted in a PBS/Glycerol mountant. The 
ce lls  were exam ined under a fluorescent m icroscope for v isu al ev idence o f  
infection. If infection was observed, all viable cell stocks were destroyed. The cell 
culture unit was thoroughly cleaned by successive treatments with Hypochlorite, 
Savlon and 70% (v/v) ethanol. New cell stocks were then ordered from the 
European animal cell culture collection.
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3 .3 .3 .2  Preparation of Frozen Cell Stocks
Frozen stocks o f  ZR-75-1 cells were prepared as follows:
Cells were grown in 175 cm2  flasks in DMEM + 10% (v/v) FCS until they were 80 - 
90% confluent. C ells were harvested in trypsin/versene, then recovered by 
centrifugation at 1000 g for 5 mins at 4°C and resuspended in 1 ml 90% FCS (v/v) + 
10% (v/v) DMSO per flask. 1.5 ml aliquots were transferred to biofreeze vials. Cells 
were frozen in two stages, an overnight incubation at -70°C followed by long term 
storage at -170 °C under liquid nitrogen.
3 .3 .3 .3  Recovery of Frozen Cells
Cells were recovered from the -170°C freezer, thawed rapidly to 37°C in a 
water bath and transferred to a Sterilin vial containing 10 ml o f  prewarmed 
medium (DMEM + 10% (v/v) FCS). The vial was then centrifuged at 1000 g for 5 
mins at 4°C and the supernatant discarded. The pellet was resuspended in 5 ml of  
medium which was transferred to a 25 cm 2  flask containing 10 ml o f medium.
3 .3 .4  Experimental M ethodology
3 .3 .4 .1  DNA Synthesis Experiments
Cells were plated down overnight in DMEM + 10% (v/v) FCS in 24 w ell F.B. 
plates. This medium was removed and the cells washed with two changes o f sterile
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PBS-A (1 ml). Experimental medium DMEM + 5% (v/v) D ialysed HIDCCFCS ± 
hormones/growth factor were added to a final volume o f 0.5 ml per well.
At appropriate incubation times, w ells were harvested by the removal of the 
medium, washing twice PBS-A (1 ml). To each well 100 jil aliquots 0.2% (w/v) SDS 
in ETN buffer was added. Samples were solubilised by incubation at 37°C for 30 
minutes. Solubilised samples were transferred to RT-30 tubes and stored at -20°C  
until the day o f DNA assay.
3 .3 .4 .2  Hoechst DNA Assay
The assay methodology is essentially that described by Leake & Habib (1987). 
To each tube 2.4 ml o f ETN buffer containing Hoechst 33258 (100 ng. m l-1 ) and 
RNAase (5 pg. m l'1) was added. The tubes were then vortexed and incubated at 37°C 
for 15 mins in the dark. Fluorescent enhancement at 450 nm was measured using 
a Hitachi-Perkin Elmer MPE-2A fluorescent set at an excitation wavelength o f 360 
nm with both slit widths set at 5 nm. The results obtained were compared to a 
standard curve range o f calf thymus DNA o f 0 - 5 0  pg. ml"1.
3 .3 .4 .3  Total Membrane EGF Receptor Assays
Cells were plated down overnight in DMEM + 10% (v/v) FCS in 175 cm 2  tissu e
culture flasks. This medium was removed and the cells washed with two changes
o f sterile PBS-A (10 ml). Experimental medium DMEM + 5% (v/v) Dialysed HIDCCFCS 
± hormones/growth factor were added to a final volume o f 20 ml per flask. At 
appropriate incubation times flasks were harvested by using a rubber policem an
to resuspend the cells into the medium o f  the flask. The suspension was then
decanted into centrifuge tubes and centrifuged at 1000 g for 5 mins at 4°C. The
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supernatant was discarded and the pellets washed twice with 1 ml ice cold PBS-A. 
The pellet was finally resuspended in 0.5 ml EGFR assay buffer (see section 3 .1 .2 ) . 
100  pi was retained for DNA estimation (see section 3 .3 .4 .2) and the remaining 
suspension assayed for EGF receptor content (see section 3 .3 .4 .3 ) .
3 .3 .4 .4  Preparation of Samples for Hoeschst DNA Assay
100 p i aliquots o f cell suspension were centrifuged at 1000 g for 5 mins at 4°C. 
The supernatant was discarded and 100 p i o f 0.2% ( w/v) SDS in ETN buffer added. 
The pellet was solubilised at 37°C for 30 mins. DNA estimation was by the hoechst 
method (see section 3 .3 .4 .2 ) .
3 .3 .4 .5  Total Membrane EGF Receptor Assay Methodology
The remaining cell suspension from section 3 .3 .4 .3  was sonicated for 5 secs 
on ice using a Dawe 7532 A sonicator at a setting o f 5. The sonicated cells were 
transferred to eppendorf vials and centrifuged for 10 mins at 15 000 g at 4°C. The 
supernatant was discarded and the pellet resuspended in 0.4 ml o f  EGF assay
buffer. Duplicate 100 pi aliquots were added to equal volumes o f [ 1 2 5 I] - EGF in EGF
assay buffer at a final concentration o f  ln g  (c.p.m. 200,000). To determine the 
non-specific binding, duplicate 100 p i aliquots were added to ln g  [ 1 2 5 I] - EGF 
containing a 100 - fold excess o f unlabelled EGF. This resulting labelled ligand 
suspension was incubated for 1 hour at room temperature. B inding was 
terminated by the addition o f  1.0 ml ice cold EGF assay buffer follow ed by
immediate centrifugation at 10 000 g for 15 mins at 4°C. The supernatant was
aspirated and the pellet solubilised in 100 p i o f 5N NaOH which was transferred to 
gamma counting tubes and counted. All calculations were as in section 3 .1 .7 .1  
final values were quoted as EGFR concentration, mg - 1  DNA.
3 .3 .4 .6  Cell Surface Binding Experiments
Cells were plated down overnight in DMEM + 10% (v/v) FCS in 24 well F.B. 
plates. This medium was removed and the cells washed with two changes o f sterile 
PBS-A (1 ml). Experimental medium DMEM + 5% (v/v) Dialysed HIDCCFCS ± 
hormones/growth factor was added at a final volume o f 0.5 ml per well. Following 
incubation, the plates assayed for EGFR by the whole cell binding assay technique 
(see 3 .3 .4 .7 . )
3.3 .4 .7  Whole Cell EGF Receptor Binding Assay
The medium o f  each well was removed and the cells washed twice with 1 ml 
ice cold PBS-A. To quadruplicate sets o f wells 100 pi aliquots o f 0.5 ng [ 1 2 5 I] - EGF 
(final conc.) in DMEM + 0.1% (w/v) BSA was added. To a further set of 
quadruplicate wells, 100 pi aliquots o f 0.5 n g [ 1 2 ^I] - EGF plus a 100 - fold excess of 
unlabelled EGF in DMEM + 0.1% (w/v) BSA was added. The w ells were then
incubated at 37°C for 30 mins in a 5% CO2  atmosphere. Binding was terminated by
the addition o f 1 ml ice cold PBS-A. This was aspirated and the wells washed twice 
with 0.5 ml aliquots o f ice cold PBS-A. 100 pi aliquots o f 5N NaOH were added to each 
well, after 15 mins incubation at 37°C the extract was transferred to gamma tubes 
and counted.
The technique for full scatchard analysis was essentia lly  the same. A
complete 24 well F.B. plate was used for each assay. To 15 w ells increasing
concentrations o f  [ 1 2 5 I] - EGF was added (0.01 - 5.0 ng, 0.017 - 8.35 nm depending
on the specific activity 100-170 pCi. p g" 1). To determine non specific binding 
unlabelled EGF (at 100 - fold excess) was added to the wells containing the five 
highest concentrations o f  labelled EGF.
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The remaining four wells were retained for DNA estimation (see section 3.3.4.1 &
3 .3 .4 .2 ) .
3 .3 .5  Indirect Immunofluorecence Studies
Cells were plated down overnight having been seeded at a cell density o f 1 - 2 
x 1 0 4  cells  per w ell into 8  w ell glass slide/tissue culture vessels. Follow ing
overnight incubation the wells were aspirated and washed twice with PBS-A, then 
0.25 ml o f DMEM + 5% (v/v) dialysed HIDCCFCS ± hormones was added. 48 hours
later the wells were aspirated and washed twice with PBS-A.
3 .3 .5 .1  Indirect Immunofluorescence Method
This technique is essentially that proposed by Waterfield et al  (1982). The
cells were fixed by the addition o f 200 p i acetone:methanol at -20°C per well for
one minute and allowed to air dry. PBS containing 3% (v/v) sheep serum (200 p i)  
was then added for 20 mins at room temperature. This was then removed and
primary antibody (200 pl/well) EGFR 1 ( 1:300 in PBS + 0.1% (w/v) BSA) added. The 
w ells were then incubated for two hours at room temperature in a humidified 
chamber. The slides were then washed five times with 0.5 ml aliquots o f PBS + 
0.1% (w/v) BSA. Fluorescent labelled goat antimouse IgG (200 pl/w ell) diluted 1:100 
(approx. 20 pg. ml"1) in PBS + 0.1% (w/v) BSA was then added and incubated as 
before. Follow ing incubation the wells were then washed five times with PBS + 
0.1% (w/v) BSA.
The cells were then counterstained by the addition o f 100 ng. m l" 1 hoechst 
33258 stain for five mins at room temperature. The slides were then dehydrated by 
sequential one minute dips in graded alcohols ( 50, 70, 90, 100% (v/v)) followed by
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clearance in xylene. The slides were then mounted with DPX mountant and 
imm unofluorescence examined using a LIETZ fluorescent m icroscope.
3.3.6 Im m unoprecipitation Studies
C ells were plated down overnight in 850 cm 2  roller bottles. Follow ing  
incubation the medium was aspirated and cells were washed tw ice with 25 ml 
sterile PBS-A. To each roller bottle 25 ml Methionine free DMEM containing 0.5% 
(v/v) dialysed HIDCCFCS + 10 pCi. ml- 1  [2 5 S] - Methionine ( Specific Activity: 1420 
Ci/mM ) fo llow in g  24 hours incubation, horm ones were added. C ells were 
incubated at 37°C and harvested for at specific time points. The cells  were 
harvested by removal o f the medium and washing twice with PBS-A. To each bottle 
15 ml o f trypsin/versene was added and the cells incubated until cell detachment
from the substrate. To prevent further trypsinisation 15 ml o f DMEM + 10% (v/v)
FCS was added and the cell suspension thoroughly mixed. The suspension was
then decanted into centrifuge tubes and centrifuged at 5000 g for 10 mins at 4°C. 
The supernatant was discarded and the pellet washed twice with 5 ml Tris buffer. 
Finally to each pellet, 0.5 ml o f NP-40 solution was added and the cells incubated at 
37°C for 30 mins. Following incubation the extract was centrifuged at 5000 g for 10 
mins at 4°C. The supernatant was transferred to eppendorf tubes and stored at 
-70°C until the day o f  immunoprecipitation.
3 .3 .6 .1  Immunoprecipitation M ethodology
This permits the isolation and identification o f small amounts o f  a particular 
protein in a com plex mixture by means o f  its interaction with an antibody. 
Immunoprecipitation o f antigens is usually performed in two steps.
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First, specific antibody is added to a detergent lysate containing radiolabelled 
antigens. Next, the immunocomplexes are bound to a second agent which can be 
an im m unoglobulin  directed against the first antibody (doub le antibody  
precipitation system ) or chem ically  fixed  protein A bearing strains o f  
Staphylococcus Aureus  bacteria. The isolated im m unocom plexes can then be 
resolved by SDS/PAGE and be detected by autoradiography.
3 .3 .6 .2  Preparation of Pansorbin™
3 ml o f 10% (w/v) S .A u reu s  bacteria (Pansorbin™ ) was washed twice with 
12 ml o f NP-40 solution by centrifugation at 1000 g for 5 mins at 4°C. The final 
pellet was resuspended in 3.0 ml o f NP-40 solution, to which 100 p i o f 10% (w/v) 
BSA was added and stored on ice.
3 .3 .6 .3  Immunoprecipitation
Removal o f  nonspecific binding was achieved by adding 10 p i o f washed 
P a n so r b in ™  to 100 p i o f NP-40 solubilised cell extract with gentle m ixing for 30 
mins at 4°C, follow ed by centrifugation at maximum speed in MSE microcentaur 
for 4 mins at 4°C. The supernatant was transferred to fresh eppendorf polytubes 
and the procedure carried out a further two times.
Whilst "clearing" the samples, 90 p i o f  primary antibody EGFR I at a dilution 
of 1: 100 was preabsorbed to 900 pi o f washed Pansorbin™  plus 10 pi o f 10% (w/v) 
BSA for one hour at room temperature. Follow ing incubation the preabsorbed 
antibody was dispensed into 20 x 50 p i aliquots and centrifuged for 30 secs at 
maximum speed at 4°C. The supernatant was discarded and the pellet placed on 
ice. To the appropriate polytube cleared sam ples were added and the tubes 
vortexed and placed on ice for one hour. The tubes were then centrifuged as
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before and the supernatant discarded. The pellets were resuspended in 0.5 ml 
NP-40 solution, centrifuged as before and the supernatant discarded.There then 
followed two washes with 0.5 ml SDS buffer and 0.5 ml Tris buffer respectively.
Following this final step the pellets were stored at -70°C until SDS/PAGE analysis.
Prior to analysis by SDS/PAGE (see section 3 .2 .5 )  the pellets were boiled for 3 
mins in 100 pi o f sample buffer. Following SDS/PAGE the gel was dried at 80°C 
under vacuum for 2  hours and subjected to autoradiography using hyperfilm for
one month at -70°C.
3 .3 .6 .4 . Densitometric Analysis
Densitom etric A nalysis o f  the autoradiograph produced was by using a 
Bio-rad model 620 video densitometer.
3 .3 .7  Conditioned Medium Studies
Cell culture was essentially that outlined in section 3 .3 .4 . 6 . After 48 hours 
incubation in the presence o f  hormones/growth factor the conditioned medium
(CM) was removed. The CM was then filter sterilised, charcoal stripped without 
heat inactivation or dialysis ( see section 3 .3 .1 )  and added to fresh medium + 5% 
(v/v) dialysed HIDCCFCS at final concentration o f 50:50 (v/v). This medium was 
then added to fresh medium and subjected to the fo llow ing treatments where 
a p p rop ria te .
(a) Trypsin Treatment
Trypsin was added to a final concentration o f 10 pg. ml _ 1  and incubated for 
30 mins at 37°C. The trypsinisation reaction was terminated by the addition o f two 
- fold excess soya bean inhibitor.
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(b) Heat Inactivation
The CM was incubated for 30 mins at 56°C.
(c) Cycloheximide Treatment
Cvclohexim ide was added to the CM: fresh medium preparation to a final 
concentration o f 40 nM.
The treated CM: fresh medium preparations were then added to unstimulated cells 
and EGF receptor contents (see section 3 .3 .4 .7 )  and DNA contents (see section
3 .3 .4 .2 )  assessed after 48 hours incubation at 37°C in 5% CO2  atmosphere.
3 .3 .8  Prolactin Receptor Assays
Cell culture methods were the same as those outlined in section 3 .3 .4 . 6 . 
Prolactin receptor estimation was essentially the same as that proposed by Shiu
(1979) with the modifications proposed by Sakai & Suzuki (1989). In the E2  dose
response studies ( see Fig. 4 .3 .9 )  and in the time course studies ( see Fig. 4 .3 .1 0 )  
estim ation o f  receptor leve ls  was by the single point m ethod. To remove 
endogenous PRL, each well was washed tw ice with 4M  MgCL (0.5m l) at room 
temperature, followed by two washes with ice cold assay buffer ( 10 mM Sodium 
phosphate, 150 mM Nacl, 10 mM EDTA, 0.1 (w/v) BSA). To washed quadruplicate 
wells, 0.5 ml o f [ 1 2 ^I] - hPRL in assay buffer at a final concentration o f  InM ± a 
100 - fold excess o f  unlabelled hPRL was added. Incubation was carried out for six 
hours at room temperature. The cells were then washed twice with ice cold PBS-A  
and the wells extracted and counted as outlined in section 3 .3 .4 .7 .
Scatchard analysis was performed by the same techniques as above using a 
concentration range o f nine points in duplicate o f 0.01 - 5 nM [ 1 2 ^I] - hPRL.
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Estimation o f non specific binding was by the top three concentrations plus a 100 
- fold excess o f unlabelled hPRL.
3 .3 .9  Inositol Phosphate Assays
After plating on 24 well F.B. plates in DMEM and 10% (v/v) FCS for 24 hours 
the medium was then removed and the cells washed twice with sterile PBS-A. 1 ml 
o f  DMEM and 1% (v /v) dialysed HIDCCFCS with either lp C i. m l" 1 (total 
Inositolphosphates (InsPs) ) or 5 pC i. m l- 1  (individual InsP.) o f  myo- [2-3 H] - 
inositol was added. The cells were then incubated for 48 hours. Labelling medium 
was aspirated and the cells incubated in 1 ml Hanks buffered saline (pH 7.4) for 3 
minutes at 37°C. This was followed by an incubation in 1 ml Hank's/BSA/Glucose 
(HGB) containing 10 mM lithium chloride for 20 minutes. Finally the cells were 
incubated with 200 p i o f HGB and lithium chloride containing prolactin at the 
final concentrations and tim es indicated. For assays o f  total phosphates, 
incubations were terminated by direct addition o f 500 p i o f  ice cold methanol. 
After scraping, the cell debris was transferred into a 2 ml plastic polytube, each 
well was washed again with a further 2 0 0  p i o f methanol and the two washes 
pooled. Phospholipids were extracted from the cell debris by addition o f  300 p i of  
chloroform followed by vortexing and standing on ice for 30 minutes.
Following the addition o f 300 p i o f ice cold distilled water the samples were 
centrifuged at 10 000 g for 3 mins at 4°C to split phases , 1ml o f the upper aqueous/ 
methanolic phase was transferred to 5 ml scintillation vials and 3 ml o f Optiphase 
H i-safe scintillation fluid was added and the total inositol phosphate fractions 
counted on an LKB scintillation counter, counting efficiency 65%.
Assays o f individual phosphate fractions follow ed a different m ethodology. 
The wells were aspirated and 150 p i o f ice cold 10% (v/v) perchloric acid added, 
inositol phosphates were extracted on ice for 2 0  mins followed by scraping and
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removal o f  all debris into an eppendorf tube. The 24 well F.B. plates were then 
washed with a further 150 p i o f distilled water, which was pooled with the 
acid ified  extraction and centrifuged at 10 OOOg for 10 m ins at 4°C
The supernatants were neutralised by the addition o f  1.5 M potassium  
hydroxide/60m M  HEPES in the presence o f  universal indicator and the 
precipitated potassium perchlorate removed by centrifugation at 10 OOOg for 10 
m ins. The supernatants were analysed by ion exchange chromatography on 
Dowex 1x8 formate column.
Neutralised supernatants were diluted in 3ml o f 5 mM sodium tetraborate/0.5 
mM EDTA (pH 6.7) and applied to 1 ml columns o f Dowex formate 1x8. 200-400 mesh 
prepared in glass wool plugged pasteur pipettes. The columns were then washed 
with 12 ml o f water followed by 12 ml o f 60 mM ammonium formate/5 mM sodium 
tetraborate to rem ove free inosito l and glycerophosphoinosito ls respectively . 
Inositol mon-, bis-, tri- and tetraphosphates were eluted with sequential 10 ml 
washes o f 0.1M  formic acid containing 0.2, 0.4, 0.8 and 1.2 M ammonium formate 
respectively. Aliquots o f each fraction (3 ml) were mixed with Optiphase Hi-safe 
scintillant and the radioactivity determined by liquid scintillation counting.
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Chapter 4 Results
R esults C hapter 4.1  
4.1 Introduction
Although there are studies available for EGF receptor levels as assessed by 
ligand binding assay for other parts o f the U.K. and in other countries. No data
were available for Scotland at the time o f conception o f this project.
A ll assays were carried out between the period o f Novem ber 1987 and 
January 1990 from biopsies received from patients in hospitals throughout the 
Strathclyde region. The majority came from the Glasgow Western Infirmary.
This chapter reports data on the ligand binding assay system used to assess 
EGF receptor leve ls , and presents the results in relation to the oestrogen  
receptor status o f the biopsies.
7 3
4.1 .1  Optimum Time course of [125I] - EGF binding
Prior to assay o f breast tumours, it was decided to assess the time course of  
total binding o f labelled EGF to its receptor. Incubation was carried out at 4°C, 
room temperature (21°C) and 30°C by the m ethodology outlined in section
3 . 1 . 7 . 1 ,  using as p ositive  control tissu e , fresh ly processed  placental 
m em b ran es, prepared  as d e scr ib ed  in  m eth od s s e c t io n  3 . 1 . 3 .
Follow ing the addition o f [ 1 2 ^I] - EGF at a final concentration o f InM to
placental membranes at a final concentration o f 50 |ig  protein, it was found that 
maximum total binding occurred from 19 hours at 4°C (see figure 4 .1 .1 .1 ) ,  60 
minutes at room temp (21°C) (see figure 4 .1 .1 .2 ) ,  and 40 mins at 30 °C (see 
figure 4 .1 .1 .3 ) .  On the basis of these findings, assay incubation time course 
was set at room temperature for one hour.
The rationale behind choosing InM [ 1 2 ^ I ] - E G F  was based on reports by
other workers who have reported Kd values for EGFR in human placenta in the 
region o f 1 0 '^  and 10'^ M. The concentration chosen above does not o f course 
saturate the lower affinity site, but it does avoid influencing the binding 
kinetics which can be caused by a significant amount o f binding to non 
receptor sites seen at high ligand concentrations.
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Figure 4.1.1.1
Time course of - EGF binding to placental membranes at 4°C
Each point represents the mean of quintiplicate assays ( SD< 7%). Each 
assay involved 50 pg total protein content of human placental membrane 
incubated with 1 nM [125l] - EGF at 4°C for the times shown
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Figure 4.1.1.2
Time course of [125l] - EGF binding to placental membranes at 21 °C
Each point represents the mean of quintiplicate assays ( SD< 5%). Each 
assay involved 50 pg total protein content of human placental membrane 
incubated with 1 nM [125l] - EGF at room temp 21 °C for the times shown.
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Figure 4.1.1.3
Time course of [125l] - EGF binding to placental membranes at 30°C
Each point represents the mean of quintiplicate assays ( SD< 6%). Each 
assay involved 50 pg total protein content of human placental membrane 
incubated with 1 nM [125l] - EGF at 30°C for the times shown.
4 .1 .2  Determination of non-specific binding (NSB)
In any ligand binding assay system , a portion o f total binding is not
specific. The most common method o f assessing NSB is to compare total binding
o f labelled ligand to that o f binding derived in the presence o f  an excess of 
unlabelled ligand. The optimum concentration o f excess unlabelled ligand is that
which competes for the maximum amount o f EGFR without competing for [ 1 2 5 I] - 
EGF binding to proteins other than receptor. Incubation was carried out at room 
temperature using the methodology outlined in section 3 .1 .7 .1 .
[ 1 2 5 I] - EGF (InM  final concentration) was displaced by the addition of
increasing concentrations o f unlabelled murine ligand ( see figure 4 .1 .2 .1  ). 
Residual (NSB) binding was deemed to be that retained at a concentration o f 100 
- fold excess or greater. On the basis o f these findings it was decided to
incorporate NSB estimation at a concentration o f 100 - fold excess o f  unlabelled
ligand both for single point screening and full multipoint analysis. To assess
the b iological equivalance between the murine labelled assay system  and the 
human ligands EGF and TGFa. Exchange o f labelled murine EGF by increasing
concentrations o f unlabelled human EGF and TGFa was carried out ( see figure
4.1.2.2 ). Plots derived from experimental data displayed sim ilar displacement
kinetics to those seen with murine EGF ( see figure 4 .1 .2 .1  ). 50% displacement
values were 74 nmoles, litre" 1 for human EGF and TGFa and 62.5 nmoles, litre" 1 
for murine EGF.
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Fig. 4.1.2.1
D isp lacem ent of murine [125l] - EGF from placental m em brane.
Human placental membrane was exposed to 1 nM murine [125l] -EGF for one hour 
at room temperature in the presence of increasing concentrations of unlabelled murine 
EGF.
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Figure 4.1.2.2
Displacement of murine [125 I] - EGF by human EGF 
and TGF Alpha
Human placental membrane was exposed to 1 nM murine 
[I25 I ] - EGF for one hour at room temperature in the 
presence of increasing concentrations of unlabelled human EGF 
and human TGF Alpha. Specificity of displacement was compared 
against displacement of 1nM murine [125 I] - EGF by ovine 
Prolactin and Bovine Insulin.
Note that the displacement kinetics of both human EGF and 
human TGF Alpha are similar to those of murine EGF alone.
( see figure 4.1.2.1)
4 .1 .3  Comparison of Assay Methods
One o f the major problems in EGFR estimation by ligand binding assay has 
been the variations in m ethodology cited in the literature (see Introduction 
1 .8 .1 3 )  e.g . whether there was single or m ultiple concentrations o f labelled  
ligand with NSB estimated by an excess variable concentration o f unlabelled 
ligand. Further, the m ethods o f  separating bound from free ligand differ,
preparation of tissue sample, time and temperature o f incubation etc.
Due to these variables it was decided to compare our method (see section 
3 .1 .7 .2 )  with the common methodology proposed by the European Organisation 
for the Research and Treatment o f Cancer (EORTC) study group (see section
3 .1 .7 .4 )  using the lyophilised  placental membrane quality control standard 
provided. Each vial was reconstituted in 2ml deionised d istilled  water. The 
purpose o f the EORTC method was to establish whether a common methodology 
could lead to similar conclusions from all centres on the clinical value o f EGFR 
determination in different human cancers.
As can be seen total receptor concentration determined by our method ,
18.9 fm oles. m l-1 , was very similar to the result recorded using the EORTC 
protocol, 18.8 fmoles .ml"1. The Kd values recorded showed some variation 0.064 
nM " in house " compared to 0.049 nM EORTC ( see figure 4 .1 .3 .) . No low affinity 
binding component was observed by either method. This may be a result o f the 
lyophilisation process. It should be noted that our results using the EORTC
protocol correlated with the median point o f the values reported by all members 
o f the EORTC receptor study group in the first two rounds o f EGFR assay quality 
c o n tro l.
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Fig. 4.1.3
Com parison betw een "In house" and EORTC a s s a y  p rotoco ls  
for EGFR determ ination using lyophilised  hum an placental 
m em brane
4 .1 .4  Single Point Screening and Multipoint Scatchard Analysis.
Initial screening o f breast tumour membrane preparations (see methods 
se c tio n  3.1.3) was by the single point method ( see methods section 3 .1 .7 .1 ) .  On 
the basis o f the screen a positive result was recorded if  the membrane fraction 
contained greater than 1 0  fm oles sp ec ific  binding .m l" 1 o f  membrane 
suspension. No specific  [ 1 :^ I ]  - EGF binding was observed in membrane
fractions derived from pathologically normal breast epithelium ( n = 4).
W herever su ffic ien t m aterial was availab le  fu ll m ultipoin t binding  
analysis ( see methods section 3 .1 .7 .2 )  was carried out on samples found to be
positive in the single point screen. Multipoint analysis was also carried out on 
random negative samples to ensure that the single point screen was correctly 
indentifying EGFR positive samples. Correlation coefficent for the single point 
screen and Scatchard values recorded for the low  capacity high affinity
binding site was r = 0.775 (see figure 4 .1 .4 ) .
4 .1 .5  Multipoint Analysis
Figure 4 .1 .5  refers to an example scatchard plot o f a patient biopsy  
received for ER/EGFR analysis from the Glasgow Western Infirmary. Initial two 
point screening revealed EGF binding levels o f 92 fm oles. m l-1 . Subsequent 
analysis demonstrated " Classical " double binding site kinetics. A high affinity 
low  capacity binding component o f 1 2 0  fm oles. m l" 1 and a low  capacity
component o f 400 fm oles.m l'1.
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Log plot of receptor levels as a sse sse d  by single point screening assay  
versus that of high kd receptor levels by multipoint analysis .
V a lu e s  fo r  E G F R  d e te rm in e d  b y  th e  s in g le  p o in t s c r e e n  w e re  c o m p a r e d  with 
th e  h ig h  K d re c e p to r  v a lu e s  (i.e . low  Kd re c e p to r  v a lu e s  w e re  ig n o re d  fo r th is  
p u r p o s e  b e c a u s e  th e  s in g le  s c r e e n  c o n c e n tra t io n  w a s  on ly  1 nM ) d e te rm in e d  
b y  S c a tc h a r d  a n a ly s is .
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PATIENT WIG 358 895
TRC1120.0 fmoles. ml’1 KD 0.49 nmoles, litre*1. 
TRC 2 400.0 fmoles. ml*1 KD 10.3 nmoles, litre*1 
(TWO POINT SCREEN 92.0 fmoles. ml*1)
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F ig  4 .1 .5
Example Scatchard binding data derived from membrane 
preparation of abreast tumour biopsy receieved for ER/EGFR 
analysis.
The assay conditions were those of the " in house " method.
Data was computed manually and the curve fits resolved on a 
Apple Macintosh plus system using the Cricket Draw package.
4.1 .6  Oestrogen Receptor Levels in EGF Receptor 
Negative Tumour Preparations
199 patients were screened for EGFR presence by the single point method, 
124 were found to be EGFR negative i.e. had levels o f EGF binding o f < 10 fmoles. 
m l" 1. Within this group, 99 (79.8%) were ER positive i.e. contained levels of 
oestrogen binding o f greater than 2 0  fm oles. mg ' 1 protein for the cytosolic  
fraction and 150 fm oles. m g ' 1 DNA for the nuclear fraction as determined by 
ligand binding assay ( see methods section 3 .1 .4 ) . These data are summarised in 
table 4 .1 .1 .  As can be seen from table 4 .1 .2 ,  ER values recorded display wide 
variations o f receptor concentrations, in both cytosolic and nuclear fractions. 
This is probably due at least in part to tumour heterogeneity.
4 .1 .7  Analysis of EGF Receptor Positive Group.
Of the 75 patients deemed who, by the single point screen had tumours 
which were EGFR positive, 73 full multipoint plots were carried out ( Table 
4 .1 .3 ) .  Scrutiny o f the data revealed 65 plots which satisfied our criteria o f a 
linear regression coefficient o f greater then 0.7 for each binding component. 
All 65 contained high affinity, low capacity binding. Low affinity, high capacity 
binding was observed in 60. Wide variations were again recorded with respect to 
concentrations and affin ities.
Scrutiny o f initial follow up data ( mean 16.9 months from date o f biopsy) reveal 
six deaths out o f the 199 patients analysed. Because o f the relatively small sample 
pool, it is common practice that no statistical analysis is attempted until a median 
five year follow up period has elapsed.
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Table 4.1.1
Tabulation of Oestrogen Receptor and Epidermal Growth Factor 
Receptor ocurrence in 199 breast cancer patients in the 
West of Scotland
CYTOSOL NUCLEAR
Total Receptor Concentration (fmoles. mg'1 Protein) (fmoles. mg"1 DNA)
Range 19.7-1156.0 163.0-9680.0
Mean 156.9 1662.5
SD 215.5 1986.9
Age range : 33 - 94 ; Mean 61.7.
Table 4.1.2 
ER Scatchard Analysis of the EGFR -ve group
Cut-off values for ER were 20 fmoles. mg-1 protein 
for cytosol (one tumour of 19.7 fmol. mg' 1 was taken 
as = 20.150 fmoles. mg' 1 DNA was taken for the 
nuclear fraction.
High Affinity Low Affinity
Number of Observations 65 60
Total Receptor Concentration 
(fmoles.mg-1 DNA)
Range 69.6 - 28201.0 360.6 - 34466.0
Mean 1581.24 5223.76
SD 3647.64 6233.48
KD Values (nmoles, litre-1)
Range 0.010-1.4 0.108-38.7
Mean 0.362 8.892
SD 0.351 7.503
Table 4.1.3 
Scatchard Analysis of EGFR positive group
73 full scatchards were carried out in the EGFR +ve group.
Age range : 32 - 91 ; Mean: 59.5, no correlation was found between 
age and EGFR content. 14 (19.2%) patients were also ER positive, 
no correlation was found between ER and EGFR concentrations in this 
group.
Further, the ER concentrations covered the same range as in the EGFR 
negative patient group (Table 4.1.2).
4.1.8 Results Conclusion/ Discussion
The data in this chapter show that approximately 38% o f  human breast 
cancer biopsies assayed ( 75/199 ) contained appreciable levels o f EGFR, and in 
this group only 7% o f the total population contained ER. This contrasts with the 
99/124 positive for ER in the EGFR negative group ( see also table 4 .1 .1  ). EGFR 
was estimated by ligand binding parameters. Our initial single point screen 
correlated reasonably w ell with the high affinity low  capacity sites calculated 
from subsequent multipoint scatchard analysis. The high affinity low  capacity 
and low affinity high capacity values recorded (o f the 73 saturation analyses 
carried out , 65 yield high affinity and 60 yield low affinity binding sites) are 
comparable with those reported by Nicholson et al. (1988). This contrasts with 
the reports o f Fitzpatrick et al. (1984), Battaglia et al. (1988) and Cappelleti et al. 
(1988), who have found only a single high affinity binding site  . This 
discrepancy is probably due mainly to differences in m ethodology although 
there may be some contribution from tumour heterogeneity, but this would 
hardly explain 60/75 tumours with low affinity sites as observed here.
W hilst confirming the inverse correlation between ER and EGFR, it was 
interesting to note that, in the group containing both receptors, no correlation 
was observed with respect to receptor concentrations suggesting that these  
tumours may be o f  a polyclonal origin. It is hoped that double staining  
immunocytochemical studies o f this group will yield data concerning location of 
the two receptors within the tumour or total tissue cell population. One thought 
provoking observation was noted in the case o f two patients who presented with 
disease in both breasts. EGFR and no ER was detected in one breast, ER and no 
EGFR in the other. This fits in with the results by Davidson et al. (1987) who 
have reported the absence o f ER gene expression in human breast cancer was 
associated with increased levels o f EGFR protein and mRNA. This suggests that 
in the ER positive/ EGFR negative breast, tumour growth is regulated in an
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endocrine dependent manner, and in the case o f the ER negative/ EGFR positive
breast, tumour growth was regulated in an autocrine/paracrine manner.
In contrast to the results seen in breast cancer biopsies in which the 
majority contain either EGF or ER but not both. Some breast cancer cell lines 
commonly used as in vitro models show an interdependence o f steroids and 
growth factors. Bates et al. (1988) using the endocrine dependent breast cancer
model (MCF-7) demonstrated regulation o f TGFa production by oestradiol, TGFa
mRNA was found in three other ER positive cell lines and in 70% o f patients 
a n a ly sed .
On binding to its ligand, EGFR usually undergoes auto- phosphorylation, 
internalisation, and degradation (Yarden & Schlessinger, 1985). These events 
cause a decrease in receptor binding (down modulation) and can lead to a 
situation where ligand binding techniques cannot detect EGFR. Up regulation of  
EGFR mRNA and protein in the MCF-7 and T-47D cell lines has been demonstrated 
in the presence o f progestins (Murphy et al., 1986; Murphy et al., 1989).
Studies within our lab have shown that prolactin at physiological levels can 
increase EGFR protein, ligand binding and mitogenic activity in the ZR-75-1 cell 
line (see results Chapter 4 .3 ) .
These reports may oversim plify the growth control m echanism  in ER 
positive breast cancer. Oestradiol controls the autocrine/paracrine production  
o f the ligand TG Fa. Progesterone, whose own receptor (PR) is induced by ER 
DNA binding (Sarup et al., 1988) controls the levels o f EGFR. Cormier et al. (1 9 8 9 )
have demonstrated that the addition o f EGF to ER dependent breast cancer cells
leads to a decrease o f progesterone binding. Other workers have found that EGF
treatment abolishes ER induction of PR (Katzenellenbogen et al., 1 9 8 7 ).
Via these events EGF/TGFa could regulate its own receptor not only in terms 
o f ligand binding and modulation, but also at the level o f its own receptor 
production due to its ability to down regulate PR. Because EGFR is in a state o f 
constant modulation, only low levels (undetectable ?) need be in operation for
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efficient m itogenic function. This latter possibilty might explain the apparent 
contrast between cell lines and solid tumours.
Loss o f endocrine function in this scheme would at first glance lead to a 
total loss o f EGFR levels, due to loss o f PR control and/or ER controlled ligand 
production. But it is possible that loss o f ligand by ER depletion leads to a 
decrease o f  ligand binding and therefore internalisation, degradation events. 
Alternatively, there may be an "over production" o f receptor in an attempt to
pick up the reduced levels o f TGFa available. Another intriguing possibilty may 
be that loss o f ER/PR control leads to uncontrolled production of EGFR and TGFa. 
This could possibly be the case in EGFR positive/ER negative breast tumours.
It is interesting to note that studies by Dickson et al. (1987) have shown 
that the addition o f EGF to breast cancer cell lines followed an inverse pattern of 
stimulation. Cell lines containing relatively small amounts o f EGF binding sites 
(less than 43,000 sites per cell) were m itogenically stimulated whereas cell lines
containing (greater than 90,000 sites per cell) displayed no response or were
inhibited. This also correlated with the ER status o f cell lines investigated.
It is tempting to speculate that high EGFR levels may be a reflection o f loss 
o f  endocrine control. In this group, tumour cell m itogenesis is no longer 
dependent on EGF/TGFa activating EGFR. Other mitogenic factors could be of  
greater im portance.
Another possibility may be that the basal intrinsic tyrosine kinase activity 
of EGFR is at a level sufficient to promote EGFR mitogenic function irrespective 
o f ligand binding. This possibility in has not been thoroughly investigated.
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Results Chapter 4.2
4.2.1 Nuclear Localisation Studies
It is accepted that the EGF receptor is localised  m ainly in the cell 
membrane. However there are some indications that the receptor is present in 
other areas o f the cell. Studies have revealed that EGF binding can be observed 
in the triton insoluble portion o f A431 Cells (Weigant et al., 1986). Indirect 
im m unofluorescence studies have revealed perinuclear localisation o f the EGF 
receptor upon EGF treatment in A431 cells and murine 3T3 cells (Murthy et al., 
1986). The insulin receptor, another tyrosine kinase cell surface receptor, has 
been demonstrated to undergo nuclear translocation in the nuclei o f isolated rat 
hepatocytes (Podlecki et al., 1987).
Studies by Rakowicz-Szulczynska et al. (1986, 1989) have shown chromatin 
binding o f EGF, NGF and PDGF in cell lines containing the appropriate surface 
receptors. However no data were available for the solid tumours. This section of  
this thesis deals with preliminary studies on the nuclear localisation o f the EGF 
receptor within a pooled breast tumour homogenate.
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4 .2 .2  Results
30 gm o f unselected breast tumour tissue were processed by the methods 
outlined in section 3.2.2 & 3.2.3. to yield both membrane and nuclear fractions.
4 .2 .3  Scatchard Analysis of Membrane Fraction
Scatchard analysis o f the membrane EGFR component revealed double site 
kinetics (Figure 4 .2 .1 ) .  A high affinity low capacity binding component o f Kd 
0.023 nmoles, litre" 1 and a receptor level o f 1.82 fmoles. ml" 1 (2.6 fmoles. mg ' 1 
membrane protein), plus a low  affinity binding com ponent high capacity  
binding component o f Kd 0.25 nmoles, litre ' 1 and a receptor level o f 9.1 fmoles. 
m l " 1 (23 fmoles. mg ' 1 membrane protein ) were detected. These values vary 
somewhat from the studies outlined in table 4.1.2 with respect to the affinity 
values noted. This could be partly due to the difference between the in house
and the EORTC method used in these studies with regard to receptor affinity (see 
figure 4 .1 .3 ) ,  or alternatively may be the result o f bulk processing o f combined 
tumour b iopsies.
4 .2 .4  Scatchard Analysis of Nuclear Fraction
Analysis o f the nuclear fraction (Figure 4 .2 .2 )  revealed a single high affinity
low capacity binding component, Kd 0.013 nmoles, litre"1, with receptor levels 
of 0.47 fmoles. ml" 1 (82.4 fmoles. mg ' 1 DNA). Salt extraction (see methods 3 .2 .3 )  
o f the nuclear fraction ( see figure 4 .2 .3 )  resulted in some changes in the 
single high affinity low  capacity binding component, Kd 0.022 nmoles, litre'1,
with receptor levels o f 0.96 fmoles. ml" 1 (72.3 fmoles. mg" 1 DNA).
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A bulk membrane fraction w as prepared from 30 gm 
of unselected breast cancer biopsy material.
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assayed  for EGFR levels using the EORTC method 
(see  methods 3.1.7.4)
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The nuclear fraction w as prepared as described in 
methods 3.2.2 and assayed for EGFR levels a s  
described in methods 3.1.7.4.
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Scatchard Analysis of Salt Extracted Nuclear pellet
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A portion (2 ml) of the nuclear pellet was salt 
extracted with 2M NaCL for 30 mins at 0°C.
The pellet was then assessed  for EGFR binding by the 
EORTC method described in 3.1.7.4.
4.2 .5  Western Blotting of Tumour Fractions
W estern blotting (see m ethods 3.2.5 - 3 .2 .11) o f the tumour fractions 
reveal that the nuclear localised form o f the receptor appears to be the same
m olecular w eight as that o f  the membrane bound form as assessed  by 
autoradiography ( figure 4 .2 .4 ) .
4 .2 .6  Membrane Marker Enzymes
To ensure that there is no contamination o f the washed nuclear fraction by
plasm a m em branes. The relevant fractions were assayed for two known
membrane enzyme markers, 5' nucleotidase and alkaline phosphatase ( see
m ethods 3 .2 .1 2  and 3 .2 .1 3 ) .  As can be seen from table 4 .2 .1  whilst there is 
appreciable enzym ic activity in both the plasma membrane and unwashed  
nuclear fractions, there is no activity in the washed nuclear fraction for either 
en z y m e .
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Membrane Washed Salt Ext. Washed 
Frac. Nucl. Frac. Nucl. Frac.
M.LU. (kD
p i  70
97 ,4
-  37 .5
-  20 . 1
Figure 4 . 2 . 4
7.5% PAGE/Western Blot/Autoradiogram of Breast 
Tumour Pool see methods 3 .25  - 3 .2 .11
Table 4.2.1 Plasma Membrane Marker Analysis of Tumour Fractions
. . .  Membrane Fraction Nuclear Fraction W ashed Nuclear Fraction
Membrane Marker
Alkaline Phosphatase 0 038 o.021 o.OO
( OD 600 nm. mg ' 1 Protein)
5' Nucleotidase 
( pg. KH2P 04 std. mg' 1 Protein-1  6 -7 5  15.23 o .O O
Table 4.2.1
Marker enzymes were assayed by the methods outlined in 3.2.12 
and 3.2.13.
Each value cited is the mean of triplicate determinations.
4.2 .7  Result Conclusion/Discussion
Three tentative conclusions may be derived from this study
(a) There appears to be a single high affinity low capacity binding class o f the 
EGF receptor located within the chromatin com plex in breast tumours 
containing surface EGF receptors
(b) High salt extraction o f the chromatin complex (although affecting receptor 
affinity and concentration to some degree by appearing to double both values ( 
See Figures 4 .2 .2  and 4 .2 .3 )  did not eliminate binding. Therefore the nature of  
receptor/chromatin interaction is likely to be highly specific.
(C) The chromatin bound receptor form appears to be the same m olecular 
weight as the membrane bound. This suggests that the chromatin bound 
receptor form is not significantly processed before binding to the chromatin.
W hilst the above to data appears to confirm the early observations that 
there may be nuclear localised form of the EGF receptor. It should be noted that 
previous reports have not attempted to assess possib le contamination o f  the 
nuclear fraction by plasm a membrane, the m ain site  o f  EGF receptor 
localisation. From our results, no activity o f the two membrane associated  
enzym es, Alkaline phosphatase and 5'Nucleotidase was observed in the nuclear 
fraction. H owever it is possible that there may be contamination from the 
transmembrane portion o f  the membrane. In retrospect assessm ent o f  a 
transmembrane associated enzyme, such as Adenylate cyclase would have been a 
valuable indicator o f  transmembrane contamination.
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Although it generally accepted that EGF initiates its m itogenic activity 
through specific cell surface receptors, follow ed by activation o f the protein 
tyrosine kinase in the cytoplasmic domain o f the receptor, it is not known what 
secondary processes are required for their ultimate effect. Translocation o f EGF 
into the nucleus has been demonstrated by a few authors (Johnson et al., 1980a, 
Johnson et al., 1980b, Savion et al., 1981, Rakowicz-Szulczynska et al., 1986). 
Johnson et al. (1980b) demonstrated that in addition to m itogenesis, EGF alters 
the activity o f several genes and m odifies the chromatin structure. Studies by 
R ak ow icz-Szu lczynska  et al. (1989) have shown that EGF can bind to a single 
EcoRI fragment. Further, binding o f EGF appears to confer a DNAase II 
protection effect. This promotes the possibility that EGF receptor complex may 
bind within the specific promoter/enhancer regions o f unknown genes.
The interaction o f growth factor receptors with the genetic apparatus o f  
solid tumours is an exciting prospect. It is outwith the scope o f this thesis to 
investigate further these observations. However it is tempting to speculate on 
possib le avenues o f  investigation, one important clinical application could be 
the assessment nuclear localisation o f EGF, PDGF, IGF I & II receptors in solid 
tumours and their possible prognostic significance. Nuclear localisation studies 
o f tyrosine kinase oncoproteins such as Neu and verb B could lead to greater 
understanding o f  their role in cell m itogenesis. Further, the potential for 
blocking growth signals at the nuclear lev e l g iv es  hope for im proved  
anti-cancer agents.
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Results Chapter 4.3
4.3.1 Introduction
Regulation o f the EGF receptor by oestrogen and progesterone has been 
reported in ce ll culture system s used as m odels for oestrogen dependent 
carcinom a (see  Introduction 1.8.9). This section o f the thesis deals with the 
possib le involvem ent o f other hormones in EGF receptor regulation and in 
particular with that o f Prolactin .
Prolactin (PRL) has been shown to have a role in both the induction and 
growth o f rodent mammary tumours (W elsch, 1987), and is m itogenic both in  
vivo  (Kiss et al ., 1987; Muldoon, 1987) and in vitro (Manni et al., 1985 & 1987). 
PRL has been found to promote the growth o f human mammary carcinoma cells 
in culture (Malarkey et al., 1983; Simon et al., 1984; Vonderhaar & Biswas, 1987). 
The precise function o f PRL in human breast cancer is unclear, but it may 
contribute to breast cancer risk due to its ability to stimulate breast epithelial 
growth (Bruning, 1987). Elevated plasma PRL has been reported in women 
considered to be high risk. These studies are confounded by many variables 
such as blood sampling, stage o f menstrual cycle, etc (Wang et al., 1987). 
Reports have suggested that the presence o f  PRL receptor (PRLR) is a 
significant prognostic factor in the relapse free survival o f oestrogen receptor 
(ER) positive patients (Bonnetre et a l ,  1987). This is in addition to the findings 
o f Murphy et al. (1984), that there is significant linear correlation between 
PRLR and ER in cell lines in long term tissue culture and breast biopsies. Using 
the established breast cancer cell line ZR-75-1 (Engel et al., 1978) which 
contains relatively small amounts o f EGF receptor (Fitzpatrick et al.,  1984; 
Davidson et al., 1987), we studied the effect o f PRL on cell growth and EGF 
Receptor (EGFR) synthesis .
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4 .3 .2  Hormone / Growth Factor action on DNA synthesis.
Our prelim inary observations were concerned w ith the e ffe c t  o f  
p-Oestradiol (E 2 ), ovine Prolactin (oPRL) and murine Epidermal Growth Factor
(EGF) on DNA synthesis o f ZR-75-1 cells using the hoechst DNA assay technique 
(M ethods 3.3.4.1 & 3 .3 .4 .2). Initial studies involved ascertaining the cellular 
response o f  the above m itogens over a range o f concentrations and time 
courses (see Figures 4.3.1 - 4 .3 .3).
From the results o f the above experiments, it was decided to use the 
follow ing optimal mitogenic concentrations o f E 2  lxlO '^M  and EGF 5 ng. ml' 1 
for assessing the effects o f horm one/growth factor com binations on DNA  
synthesis o f ZR-75-1 cells. oPRL ljig . m l ' 1 was also included at the stated 
concentration, whilst oPRL did not appear to be mitogenic over 48 hours it was 
mitogenic over 72 - 96 hours ( see Figure 4 .3 .2 )
The results o f the combination experim ents are summarised in figure  
4 .3 .4 , as can be seen oPRL synergistically raised the mitogenic effect o f EGF. 
Cell growth in terms of DNA levels were more than twice that o f control values
after 48 hours. EGF and E 2  had comparable effects on DNA synthesis at
approximately 1.4 times control values. All three in combination boosted DNA  
synthesis 2.5 times higher than control values.
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Figure 4.3.1
Effect of E2 concentration range and time course 
on DNA synthesis of ZR-75-1 cell line
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N = 6 experimental determinations. Each determination is the mean 
of quadruplicate wells. Cell DNA content was assessed after 
incubation times noted above by the method of Leake and Habib (see 
Methods 3.3 4.2). Note in figs.4.3.1 - 4.3.6 DME medium contained 
Phenol red (15 mg/l).
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Figure 4.3.2
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N = 6 experimental determinations. Each determination is the mean 
of quadruplicate wells. Cell DNA content was assessed after 
incubation times noted above by the method of Leake and Habib (see 
Methods 3.3.4.2). Note in figs.4.3.1 - 4.3.6 DME medium contained 
Phenol red (15 mg/l).
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Figure 4.3.3
Growth response to EGF over time and concentration 
range in the ZR-75-1 cell line
EGF (ng. ml'1)
N = 6 experimental determinations. Each determination is the mean 
of quadruplicate wells. Cell DNA content was assessed after 
incubation times noted above by the method of Leake and Habib (see 
Methods 3.3.4.2). Note in figs.4.3.1- 4.3.6 DME medium contained 
Phenol red (15 mg/l).
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Figure 4.3.4
Effect of E2, oPRL and EGF on DNA synthesis In ZR-75-1 cells
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N = 6 experimental determinations. Each determination is the mean 
of quadruplicate wells. Cell DNA content was assessed  after 48 
hours incubation by the method of Leake and Habib (see Methods 3.3 
4.2). Note in figs.4.3.1- 4.3.6 DME medium contained Phenol red 
(15 mg. litre’1). Student T-test analysis of the data presented above 
recorded levels of significance at < 0.001, where mitogenesis is 
observed.
4.3 .3  Dosage response of oPRL on [125I] - EGF binding
On the basis o f the findings recorded in figure 4.3.4, it was decided to 
assess the effect o f oPRL on EGF binding to its receptor in the total membrane
fraction(by the methods outlined in 3.3.4.3 - 3 .3 .4 .5) as a function o f (a) oPRL
concentration and (b) over a time course.
(a) The binding of [ 1 2 5 I] - EGF was found to increase in a dose dependent 
manner upon oPRL addition with optimal binding at around lj ig . ml' 1 oPRL 
over a 48 hour time course (Figure 4 .3 .5 ) .  The conclusion derived from these 
experiments was that in all subsequent studies o f oPRL effects on the EGF 
receptor , the concentration of oPRL used was set at lp g . m l-1 .
(b) The addition o f oPRL resulted in a maximal 3-4 fold increase in EGF 
receptor lev e ls  in the total membrane fraction reached and m aintained
between 4-6 days (Figure 4 .3 .6 ) . EGF receptor levels were seen to decrease at 
6 - 8  days , this was associated with the onset of confluence in the culture vessels.
Cells grown in the presence of oPRL and 40 nmoles, litre" 1 C yclohexim ide  
(sub-lethal concentration) display little or no receptor leve ls  although cell 
growth continued at the control levels.
These findings suggest that the increase in receptor concentration is a 
protein synthesis associated event and not merely an increase in receptor 
capacity for the ligand.
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Figure 4.3.6
Induction of EGF R eceptor by 1 jug. ml-1 oPRL
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N = 6 experiments, each expt is the mean of quadruplicate 
flasks. EGF-R concentration w as a ssesse d  using the 
membrane binding assay technique (methods 3.3.4.5).
4.3 .4  Effect of Hormones/Growth Factors on cell surface
binding of EGF
To further extend the study, it was deemed necessary to assess that the 
increases in EGF binding in the total membrane fraction was realised at the
cell surface. Cell surface binding experiments were carried out as outlined in 
methods section  3.3.4.7.
Several key changes in methodology were also incorporated at this stage. It 
was decided to use phenol red free media (see methods 3 .3 .3 )  to remove any 
p ossib le  oestrogenic effects o f phenol red (W elshons et al., 1988) in the
experimental system. It should be noted however that we detected no effects of 
phenol red on the oestrogen receptor levels in this cell line (see Figure 4 .3 .7 )  
Further, the use o f human prolactin (hPRL) at a physiological concentration of 
40 ng. m l- 1  replaced the pharmacological levels o f ovine prolactin.
The results display an interesting pattern (see Figure 4 .3 .8 ) .  W hilst hPRL 
still stimulated increases in binding at the cell membrane (5 3 % above the
control values) and addition o f E 2  cause a small but consistent stimulation (26%
above the control values).W hich was not observed using phenol red containing
medium (data not shown). The addition of hPRL and E2  in conjunction resulted
in the greatest increases (151% above the control values). Co-culture with EGF 
resulted in a decrease in binding as would be expected from the down 
regulation effect o f EGF. However residual binding o f 37% above the control
values was still observed in the hPRL + E2 + EGF treated cells.
Scatchard analysis o f the hPRL + E2  treated cell (Figure 4 .3 .9 )  revealed that
the stimulation of ligand binding was purely a consequence o f an increase in 
receptor concentration and did not reflect a change in receptor affinity.
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F ig u re  4.3 .7
Effect of Phenol Red concentration range and 
time course on Oestrogen Receptor Levels in 
ZR-75-1 cell line
Oestrogen receptor levels were detected by ligand binding 
assay (Offord, 1988), the opposite series of histogram plots 
are example binding data derived at 24, 48 and 96 hours. No 
effects were observed at the above time points, no effects 
were noted even after 2 weeks in culture. Full scatchard 
analysis revealed no effects with regard to receptor affinity.
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Effect of Phenol R ed on ER levels in ZR-75-1 cell line after 24 h ours
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Effect of Phenol Red on ER levels in ZR-75-1 cell line after 48 hours
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Figure 4.3.8
EFFECT OF E2, hPRL AND EGF ON WHOLE CELL BINDING OF [125l] - EGF
CNTL PRL E2 EGF PRL+E2 PRL+EGF EGF+E2 PRL+EGF+E2 
H O R M O N E / G R O W T H  F A C T O R
N = 6 experiments, each expt. is the mean of quadruplicate 
wells.
Hormone/Growth factor effects were assessed after 48 
hours. Binding estimated as the percentage 
increase/decrease compared to control values using the 
whole cell binding assay technique (see methods 3.3.4.7).
Figure 4.3.9
Scatchard Analysis of Whole Cell Binding of [125l] - EGF
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hPR L  + E-
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Example scatchard analysis plot of whole cell binding in 
hPRL + 10'9M E2 treated cells compared to control cells.
4.3.5 Indirect Im m unofluorescence studies
From the findings o f the experiments discussed in sections 4 .3 .1 -4 .3 .4  it
was decided to assess the effect of hPRL and E2  on the EGF receptor by other
param eters, in particu lar, im m u n o log ica l tech n iq u es u t ilis in g  the
commercially available EGFR 1 monoclonal antibody.
Initial studies used indirect im m unofluorescent techniques outlined in 
methods 3.3.5 & 3 .3 .5 .1 . .  Figure 4 .3 .1 0 .1  displays the surface morphology of
ZR-75-1 cell surface morphology when grown on glass/slide culture vessels. No 
apparent difference between surface morphology was observed with that o f  
plastic culture vessels. Cells were stained by the indirect immunofluorescent 
technique and counterstaining was acheived with Hoechst dye. Figure 4 .3 .1 0 .2
displays a counterstain pattern typical o f ZR-75-1 cells. These experiments were 
carried out four different occasions and the photographs represent a random 
selection  o f  results obtained. During each experim ent, A431 ce lls  where 
cultured to provide a positive control for the experiments (Figure 4 .3 .1 0 .4 ) .
Incubation w ith the primary antibody resu lted in re la tive ly  low  
fluorescence in hormone untreated ZR-75-1 ce lls  (Figure 4 .3 .1 0 .6 )  when 
compared to the positive A431 cells. This is only to be expected in a cell line 
containing low  levels o f the receptor. Treatment with hPRL alone (Figure
4 .3 .1 0 .7 ) ,  and in conjunction with E 2  (Figure 4 .3 .1 0 .8 )  after 48 hours
incubation resulted in visual increases in staining intensity. Unfortunately it 
was not possible to quantify the fluorescent staining observed. The process o f  
photographing slides and the production of prints has reduced the visual 
impact o f these experim ents. However these results appear to confirm the 
earlier bindings studies (see Figures 4 .3 .1  - 4 .3 .9 ) ,  in that more cells express 
sufficient EGFR after stimulation (relative to controls) as seen by retention of  
sp ec ific  flourescence.
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Figure 4.3.10.1
Surface morphology of ZR-75-1 cells in culture 
(x 200 magnification)
Figure 4.3.10.2
Example Hoechst counterstain of ZR-75-1 cells 
grown in these experiments (x 200 Magnification)

Figure 4.3.10.3
Non Specific Binding Fluorescence of A431 cells 
( x 400 magnification)
Figure 4.3.10.4
Fluorescence of A431 cells when incubated with EGFR 1 
Monoclonal Antibody (x 400 Magnification)

Figure 4.3.10.5
Example Non Specific Binding Fluorescence of ZR-75-1 
cells ( x 200 Magnification)
Figure 4.3.10.6
Example Fluorescence of Control ZR-75-1 cells 
when incubated with EGFR 1 Monoclonal Antibody 
(x 200 magnification)

Figure 4.3.10.7
Example Fluorescence of hPRL treated ZR-75-1 cells 
when incubated with EGFR1 Monoclonal Antibody 
(x 200 magnification)
Figure 4.3.10.8
Example Fluorescence of hPRL + E2 treated
ZR-75-1 cells when incubated with EGFR 1 
Monoclonal Antibody (x 200 magnification)

4 .3 .6  Immunoprecipitation Studies
W hilst increased staining for EGF receptor was observed in the previous 
section, it was im possible to quantify these results on the m icroscope used.
With this in mind it was decided to assess the effects o f hPRL and E2  on the
immunoprecipitatable levels  o f incorporated [ ^ S ]  _ methionine labelled EGF 
receptor. The experimental protocol is outlined in section 3 .3 .6 .
Figure 4 .3 .1 1 .1  is an example autoradiogram derived from after one month 
exposure at -70'C. There is some curling at the ends o f the gel. Of four separate 
imm unoprecipitation experim ents, Figure 4 .3 .1 1 .1  was the one which gave the 
b est resu lt in term s o f  low  background sta in in g . In creases in 
immunoprecipitated receptor were seen as as a function of time i.e. 6 - 2 4  hours. 
The greatest increases were observed with hPRL alone and with hPRL + E2
treated cells. E 2  appeared to have no effect in this assessment o f EGF receptor 
levels . Subsequent densitom etric analysis (Table 4 .3 .1  and Figure 4 .3 .1 0 .3 )  
revealed that EGF receptor content is increased with hPRL + E 2  treatment to 60%
above control values after 24 hours. E 2  alone had little effect although some
stimulation was observed after 48 hours.
It should be noted that these experiments were carried out at low  serum 
concentrations (0.5% (v/v) Dialysed HIDCCFCS). cell division in control and 
horm one treated ce lls  were comparable. Therefore the increases in 
immunoprecipitated EGF receptor were not a function o f cell division. Note that 
in Figure 4 .3 .1 0 .2  shows no increase from 24 - 48 hours. This effect is probably 
due to the low serum conditions of the experiment.
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Figure 4.3.11.1
Autoradiogram of immunoprecipitated EGFR in ZR-75-1 cells
170 kDa.
1 2 3 4 5 6 7 8  9 10 11 1213 14 15 16 171819 20
Lane Number
Time (Hours) Control 10'9M E2 50 ng.ml'1 PRL+10'9M E2 50 ng.m l1 PRL
8 1 6 11 16
16 2 7 12 17
24 3 8 13 18
36 4 9 14 19
48 5 10 15 20
At the specific time points above, cells were harvested and 
immunoprecipitation of the [35S] - Methionine labelled EGF receptor carried 
out using the EGFR 1 monoclonal antibody.
The preparations were then subjected to SDS/PAGE followed by 
Autoradiography ( see  methods 3.2.5 -3.2.10 and 3.3.6 - 3.3.6.4 ). The 
above table dispays time point according to lane number assigment.
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Figure 4.3.11.2
Densitometric Analysis of Figure 4.3.11.1.
70
45 -
20 -
-5 -
-30
E |  10'9M e 2
H  50 ng. ml' 1 PRL 
^  50 ng. ml’1 PRL+10‘9 M E2
16 24
T im e  (h rs )
36 48
V a lu e s  q u o te d  a s  %  d e c r e a s e / in c r e a s e  o v e r  c o n tro l  v a lu e s .
4 .3 .7  Conditioned Medium Studies
This section of the thesis deals with the possible mechanisms by which PRL 
may induce the EGF receptor. Initial studies were concerned primarily with a 
p ossib le  autocrine/paracrine approach.
Crude conditioned medium studies (see methods 3 .3 .7 )  reveal that media 
conditioned (CM) by cells exposed hPRL alone and in conjunction with E2
stimulates the binding o f  EGF to its receptor. Treatment with cyclohexim ide,
heat or trypsin appeared to negate this response. An interesting finding in this
series o f  experiments was that E2  CM also increased specific EGF binding to its
receptor 94% over control compared to 62% for hPRL CM. Again this effect was 
negated by cyclohexim ide, heat or trypsin treatment. All data is presented in 
Figure 4 .3 .1 2 .
It was outwith the scope o f this lab to assess the "carry over" o f any o f these 
horm one/growth factors. H owever dextran coated charcoal treatment o f  the 
CM, a prerequisite o f CM preparation (See m ethods 3 . 3 . 7 )  has been
demonstrated to remove both E 2  and oPRL biological activity (Manni et aL,
1986). Treatment with EGF appeared to inhibit any stim ulation observed. 
However it is possible that the "carry over" o f EGF is responsible for down
regulation o f EGF binding observed in the CM containing EGF.
Isolation and purification o f the factor or factors involved  in these  
responses was considered. However the necessary prerequisite for a study o f  
this nature is serum free culture. Unfortunately all attempts to culture ZR-75-1 
in serum free conditions where unsuccessful. It was with regret that this 
avenue o f investigation was abandoned.
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Figure 4.3.12
EFFECT OF E2, hPRL AND EGF CONDITIONED MEDIUM 
ON [125l]-EGF WHOLE CELL BINDING
CNTL PRL E2 EGF PRL+E2 PRL+EGF EGF+E2 PRL+EGF+E2
HORMONE/GROWTH FACTOR CONDITIONED MEDIUM
N = 6 experiments, each expt. is the mean of quadruplicate 
wells after 48 hours incubation ( |  ). Stimulation of binding 
following 48 hours incubation was negated by Cycloheximide 
( U ), Heat inactivation (H ) and Trypsin (Hi ) pretreatment 
of the conditioned medium. See methods section 3.3.7 for 
details of Trypsin, Heat Inactivation and Cycloheximide 
treatments.
4.3.8 Mechanism of Oestrogen Involvement.
It is well established that E 2  upregulates TGFa mRNA in some breast cancer
cell culture models (see Introduction 1.7.2 - 1.7.4). This may play a role in the 
responses noted. H owever it has been demonstrated that oestrogen and 
progesterone both play a role in the stimulation o f PRL production in human 
endom etrial c e lls  (Huang et  al., 1987), and that PRL can stim ulate the 
production o f its own receptor (Barash et al., 1988). With these studies in mind it 
was decided to study the effect o f E2  on the PRL receptor in the ZR-75-1 cell line 
using the methodology outline in methods 3 .3 .8 .
These studies found that E2  increased the specific binding o f PRL to its receptor 
both as a function o f E 2  concentration (Figure 4 .3 .1 3 )  and tim e (Figure
4 .3 .1 4 ) .  Subsequent Scatchard analysis reveals that E2  treatment causes a
doubling o f PRL levels with no relative changes in receptor affinity (0.75  
nm oles, l itr e '1) after 48 hours ( Figure 4 .3 .1 5 ) .  It should be noted that that 
these experiments were only initial findings i.e. only three experiments were 
carried out.
A tentative conclusion that may be derived is that enhancement o f EGF
receptor levels in cells treated with hPRL and E 2  is due at least in part to E2  
upregulation o f PRL receptor levels. In the light o f the CM studies where it was 
observed that E2  CM alone can increase EGF receptor levels, it is possible that in
addition to E 2 . E 2  CM induces the PRL receptor levels raising the possibility
(not yet tested) that TG Fa m ight stim ulate PRL receptor syn th esis . 
Alternatively, it is much more likely that this situation is more complex and 
other mechanisms are involved.
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Figure 4.3.13
E2 dose response of specific human 
[125l] - Prolactin binding after 48 hrs.
60 n
\  A
O  -  ■■:■
Oestradiol (M)
The above histogram plot is the mean results of 
quadruplicate expts ( S.D. ± 6.3%). PRL binding was 
determined by a single point binding assay , 1 
nmole, litre"1 human [125l] - PRL ± 100 - fold excess 
of unlabelled human PRL (see methods 3.3.8).
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Figure 4.3.14
Time course study of the effect of 10‘9M E2 
on human [125l] - Prolactin binding
100
80
60
40
20
0
The above plot is the mean results of quadruplicate 
expts (S.D. ± 5.5%). PRL binding was determined by a 
single point binding assay, 1 nmole, litre'1 human 
[125 |]. p r l  ± 100 fold excess of unlabelled human 
PRL (see methods 3.3.8) over time course indicated.
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Figure 4.3.15
E2 (10‘9M) Induction of Prolactin Receptor
0.04
•  Control 
O 10'9M e2
0.03
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0.01
0.00
2010 300
Bound
(fmoles. mg'1 cell protein)
Comparative Scatchard analysis of human 
[125l] - PRL binding in ZR-75-1 cells after 
48 hours exposure to 10'9M E2 ( see methods
3.3.8)
4 .3 .9  Prolactin and the Phosphatidylinositol Pathway
It has been noted that stim ulation o f  the phosphatidylinositol pathway 
(PIP) by phorbol esters can lead to increases in EGF receptor protein and mRNA 
(Shelton-E arp et al., 1988). During the period o f research involved in this 
thesis, it was demonstrated that addition o f prolactin could stimulate the flux of 
the PIP in mouse mammary explants (Etindi & Rillema, 1988). With this in mind 
it was decided to assess the effects of hPRL on the PIP in ZR-75-1 cells using the 
methodology outlined in methods 3 .3 .9 .
Studies reveal that treatment of cells with 50 ng. ml- 1  hPRL resulted in 
small increases in secondary m essengers, inositol triphosphate (IP 3 ) (Figure
4 .3 .1 6 )  and inositol tetraphosphate (IP4 ) (Figure 4 .3 .17), over a relatively
short time course suggesting a possible direct PRL receptor mediated response. 
But it is more likely that it is not a direct PRL receptor mediated response, 
because increases in total inositol phosphate (IP) levels could be seen as 
function o f PRL concentration over 30 mins (Figure 4 .3 .1 8 ) .  Stim ulation with 
an optimal concentration o f PRL still displayed increases in IP levels after 
three hours (Figure 4 .3 .1 9 ) .
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Figure 4.3.16
Effect of 50 ng. ml"1 human Prolactin on IP3 levels
CONTROL 
50 ng. ml'1 PRL
800 i
700 -
600 -
500 -
400 -
300 -
200
1 10 100 1000 10000
TIME (secs)
n = 4 experiments, Each experimental determination 
is the mean of triplicate wells. (SD < 7.5%.)
IP3 levels were estimated by the method outlined 
in 3.3.9.
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Figure 4.3.17
Effect of 50 ng. ml'1 human Prolactin on IP4 levels
400 n
CONTROL 
50 ng. ml-1 PRL
300 -
200 -
100
10 1001 1000 10000
TIME (secs)
n = 4 experiments, Each experimental determination 
is the mean of triplicate wells. (SD < 6.3%.)
IP4 levels were estimated by the method outlined
in 3.3.9.
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Figure 4.3.18
Effect of increasing concentration s of 
hPRL on Phosphatidylinosito l pathway turnover
4000 n
3000 -
2000 -
1000 -
0 50 100 150 200
Human Prolactin (ng. ml'1)
n = 3 experiments, Each experimental determination 
is the mean of triplicate wells. (SD < 10.5%.)
PI pathway turnover w as estimated by the method 
outlined in 3.3.9.
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Figure 4.3.19
Effect of 100 ng. ml*1 human Prolactin on Phosphatdylinositol 
pathway turnover over a 3 hour time course.
2000 n
1000 -
O CONTROL 
•  100 ng. m H  PRL
0 60 120 180
TIME (mins)
n = 6 experiments, Each experimental determination 
is the mean of triplicate wells. (SD < 7.0%.)
PI pathway turnover was estimated by the method 
outlined in 3.3.9.
4.3.10 Result Conclusion/ Discussion
Two major conclusions can be drawn from this study with regard to 
prolactin action.
(a) De novo  production o f  the EGF receptor can be induced by both 
pharmacological levels o f ovine PRL and physiological levels o f human PRL in 
the ZR-75-1 cell line .
(b) The mechanism of receptor induction is mediated at least in part by a heat 
lab ile  polypeptide autocrine/paracrine signal.
A few  compounds are known to regulate the EGF receptor at the ligand 
binding , receptor protein, and mRNA levels in breast cancer cell lines in vitro . 
1, 25 Dihydroxy-vitam in D (Koga et al., 1988), progestins (Murphy et al., 
1986,1988) and neoplastic agents (Hanuske et al., 1987) are examples.
PRL has not to our knowledge been studied in terms o f a possible role in 
EGF receptor regulation in breast cancer cell m odels. It has how ever been 
shown to stimulate the flux o f the Phosphatidylinositol pathway (PI) in mouse 
mammary explants (Etindi & Rillem a, 1988). Buckley et al. (1988) have also 
reported that prolactin stimulates protein kinase C (PKC) activity in isolated rat 
liver nuclei through the lactogenic component o f its action.
Earlier studies have shown that EGF and 12-o-phorbol-13-acetate (TPA) 
increase EGF receptor protein synthesis in the M D A -468 human breast 
carcinoma cell line (Kudlow et al., 1986; Bjorge & Kudlow, 1987). More recently 
Shelton - Earp et al., (1988) reported that EGF, Epinephrine, Angiotensin II and 
TPA stimulate PI hydrolysis and increase EGF receptor mRNA levels in rat liver 
epithelial cells .
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These finding suggest that at least part o f  the mechanism regulating EGF 
receptor protein synthesis lies within the PI/PKC signal transduction system, 
which from the data contained in this thesis and from Etindi & Rillema (1988) 
has the capacity to be stimulated by PRL.
In contrast to this proposed mechanism o f EGF receptor stimulation, earlier 
studies by Roos et al. (1986) presented findings to suggest that TPA treatment o f 
MCF-7 and ZR-75-1 cell lines resulted in a decrease not only o f receptor affinity 
(Receptor modulation), but also evidence o f a reduction the number o f receptor 
s ites .
A more recent study by Kosano & Takatani (1988) which states that the
a lkylysophospholip id , E T -I 8 -OCH 3  reduces EGF receptor levels probably by the 
inhibition o f PKC activity is supportive o f our view . It is hoped that further
studies will help elucidate this dual regulatory function of PKC in these in vitro 
breast cancer cell models.
Studies on individual cell lines have given rise to conflicting results, such 
variations are assumed to arise from differences in laboratory techniques, cell
passage number, plating density etc. Equally different breast epithelial cell 
lines although displaying sim ilar receptor complem ents g ive  in som e cases
surprising variations in results obtained. Therefore these results obtained in 
this section o f the thesis should be extended to other cell lines. This report 
however is the first occasion that PRL has been observed to regulate a growth 
factor receptor in an oestrogen dependent human breast cancer cell line.
Studies by Vonderhaar (1989) have shown that the addition o f PRL alone is 
sufficient for m itogenesis in the MCF-7 cell line suggesting a direct role for 
PRL in mammary growth. Whether this is mediated through the EGF receptor is 
still to be ascertained in their experimental system.
A recent report by Manni et al. (1990) has demonstrated that blockade of  
EGF binding to its receptor by two monoclonal antibodies markedly inhibited
both oestrogen(E 2 ) and progesterone (P2 ) conditioned m edium (CM ) m ediated
9 7
cell m itogenesis in MCF-7 cells grown in soft agar in serum free clonogenic 
assay conditions. Ovine PRL mediated m itogenesis however was unaffected. It is 
therefore possible that PRL in addition to increasing EGF induced m itogenesis, 
also stim ulates a number o f other growth promoting substances. From this
report and data contained within this thesis, E 2  CM may be acting by
increasing TG Fa production ( Bates et al., 1988) and as would appear from our 
data and that o f Berthois et al (1989) may upregulate the EGF receptor. In 
contrast to Manni et al., Arteaga et al. (1988) using one o f the same monoclonal 
antibody (Mab 528) and two other antibodies found that antibody blockade of
the EGF receptor in the MCF-7 cell line in serum free culture did not inhibit E2
induced growth.
It is clear that much more research is needed to elucidate E2  action within
these cell lines. It is unlikely that E 2  m ediated m itogenesis occurs so le ly
through the EGF receptor signalling system, as it has been shown that E 2  can 
stimulate other m itogenic factors such as IGF-I (H uff et al., 1986), IGF-II 
(Coranado et al., 1987) and cathepsin D (Vignon et al., 1986).
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Chapter 5. Overall Discussion
The work contained in this thesis can be overviewed in three sections.
(a )  We have described a ligand binding assay system for EGFR estimation 
which correlates w ell with the "common methodology" assay system proposed 
later by the EORTC study group (Benraad & Foekens, 1990). This assay can be 
used on relatively small amounts o f  tissue, yet gain full information on the 
number o f binding sites and their relative affinities for ligand.
This permits amalgamation o f  present data with that o f  other workers who 
are currently using the EORTC protocol. This is very important i f  one considers 
that the sample pool often used for study o f EGFR levels is only around 100 - 200 
patients. Amalgamation o f data allows for more accurate statistical analysis. The 
levels and incidence o f EGFR reported here fall within the range reported by 
most groups (Sainsbury et al., 1985; Nicholson et al., 1988; Fekete et  al., 1989).
In the present study 38% o f tumours were EGFR positive, 57% were ER 
positive ( a relatively low value, but it must be noted that the presence o f both
soluble and nuclear ER were required before a tissue was designated ER
positive) and 13% contained neither receptor. Only 14 o f  the 199 tumours 
studied contained both receptors and no correlation was noted with respect to 
receptor concentration s, su ggestin g  that p o ss ib ly  th ese  tum ours were 
polyclonal. H owever ligand binding assay (LBA) techniques may not be
sensitive enough to detect low  levels o f  receptor which may still be o f
relevance in determining tumour growth. The harsh m ethods o f  iodination  
such as chloramine T used in the production o f iodinated EGF and TGFa appear to 
decrease sensitivity o f  receptor detection (Leake & Benraad, 1991). More gentle 
m ethods such as iodine m onochloride and enzym obeads display horizontal 
H ollem an plot k inetics, indicating b io log ica l equivalence o f  labelled  and 
unlabelled ligand. It is possible that ligands labelled by the these latter methods
9 9
will significantly increase receptor detection and identify levels which are low  
but physiologically relevant. Enhanced sensitivity o f EGFR detection may help 
to explain the contrast between breast tumour tissue in which, the presence o f  
EGFR is associated with the absence o f ER levels and vice versa , whereas some 
breast cell lines show an interdependence o f  steroids and growth factors. It 
should be noted that the early studies o f ER levels in breast cancer tissue were 
around the 40% region, and have gradually increased with improvements and 
changes in technology until receptor incidence is now as high as 80-95%. 
Further, the relevant portion o f  the tumour with respect to disease progression 
may be diluted in the preparation o f the sample.
As more markers o f patient prognosis are being proposed, the methods o f  
detection must be modified so that there are both common methods and adequate 
material for satisfactory screening o f  appropriate markers in even small 
sam ples. LBA system s for receptor assessm ent allow  for the estim ation o f  
functional receptor, but use relatively large amounts o f  tumour and involve  
hom ogenisation. Other markers may not be receptors i.e. oncogenes and their
products (Guerin et al., 1989), secreted proteins such as Cathepsin D (Rochefort 
et al., 1988) etc. Therefore it is likely other methods o f  detection w ill overtake 
LBA. Ideally assays should be quantitative, give a measure o f  binding affinity 
yet permit a measure o f  heterogeneity o f  the marker both across tumour tissue 
and among different tissue types.
Immunocytochemistry with the appropriate antibodies is one avenue. The 
obvious advantage o f this method is that it allow s the precise assessm ent o f
markers with respect to their localisation within the tumour. H owever it does 
not test functionality ( if  the ability to bind ligand is taken as a marker o f  
function) and is not readily quantifiable. Other m ethods such as in situ
hybridisation, western, northern and southern blotting may also becom e more
widely used.
1 0 0
(b )  The demonstration that there may be a subclass o f EGFR in the nuclear 
fraction o f breast tumours bearing the appropriate receptors in the membrane 
fraction has some interesting im plications. It opens up the possib ility  that 
growth factor receptors may act through the DNA m achinery by direct 
interaction with the DNArchromatin com plex. Further, the p ossib ility  that 
related oncogenes may also bind is an intriguing p ossib ility . W hether the 
nuclear localisation  o f  EGFR (R akow icz-Szulcynska et al., 1989) and other 
growth factor receptors is either an essential component o f  their action or is a 
more accurate index o f  tumour prognosis is an area which we hope will be 
p u rsu ed .
The presence o f nuclear localised receptor offers intriguing possib ilities. 
Ligand, EGF or TG Fa, may be taken up by EGFR and in addition to signal 
transduction events, a portion is targeted towards the chromatin matrix. The 
demonstration that some m onoclonal antibodies (M Abs) directed against cell 
surface EGFR are taken up by the cell as a Mab/receptor complex and appear to 
translocate to the nucleus instead o f  the ligand/receptor com plex, may account 
for their action at the DNA level. It has been shown that activation o f  EGFR 
tyrosine kinase by some MAbs does not stimulate DNA synthesis (DeFize et al., 
1986) . Inhibition o f  the A431 cell line by MAb 423 occurs without affecting 
tyrosine kinase activity. It seems likely from these studies that tyrosine kinase 
activity does not represent the early critical point in proliferation o f  this cell 
line. Studies by Jiang & Schindley (1990) using a technique developed by 
Bishayee et al., (1982) in which EGFR was transferred in a biologically active 
state from donor hepatic membranes to EGFR deficient fibroblasts (3T3-NR), 
resulted in ce lls  that were physically  reconstituted with EGFR and which  
displayed ligand induced cell m itogenesis, have been shown to accumulate 
[125 i] _ EGF within the nucleus. An interesting report which may help in the 
elucidation o f  the nuclear localisation phenomenon was that o f  D eFize et al., 
(1989), who found that MAb 2E9 blocks EGF binding to the low  affinity
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component. No effect was noted with regard to EGFR tyrosine kinase activity. 
Addition o f  EGF resulted in the early responses associated with ligand  
activation, such as, inosito l phosphate production, release o f  Ca++ from 
intracellular stores, rise in intracellular pH, phosphorylation o f  EGF on 
threonine residue 654, induction o f  c-fos gene expression, and altered cell 
morphology. It was disappointing that DeFize never assessed or reported MAb 
2E9 with regard to EGFR nuclear localisation or cell growth which he him self 
had noted three years earlier.
Given more time and funding the nature o f EGFR localisation in breast 
cancer cell line models would have been pursued. Preliminary studies using the 
M DA-M B-231 cell line have given indications that EGFR is present in the 
chromatin matrix as assessed by ligand binding assay and western blotting. It 
was also interesting to note that both the MCF-7 and ZR-75-1 cell lines also 
appear to contain  im m u n o log ica lly  recogn isab le  EGFR w ith  nuclear  
preparations despite the low  concentrations o f  receptor available (results not 
sh o w n ).
A research scheme along the following lines is not impossible to imagine
(1) Nuclear localisation o f  [* ^ I ]  - EGF and [^ ^ 1] - TGFa over a concentration 
range and time course. The choice o f  using both ligands (w hilst displaying 
similar kinetics in terms o f  competition etc.) is due to the differential effects 
reported in the literature.
(2) R egulation o f  nuclear localisation  by EGFR sp ecific  tyrosine kinase 
inhibitors such as those described by Schlessinger's group, in particular 
Tyrphostin ( Lyall et al., 1989) which was found to inhibit EGFR tyrosine kinase 
activity and EGFR induced ce ll m itogenesis. Low affin ity site  blocking  
antibodies such as the MAb 2E9, or B4G7-IgG (Behzadian & Shimuzu, 1985) or
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EGR/G49 (Gregoriou & Rees, 1984) could answer some questions as to the role o f  
the low  affinity receptor with respect to nuclear localisation.
(3) The effect o f phorbol esters which have been shown to eliminate the high 
affinity EGFR binding component (see introduction 1 .8 .8 ) , may help provide 
an idea as to the role o f  the Protein Kinase C and inositol phosphates in the 
localisation o f nuclear receptor.
(4) The interaction o f other known growth factors such as PDGF, TGF p, IGF-I 
and IGF-II may give information on localisation with regard to receptor "cross 
talk". In particular PDGF is an interesting area, it has been demonstrated that 
PDGF in addition to phorbol esters also eliminates high affinity EGF binding ( 
see Introduction 1 .5 .3  and 1 .5 .5 ) . An exciting scenario could be that the loss 
o f high affinity EGF binding induced by PDGF (Olson & Pledger, 1990) would 
result in reduced nuclear localisation o f  EGFR and possib ly  corresponding  
increased localisation o f the PDGF receptor. Many breast cancer cell lines have 
been noted to secrete PDGF-like activity (Rozengurt, 1986). To our knowledge 
there are little data available as to levels o f PDGF receptor within breast cancer 
cell lines. The criteria for a study o f this nature must be a breast cancer cell 
line which contains receptors for both EGF and PDGF and displays m itogenesis 
to the addition o f  either ligand. Further, nuclear localisation o f  the PDGF 
receptor must be assessed by ligand binding assay and im m unological 
techniques. The ability to block PDGF binding/activity either chem ically or 
im m unologically would be required.
The role o f  hormones in nuclear localisation is another interesting area. 
The studies outlined in results chapter 4 .3  point to a role for prolactin (PRL) in 
stim ulating EGFR levels and EGF induced m itogenesis. It is possib le that 
increases in membrane associated EGFR also leads to increases in nuclear 
localised EGFR The role o f Oestrogen either acting directly, or by TGFa
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stimulation, or by the induction o f  PDGF like activity is another worthwhile 
a v e n u e .
(5) For nuclear localisation to proceed, transport through the cytoskeleton is 
probable. Electron m icroscope studies have shown cytoskeletal association o f  
high affinity EGFR in A431 cells (W eigant et al., 1986). Treatment with
cholch icin e which disrupts m icrotubules, and has been shown to inhibit 
cytoplasm ic transport o f  TSH hormone, Growth hormone and PRL (Gautvik & 
Tashjian, 1973: Hall, 1984). Cytochalasin B and anti-actin antibodies which
disrupt the function o f  actin (Mrotek & Hall, 1975) may resolve the role o f  
m icrotubules and actin in the transport o f  EGFR to the nucleus. The
cytoskeleton couples intracellularly with the nuclear matrix and provides the 
three dimensional organisation o f  DNA ( for a review see Getzenberg et al., 
1990). The precise function o f EGFR nuclear matrix interaction is difficult to 
ascertain. Nuclear matrix proteins play a key role in the regulation o f gene 
expression and have been found to be altered by a number o f post translational 
m odifications. These include protein phosphorylation, m ethylation, and ADP 
ribosylation (Henry & Hodge, 1983: Moy & Tew, 1986). Teraoke et al. (1989) have
reported a protein component o f  liver nuclear matrix which possesses tyrosine
kinase activity. It is certainly possible that EGFR tyrosine kinase and indeed 
other tyrosine kinase growth factor receptors have a role in the tyrosine 
phosphorylation o f matrix proteins. The precise function o f  tyrosine kinase 
phosphorylation o f nuclear matrix proteins has still to be elucidated. Other 
aspects o f  research could include, site directed mutagenic studies to assess the 
domains that are essential for nuclear binding. Some o f  the techniques used in 
the elucidation o f  steroid hormone receptors with respect to the nucleus could 
prove useful (See Parker, 1991).
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(c) The observation that PRL can positively regulate measurable levels o f  EGFR 
in an oestrogen receptor positive breast cancer cell line is novel. However it is 
important to realise that this study was carried out in a single cell line and 
should be extended to other lines containing PRLR (with or without ER).
Further experim ents g iven  more tim e and funding w ould in itia lly  have 
involved extending these observations to other ce ll lines in particular the
MCF-7 and T47-D lines. In principle the blockade o f  PRL binding by appropriate 
antibodies to the receptor would be advantageous in determ ining i f  the 
induction is a direct function o f  PRL and its receptor. Such an antibody 
however has not to our knowledge been described. Inhibition o f  Protein Kinase
C (by com m ercially  available enzym e inhibitors such as (+) 1
(5-Isoquinolinesu lponyl) - 2 - m ethylpiperazine hydrochloride, H-7 (Ratz,
1990)) when under PRL stimulation may give an indication as to the role o f the 
p h osp h atid y lin osito l pathway in PRL m ediated  EGFR in d u ction . The 
physiological relevance o f this study is difficult to assess. Whilst a role for PRL 
in rodent tumourigenesis is w ell established, its role within human breast 
cancer in terms o f  maintaining tumour growth is still unclear, though the 
rela tion sh ip  b etw een  pregnancy reduced p lasm a PRL and pregnancy  
protection against breast cancer remains intriguing. (W ang et al., 1987). 
However the demonstration o f  variant forms o f  PRL and more accurate methods 
of estimation with regard to diurnal variation may reveal a clearer picture. The 
possibility still remains that PRL regulation o f  the EGFR system might stimulate 
breast epithelial growth.
If PRL has a role to play in breast cancer, the time point at which its action 
might influence either the induction or promotion o f  the disease is unknown. 
Certainly anti-prolactin therapies have never been successfu l in established  
disease (Bruning, 1987). It has been demonstrated that tumours containing ER 
usually contain PRLR and have a relatively good prognosis.
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It is possible that E 2  and PRL maintain rigid control o f  the EGFR/TGFa
m itogenic system. Loss o f ER and PRLR may result in loss o f that control 
resu ltin g  in a m ore autonom ous h igh ly  p ro lifera tive  tum our. These  
experimental observations could w ell be a vestige o f PRL action with regard to 
the normal developm ent o f the breast. As with all observations contained  
within this thesis only time and more study will tell.
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